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Abstract 
In a desire to explore various areas of synthetic organic chemistry, different projects have been 
carried out, and each of the four following chapters will describe the work carried out on each of 
them. The first three chapters are related in some extent and treat the synthesis and biochemical 
applications of (phospho)lipids, while the last chapter differs and deals with the synthesis and initial 
structural studies of a C3 symmetric phosphine oxide. 
In the first chapter, a series of phospholipids have been synthesised in order to perform a short 
structure-activity relationship study of an enzyme, secretory phospholipase A2 (sPLA2) capable of 
hydrolysing phospholipids in the sn-2 position specifically. This enzyme is over-expressed in 
several types of cancer and is under evaluation as a potential trigger for drug release from a new 
generation of liposomal drug delivery systems. However, little is known about the steric and 
electronic requirements in the vicinity of the sn-2 position for an effective hydrolysis catalysed by 
the enzyme. Based on previous observations and on MD experiments, we developed a theory to 
predict and/or explain the activity of the enzyme on engineered phospholipids. According to our 
theory, two aspects of the enzyme-substrate interactions are primordial for an effective hydrolysis to 
occur: the formation of a constructive Michaelis-Menten complex, and access of water to the 
hydrolysis site. In order to verify this theory, the synthesised phospholipids were formulated as 
liposomes and the enzymatic activity was studied. Hydrolysis (or absence of hydrolysis) was 
monitored by MALDI-TOF-MS. The results observed in these experiments are compared to MD 
predictions and confirm them. 
The second chapter deals with surface functionalization of liposomes. The copper mediated [3+2] 
azide-alkyne cycloaddition has been successfully applied for this purpose by different groups, but 
no general optimization has been developed for the reaction on functionalised liposomes. Since the 
reaction generally takes place between one functionality on the surface of the liposomes membrane 
and a functionality covalently linked to a coupling partner (such as small molecule, peptide, etc.), 
we investigated the efficiency of the reaction depending on the position of the functional groups 
(whether on the liposome or on the coupling partner). Our results indicate that the reaction is most 
efficient when the liposome carries the alkyne functionality rather than the azide. We also 
investigated and developed a novel selective method for functionalizing liposomes, which has not 
yet been reported in the literature, based on the reaction between propargyl-amine decorated 
liposomes and isothiocyanate derived coupling partners that results in a coupling via formation of 
an iminothiazolidine. 
In the third chapter, the synthesis of sn-2 glyceryl 10,16-dihydroxyhexadecanoate is reported, in the 
context of the identification of the process of formation of the cutin polymer, one of the primary 
protective components of the epidermis of land plants. The enzyme responsible for the 
polymerization (CD1), as well as its substrate, has been identified, and the role of the enzyme has 
been demonstrated by its activity on the synthetic dihydroxyacylglycerol. 
Finally, the last chapter differs greatly from the first three by its focus: a C3 symmetric phosphine 
oxide has been synthesised, which we intend to test, after reduction to the phosphin, as a ligand in 
organometallic catalysed reactions. The ultimate goal is to obtain enantioselectivity, introduced by 
the organization of aryl substituents around phosphorous in our ligand. 
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Resumé 
Ud fra et ønske om at udforske forskellige grene af syntetisk organisk kemi er forskellige projekter 
blevet udført. Hvert af de følgende kapitler vil beskrive det arbejde, som er blevet udført på disse 
projekter. De første tre kapitler er til en vis grad relaterede og omhandler syntese og biokemisk 
anvendelse af (phospho)lipider. Det fjerde kapitel er noget forskelligt, da det beskriver syntese og 
foreløbige strukturelle studier af et C3 symmetrisk phosphinoxid. 
I det første kapitel beskrives syntesen af en række phospholipider, med det formål at undersøge 
sammenhængen mellem struktur og aktivitet af substrater for enzymet sekretorisk phospholipase A2 
(sPLA2), som selektivt kan hydrolysere phospholipider i sn-2 positionen. Dette enzym er 
overudtrykt i adskillige cancertyper og bliver undersøgt i forbindelse med udvikling af en ny 
generation af lægemiddelfremføringssystemer baseret på kontrolleret frigivelse i tumorvæv. 
Imidlertid er der begrænset viden om de steriske og elektroniske forudsætninger for enzymets 
hydrolyse i sn-2 positionen, hvorfor vi, baseret på tidligere observationer og MD simuleringer, har 
udviklet en teori til at forklare og forudsige enzymaktiviteten overfor nye typer phospholipider. 
Ifølge denne teori er der to aspekter af enzym-substrat interaktionen som influerer effektiv 
hydrolyse: Dannelse af et produktivt Michaelis-Menten kompleks og tilgang af vandmolekyler til 
det aktive site. For at verificere denne teori blev de syntetiserede phospholipider formuleret som 
liposomer og enzymaktiviteten på disse substrater blev undersøgt. Hydrolyse, eller mangel på 
samme, blev fulgt med MALDI-TOF-MS og resultaterne blev sammenlignet med MD simuleringer. 
Resultaterne viste god overensstemmelse mellem eksperimenter MD simuleringer. 
Det andet kapitel handler om overfladefunktionalisering af liposomer. Den kobberkatalyserede 
[3+2] azid-alkyn cykloaddition har været anvendt med succes til dette formål af andre grupper, men 
en generel optimering af reaktionen på funktionaliserede liposomer har ikke været foretaget. 
Reaktionen finder generelt sted mellem en funktionalitet på overfladen af liposommembranen og en 
anden kovalent bundet til en koblingspartner, såsom et lille molekyle eller et peptid. Vi har 
undersøgt betydningen af placeringen af de to funktionelle grupper, dvs. hvorvidt de er placeret på 
overfladen eller i opløsning. Resultaterne indikerer at reaktionen er mest effektiv, når liposomet 
bærer alkynfunktionaliteten fremfor azidet. Vi har også undersøgt og udviklet en ny selektiv metode 
til at funktionalisere liposomer. Reaktionen har ikke tidligere været beskrevet i litteraturen til dette 
formål og er baseret på reaktion mellem en propargylamin på liposomoverfladen med et 
isothiocyanat i opløsning og fører til dannelse af en iminothiazolidin 
I det tredje kapitel rapporterer vi syntesen af sn-2 glyceryl 10,16-dihydroxyhexadecanoat med det 
formål at identificere en proces involveret i dannelse af cutin, en polymer som udgør en af de 
primære beskyttende komponenter i planters epidermis. Enzymet, som er ansvarlig for 
polymerisering (CD1) samt substratet blev identificeret og enzymets funktion og rolle i cutin 
syntese blev verificeret ud fra dets aktivitet overfor det syntetiske dihydroxyacylglycerolmolekyle.   
Det fjerde og sidste kapitel adskiller sig væsentligt fra de tre foregående ved at fokusere på 
fremstilling af et nyt C3 symmetrisk phosphinoxid. Vi ønsker at teste stoffet, efter reduktion til den 
tilsvarende phosphin, som ligand i metalkatalyserede reaktioner, med det det endelige mål at opnå 
enantioselektivitet, induceret af organisationen af tre aryl substituenter bundet til phosphor. 
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1. Structure-activity relationship study of potential substrates for sPLA2 
 
1.1. Introduction 
1.1.1. Liposomes are valuable drug delivery systems 
Despite advances in the research for cancer treatment, the main issues inherent to anti-cancer drugs 
remain their high toxicity towards healthy cells resulting in severe side effects. The potential of 
liposomes as drug carriers was first introduced in 1974,1 about ten years after the discovery of those 
structures by Alec Bangham,2,3 and intensive research lead to the effective use of liposomes as drug 
delivery systems (DDS) for antitumour drugs. Liposomes can be designed for specific purposes, by 
altering their biophysical properties through the use of diverse formulations. By doing so, 
pharmacological and therapeutic properties of parenterally administered drugs have been improved. 
Indeed, the use of liposomes as DDS resulted in enhanced activity of the encapsulated drug and 
reduced toxicity towards healthy tissues.4 
Among the drug properties that have been improved and/or issues that have been addressed through 
encapsulation of free drugs in liposomal DDS, we can mention the poor solubility of hydrophobic 
drugs in aqueous media. Free drug solubility is enhanced by the use of liposomes, which provide 
both hydrophilic and hydrophobic environments (this property of liposomes is explained in more 
details in section 1.1.2.). Another example is the protection provided by encapsulation of the drug 
into the liposomes, which prevents premature degradation of the drug in vivo when the drug is 
unstable at physiological pH for instance. This protection also alters the drug pharmacokinetics, by 
preventing degradation of the drug via metabolic pathways in the blood stream and by reducing 
renal clearance of small molecules. Finally, the use of liposomes as DDS reduces toxicity toward 
healthy tissues by improving selectivity toward target tissues. This can be achieved by taking 
advantage of the enhanced permeability and retention effect and/or via ligand-targeting (passive and 
active targeting respectively), these last notions will be described in detail in section 2.1. 
Liposomes are especially suited for carrying small molecules, of which they can encapsulate up to 
tens of thousands of drug molecules,5 and liposomal formulation of anticancer small molecules have 
reached the market. As an example, the pegylated liposomal doxorubicin marketed as 
Doxil/Caelyx,6 is reported to encapsulate 15,000 molecules of doxorubicin per liposome, the latter 
displaying an average diameter of 80-90 nm.7 
 
1.1.2. Liposomes structures and nomenclature 
Liposomes are spherical structures, formed by aggregation of amphiphilic molecules such as 
phospholipids in aqueous media. They can consist of one or several concentric spheres of lipid 
bilayer(s) (unilamellar vesicles or multilamellar vesicles, respectively), in the case of multilamellar 
vesicles, lipid bilayers are separated by aqueous compartments.11 When dispersed in a polar 
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aqueous medium, the polar head-groups of the amphiphilic molecules interact through hydrogen 
bonding and solvation, and the hydrophobic tails aggregate by virtue of the hydrophobic effect, 
forming bilayer structures that “protect” the hydrophobic tails from water. Therefore, liposomes 
consist of one or a series of closed bilayer(s), the space inside the bilayers being hydrophobic, while 
the compartments between the bilayers and core of the sphere are polar and filled with the buffered 
acqueous medium. Spontaneously formed liposomes are multilamellar vesicles as depicted in 
Figure 1, having an average diameter above 500 nm and these were the structures originally 
observed by Bangham.2,3 However, multilamellar vesicles can be forced into unilamellar vesicles by 
sonication8,11 or extrusion.9,11 Liposomes used as DDS are the large unilamellar vesicles (typically 
around 100 nm in diameter). As a consequence of the structural properties of liposomes (as 
unilamellar vesicles) hydrophilic drugs can readily be entrapped in the aqueous core of the 
liposomes, but neutral drugs, or drugs with a poor to intermediate water solubility tend to be 
released rapidly, especially in the presence of other membranes or proteins.10 Alternatively, apolar 
drugs can be contained within the lipid bilayer.11 Phospholipids with a glycerol backbone are the 
major constituent of biological membranes and are very commonly used for liposomes 
formulations. A schematic description of the assembly of glycerophospholipids into liposomes as 
multilamellar vesicles and as unilamellar vesicles is shown in Figure 1. A phosphodiester linked to 
the third position of the glycerol backbone and to various organic alcohols such as glycerol, choline, 
ethanolamine, serine and inositol can make up the polar head group. Similarly, a variety of either 
saturated or unsaturated alkyl chains can be attached to the first two positions of the glycerol 
backbone via ether or ester functionalities to afford the aliphatic tails.11 
 
 
Figure 1: Liposomes are structures made by the spontaneous assembly of amphiphilic compounds such as 
phospholipids (here DSPG) and can be multilamellar vesicles or unilamellar vesicles. Adapted from ref. 11. 
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A widely applicable and generally used nomenclature for phospholipids is the sn-nomenclature 
(stereospecific numbering) introduced by Hirshman,12 which relies on a stereospecific numbering of 
the carbon atoms of the glycerol backbone, and associates a number (sn-1, sn-2 and sn-3) to the 
carbons atoms of the backbone independently of the substituents on those atoms. The sn-1 position 
refers to the carbon at the top of a Fischer projection of the glycerol, having the hydroxyl group in 
the second position (sn-2) on the left, and the bottom carbon of the chain in the Fischer projection is 
the sn-3 carbon. An example is given in Figure 2. 
 
 
Figure 2: Use of the sn-nomenclature with 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylcholine (POPC). 
 
1.1.3. Triggering drug release 
If the shielding offered by a DDS and the effective encapsulation of the drug in liposomes are an 
advantage during their transit in the blood stream, this characteristic becomes a drawback when the 
liposomes have reached the targeted tissue, since the drug remains inactive when encapsulated in 
the liposome. Thus too slow release of the drug after accumulation of the liposomes at the tumour 
results in poor therapeutic effect.13 Therefore, release of the drug from the liposome is a prerequisite 
for the efficacy of the drug. Leakage of the drug from the liposome is generally achieved passively 
upon destabilization of the liposomes with time. However, intensive research has focused on 
designing liposomes that can be destabilized under specific conditions and can deliver their content 
at controllable rates. For that purpose, different potential triggers have been explored, and pH-
,14,15,16,17,18 temperature-19,20,21 and light-sensitive liposomes, 22,23,24,25 have been engineered, to take 
advantage of tumour physiological properties and/or external stimuli to trigger the drug release 
from the liposomes when and where desired. However, despite encouraging results, these strategies 
have yet to translate into marketed DDSs and the clinic.  
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1.1.4. sPLA2 triggered drug release 
Another potential trigger considered for release of the active compound in tumour tissues was 
envisioned to be the enzyme secretory phospholipase A2 (sPLA2). This enzyme is over-expressed in 
various types of cancers and its serum concentration increases in advanced stages of the disease.26 
The enzyme is secreted by the cells to act extracellularly, thus it is found and operates in the 
interstitial space.26 Moreover, sPLA2 specifically hydrolyses the sn-2-acyl position of 
phospholipids,27 and has shown increased activity toward aggregated lipids substrates,28 as is the 
organization found in the bilayers of liposomes. Those characteristics make the enzyme an ideal 
candidate as trigger for drug release from liposomes in the treatment of cancers. 
sPLA2 has attracted great interest, its mode of action has been studied extensively and a mechanism 
has been proposed for the enzyme-catalysed hydrolysis of phospholipids, which is illustrated in 
Figure 3. The enzyme is Ca2+-dependant  and the important interactions between the enzyme, its 
substrate and the required Ca2+ ion have been determined by high-resolution x-ray crystallography. 
The x-ray structure illustrates the role of the Ca2+ ion both in the binding of the enzyme to the 
substrate and in the hydrolysis reaction. Indeed, initially, the ion ensures a close interaction between 
the enzyme and the substrate and helps stabilize the sPLA2-substrate Michaelis-Menten complex by 
interacting with two residues of the active site of the enzyme (Gly 29 and Asp 48), the phosphate 
oxygen and the carbonyl oxygen in the sn-2 position of the phospholipid (marked as O22 in Figure 
3A), this increases the electrophilicity of the latter and facilitates nucleophilic attack by the water 
molecule. As a result, Ca2+ also stabilizes the transition state obtained after nucleophilic attack by 
water (shown in Figure 3B).29 The hydrolysis is initiated by deprotonation of an incoming water 
molecule by the imidazole moiety of His 47 in the active site of the enzyme and subsequent 
nucleophilic attack on the ester carbonyl in the sn-2 position of the substrate, leading to the 
intermediate shown in Figure 3B. This intermediate collapses to afford the carboxylic acid, and the 
glycerol’s sn-2 hydroxide abstracts the proton from the previously protonated His 47 to regenerate 
the active enzyme. Thus after departure of the carboxylic acid and lysolipid, the enzyme can initiate 
a new catalytic cycle for substrate hydrolysis.30,31 
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Figure 3: Mechanism of the sPLA2-catalysed hydrolysis of phospholipids. A: Ca2+-mediated formation of the 
Michaelis-Menten intermediate and initiation of the hydrolysis. B: Collapse of the tetrahedral intermediate, 
reconstitution of the carbonyl bond and proton exchange between the sn-2 oxygen and the protonated His 47 
lead to the products (C). The dashed lines highlight the important interactions (hydrogen bonds and ionic 
interactions) in the reaction. Key protein residues are drawn in blue, the substrate in red, the calcium ion and 
the water molecule both in brown. Amino acid labels and atom types indicated in parentheses refer to the 
Protein Data Bank nomenclature. Adapted from refs. 30 and 31.  
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Investigation of sPLA2 as a drug release trigger initially focused on liposomal formulations of 
common phospholipids, 1,2-di-hexadecanoyl-sn-glycero-3-phosphatidylcholine (DPPC) lipids 
formulated with 1,2-di-hexadecanoyl-sn-glycero-3-phosphatidylethanolamine- N-
[methoxy(polyethylene glycol)-2000] (DPPE-PEG2000). Upon snake venom sPLA2 activity, the 
phospholipids were hydrolysed in the sn-2 position, resulting in lyso-phospholipids and free fatty 
acids and the liposomes were destabilized, delivering their contents.32 The study also shows that the 
products of hydrolysis enhance the permeability of the target cells, thereby constributing to the 
cytotoxicity of the system.32 
Later on, studies carried out in our group aimed at engineering new liposomes, which could deliver 
their active compounds content in cancer tissue upon sPLA2 destabilization. The studies were 
aiming for an improved DDS, and thus liposomes design had to be compatible with degradation by 
human sPLA2. It is known that human sPLA2 does not bind (or binds very weakly) to zwitterionic 
membranes, but has a higher affinity for anionic membranes.33 Therefore, the lipids were designed 
with a phosphatidylglycerol (PG) head group. Another interest in the project was to introduce the 
active compound in the hydrophobic bilayer, via a covalent ester bond at the sn-2 position. The 
liposomal formulation of anticancer drugs obtained with this design has the great advantage over 
other formulations that release of the cytotoxic compound can only occur upon hydrolysis of the sn-
2 position of the lipids. This should decrease loss of the contained drug by leakage during the 
liposomes´ circulation in the blood stream and increase the specificity of the drug release at the 
tumour by virtue of the elevated activity of sPLA2 in tumour tissues, thus decreasing side effects. 
Several lipophilic compounds with known anticancer activity have been linked via an ester bond to 
the sn-2 position of phospholipids, formulated as liposomes and the ability of the enzyme to liberate 
the active compounds was monitored. The study focused on chlorambucil,42 all-trans retinoic acid 
(ATRA),63,70 α-tocopheryl succinate, a derivative of vitamin E,34 and 15-deoxy-Δ12,14-PGJ2, a 
prostaglandin derivative .71 The synthesized prodrug lipids are shown in Figure 4. 
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Figure 4: Phospholipid synthesised as potential prodrugs for triggered release by sPLA2. A: Chlorambucil 
derivative;42 B: ATRA derivative, not hydrolysed by sPLA2;63 C: α-tocopheryl succinate derivative, not 
hydrolysed by sPLA2;34 D: 15-deoxy-Δ12,14-PGJ2 derivative;71 E: ATRA derivative effectively hydrolysed in the 
presence of sPLA2.70 
 
All phospholipid prodrugs were synthesised and shown to form stable liposomes upon formulation, 
generally in the 100 nm range, except for liposomes formed from conjugates containing 
prostaglandins (Figure 4D),71 which were in the 50-80 nm range following extrusion. Hydrolysis by 
snake venom sPLA2 was investigated by MALDI-TOF-MS for all formulated liposomes and 
revealed a distinct difference in the ability of the different sn-2 ester to undergo hydrolysis: the 
chlorambucil prodrug (Figure 4A) was an excellent substrate and was almost fully hydrolysed in 24 
h and the same was observed for the prostaglandin prodrugs (Figure 4D).42,71 However, the α-
tocopheryl succinate prodrug (Figure 4C) was not hydrolysed by sPLA2,34 neither was the ATRA 
conjugate (Figure 4B).63 For the sn-2 ATRA phospholipid, molecular dynamics (MD) simulations 
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of the lipid-enzyme complex indicated that the α,β-unsaturation and/or the β-methyl substituent led 
to an unproductive enzyme-substrate complex, which rendered hydrolysis impossible. This was 
circumvented by preparation of the ester derivative of ATRA having an additional six carbon 
spacer, in the form of a saturated ester at the sn-2 position (Figure 4E), affording a lipid that was 
efficiently hydrolysed by sPLA2 within hours.70  
These observations prompted us to investigate the effect of unsaturation and substitution in close 
proximity to the sn-2 position on the ability of modified lipids to serve as substrates for sPLA2. 
Hence, we set out to prepare the phospholipids shown in Figure 5. As evident, these potential 
substrates cover the complete range of saturated, E- and Z-unsaturated esters as well as the presence 
of a methyl substitution both at the α- and the β-position of the unsaturated esters. We envisioned 
that a study of the ability of these lipids to undergo hydrolysis catalysed by sPLA2 would provide 
detailed information about the structural requirements for enzyme activity; data that would both 
help explain our previous observations and also aid in the future design of prodrug-lipid systems for 
triggered release by sPLA2. Furthermore, the data could be compared to simulation results from MD 
investigations of the same substrates, aiding in validating and potentially refining modelling tools 
for prediction of the enzyme activity. 
 
 
Figure 5: Target phospholipids to be tested as potential substrates for sPLA2 in order to investigate the effect of 
unsaturation and substitution in the vicinity of the sn-2 position on the ability of the enzyme to hydrolyse 
modified lipids. 
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1.2. Synthesis of the potential substrates 
Well-established routes have been described for the synthesis of symmetrical glycerol derivatives, 
as well as for mixed chain glycerol derivatives and glycerophospholipids.35,36,37  Since the 
phospholipids we want to synthesise and investigate only differ at the sn-2 position, a synthetic 
route allowing the insertion of the sn-2 ester in a late stage as described by Murakami et al 38 would 
be preferable, however, that strategy is not commonly applied, and only few articles refer to such 
syntheses. Furthermore, since the intermediate phosphotriester is chiral, and the PG headgroup has a 
well-defined stereocenter, such an approach would force us to handle mixtures of diastereoisomers 
over several steps. Therefore, it was chosen to follow a more extensively described route, installing 
the stearoyl chain in the sn-1 position via selective monoacylation on a 3-O-protected-glycerol, as 
previously reported by Greimel et al.39 followed by acylation of the sn-2 position, deprotection of 
the sn-3 position and insertion of the phosphatidylglycerol head group. The control of the 
stereocenter in the sn-2 position is provided by the starting material: enantiomerically pure 1,2-O-
isopropylidene-sn-glycerol or 2,3-O-isopropylidene-sn-glycerol can be used as precursors in the 
synthesis of phospholipids. The chosen strategy still presents some challenges such as the necessity 
of multiple protection and deprotection steps, as well as the risk of acyl migration during the 
deprotection of the isopropylidene group under acidic conditions or during deprotection of the sn-3 
position.38,40  
 
 
Figure 6: Retrosynthetic analysis, strategy chosen for the synthesis of the 1, 2-diacyl-sn-glycerophospholipids. R 
represents an aliphatic chain and differs for each target substrate. Pg stands for protecting group, the nature of 
which is not defined here. 
 
The 1-stearoyl-3-O-protected-sn-glycerol is a common precursor for every phospholipid to be 
synthesised, and efficient methods for introduction of the phosphatidylglycerol head group have 
been described for various mixed chain diacyl glycerol derivatives.41,42 The aliphatic chain in the 
sn-2 position differs in each substrate and the corresponding fatty acids were prepared.  
 
1.2.1. Synthesis of the acids 
All the required fatty acids were synthesised from the same precursor: 10-phenyldecanol (1) and for 
all of them, the first step of the synthesis is the Swern oxidation43,44 to the corresponding aldehyde 
(see Scheme 1). 10-Phenyldecanal (2) was obtained following the procedure described by Mancuso 
et al. for long-chain alcohols.44 The aldehyde obtained was not stable and degraded upon storage, 
even at low temperatures. It was also observed that the crude aldehyde was more stable and could 
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be kept longer at -18 °C (2 to 3 days), while it would degrade overnight at that temperature when it 
had been purified by flash chromatography. Thus, only relatively small scales (up to 1.5 g) were 
synthesised at a time, and the resulting crude aldehyde was used immediately.  
 
Scheme 1: Synthesis of acids from phenyldecanol.a 
 
a Reagents: (a): (ClCO)2, DMSO, Et3N, CH2Cl2, -78 °C; (b): methyl diethylphosphonoacetate, NaH, DME, 45-50 °C; 
(c): methyl P,P-bis(2,2,2-trifluoroethyl)phosphonoacetate, NaH, DME/THF, -78–20 °C; (d): triethyl 2-
phosphonopropionate, NaH, DME, 50-70 °C; (e): ethyl P,P-bis(2,2,2-trifluoroethyl)phosphonopropionate, NaH, 
DME/THF, -78–20 °C; (f): (i) MeMgI, Et2O; (ii) (ClCO)2, DMSO, Et3N, CH2Cl2, -78 °C; (iii) methyl 
diethylphosphonoacetate, NaH, DME, 45-65 °C; (g): aq. NaOH (10%), EtOH; (h): aq. NaOH (10%), tBuOH; (j) 
MeMgI, Et2O; (ii) (ClCO)2, DMSO, Et3N, CH2Cl2; (iii) methyl P,P-bis(2,2,2-trifluoroethyl)phosphonoacetate, NaH, 
DME, 45-65 °C; (k): TMSOK, Et2O. 
 
The α,β-unsaturated esters displaying the E configuration were synthesised by Horner-Wadsworth-
Emmons (HWE) olefination,45,46,47 utilizing stabilized phosphonate carbanions, while the esters 
displaying the Z configuration were obtained by means of the Still-Gennari modification of the 
HWE reaction, which consists in coupling an aldehyde or a ketone with bis(trifluoroalkyl) 
phosphonoesters under strongly basic conditions (KHMDS/18-crown-6).48 The E-esters could also 
have been synthesised using the regular Wittig conditions for stabilized ylides.49  
(E)-12-Phenyldodec-2-enoic acid (4) was obtained by following the experimental described by 
Keenan et al.,50 using methyl diethylphosphonoacetate and NaH in freshly distilled 
dimethoxyethane (DME) at 50 °C for 2h, followed by hydrolysis in EtOH under basic conditions 
(10 % NaOH). During the HWE reaction, both the desired E- and the Z- α,β-unsaturated esters were 
isolated, however the stereoselectivity was very satisfying, since the desired ester 3 was isolated in 
74 % yield, while only about 5 % of the Z-ester was isolated. 
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Still et al.48, described the synthesis of aliphatic Z-α,β-unsaturated esters in high yields and good 
selectivity (Z:E ratio of 12:1 and 90 % yield) using methyl P,P-bis(2,2,2-
trifluoroethyl)phosphonoacetate and KHMDS/18-crown-6 in THF, however only disappointing 
results were obtained when this method was attempted to synthesise methyl (Z)-12-phenyldodec-2-
enoate (5) (see Table 1, entry 1), and several attempts have been carried out in order to optimize the 
reaction. Increasing the equivalents of the reagents or the temperature did not improve the yield, 
however, satisfying yields were obtained using NaH in DME at low temperature (inspired from the 
synthesis of the E-isomer), see Table 1, entry 4, despite that the contrary was originally reported in 
the literature.48  
 
Table 1: Conditions attempted for the synthesis of methyl (Z)-12-phenyldodec-2-enoate 5. 
Entry Solvent Base bis(Trifluoroalkyl) 
phosphonoesters 
Temperature Yielda 
1 Anhydrous 
THF 
KHMDS (1 equiv.) 
18-crown-6 (5 equiv) 
1 equiv. -78 °C 24 % 
      
2 Anhydrous 
THF 
KHMDS (1.5 equiv.) 
18-crown-6 (7.5 equiv) 
1.45 equiv. -78 °C 34 % (10 % E- 
isomer) 
      
3 Anhydrous 
THF 
KHMDS (1.5 equiv.) 
18-crown-6 (7.5 equiv) 
1.45 equiv. 0 °C 22 %  (27 % 
E- isomer) 
      
4 Anhydrous 
DME 
NaH (1.5 equiv) 1.45 equiv. -78 °C 71 % 
a Isolated yields after flash chromatography. 
 
Hydrolysis of 5 in EtOH, NaOH (10 %) was competing with transesterification, and following the 
same procedure as for 4, 6 was only isolated in 50 % yield along with 25 % of ethyl (E)-12-
phenyldodec-2-enoate. Attempts were carried out using LiOH in THF/H2O,51 but only very little 
conversion of 5 was observed even with reaction times of several days. Switching the solvent from 
EtOH to the more sterically hindered tBuOH in the initial procedure prevented the 
transesterification, and hydrolysis of 5 in tBuOH, NaOH (10 %) afforded the desired acid 6 in 87 % 
yield after recrystallization from EtOH/H2O. However, the reaction time had to be extended to 5 
days before full conversion of the starting material was observed. 
Esters 7 and 9 were synthesised from aldehyde 2 using triethyl-2-phosphonopropionate and ethyl-2-
[bis(2,2,2-trifluoroethyl)phosphono]propionate, respectively. Again, the reaction conditions 
required some adjustments: for the synthesis of ester 7, the reaction demanded more equivalents of 
NaH and phosphonopropionate as well as more elevated temperature for a longer reaction time (see 
entry 3, Table 2).  
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Table 2: Conditions tested for the synthesis of ethyl (E)-12-phenyldodec-2-enoate 7. 
Entry Temperature NaH Triethyl-2-
phosphonopropionate 
Ea Za 
1 70 °C for 4 h, 
then 20 °C for 18 h 
1.75 equiv. 1.75 equiv 41% 12% 
      
2 65 °C for 18 h 3 equiv 2.92 equiv. 38% 16% 
      
3 70 °C for 18 h 1.75 equiv. 1.75 equiv. 59 % 8% 
a Isolated yields after flash chromatography. 
 
Taking the previous observations into account, ester 9 was synthesised using ethyl-2-[bis(2,2,2-
trifluoroethyl)phosphono]propionate and NaH in a mixture of DME and THF at 20 °C. Low 
temperatures are generally required to obtain good Z-selectivity, however, the desired reaction did 
not occur at -78 °C. Better yields than the ones obtained here were reported for olefination of 
alphhatic aldehydes, using methyl bis(2,4-difluorophenyl)phosphonoacetate,52 or different 
diphenylphosphonoacetic acid esters,53 and an excess of sodium ions has been reported to increase 
the Z-selectivity using the latter.54 
The configuration of the esters was determined by the difference in shifts of the vinylic protons: 
those being more deshielded by the electron withdrawing ester functionality in the E-α,β-
unsaturated esters (with a downfield chemical shift of 6.92 ppm for 7) than in the the Z-α,β-
unsaturated esters (with a chemical shift of 5.92 ppm for 9), and the structural assignment was 
supported by NOE measurements (see Figure 7). 
 
 
Figure 7: NOESY experiments verify the identification of esters 7 and 9: an NOE was seen between the α-methyl 
protons and the vinylic proton for the Z-ester 9, but not for the E-ester 7. 
 
Several attempts to synthesise  methyl diethyl-2-phosphonopropionate from methyl 
diethylphosphonoacetate were carried out using NaH and MeI in DME inspired by Keenan et al.,50 
but varying equivalents, reaction times and reaction temperatures repeatedly led to inseparable 
mixtures of the starting phosphonate, the desired mono-methylated phosphonopropionate and the 
bis-methylated 2-methyl-phosphono-propionate compound, and the desired compound could not be 
isolated. The three compounds were easily differenciated by 13C NMR, the carbon α to the 
phosphorus having characteristic shifts [13C NMR (75 MHz, CDCl3): δ (34.08, 1JC-P = 134 Hz) for 
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the starting material, (39.02, 1JC-P = 132.8 Hz) for the desired compound and (43.88, 1JC-P = 136 Hz) 
for the bis-alkylated compound]. As a consequence, the desired phosphonopropionate was obtained 
from Sigma-Aldrich.  
 
 
Figure 8: Attempted synthesis of methyl diethylphosphonopropionate. 
 
Based on the results observed previously with hydrolysis of 3 and 5, the hydrolysis of 7 and 9 was 
attempted in tBuOH and aqueous NaOH to avoid transesterification, however after 9 days, only 
very little hydrolysis had occurred, LiOH in THF/H2O did not provide better results, and eventually 
it was found that aqueous NaOH in EtOH was the best system for those two substrates.  
The two β-methyl-α,β-unsaturated esters were synthesised from 11-phenylundecan-2-one (16) using 
the same phosphonate as for 3 and 5 (see Scheme 2).  
 
Scheme 2: Synthesis of (E)- and (Z)-3-methyl-12-phenyldodec-2-enoic acids.a  
R O R OH R O
R
R
CO2Me
CO2Me
R
CO2H
R
CO2H
= R
2 15 16
13
11
14
12
a b
c
e
d
d
79% 93%
56%
27%
62%
71%
 
a Reagents: (a):MeI, Mg, Et2O; (b): (ClCO)2, DMSO, Et3N, CH2Cl2, -78 °C; (c): NaH, methyl P,P-bis(2,2,2-
trifluoroethyl)phosphonoacetate, DME, 65 °C; (d): TMSOK, Et2O; (e): methyl diethylphosphonoacetate, NaH, DME, 
65 °C. 
 
10-Phenyldecanal was methylated in a Grignard reaction55 in 79 % yield,56 methylation using 
MeLi50 resulted in a lower yield (65 %). The resulting secondary alcohol 15 was oxidized via a 
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Swern reaction43,44 in excellent yield to 11-phenylundecan-2-one (16). The ketone was significantly 
less reactive than the aldehyde formerly used, the subsequent HWE olefinations were challenging to 
perform, and it was especially difficult to get a good Z-selectivity. Synthesis of methyl (E)-3-
methyl-12-phenyldodec-2-enoate (11) according to Keenan et al,50 only afforded 22% of the ester, 
and the reaction required heating to 65 °C for 18 h, with 3 equiv. of NaH and 2.92 equiv. of methyl 
diethylphosphonoacetate to afford 56 % of the desired ester, and 16 % of the Z-ester (13). 
In order to synthesise Z-3-methyl-12-phenyldodec-2-enoate 13, it was first attempted to carry out 
the reaction at low temperature to favour Z-selectivity, but the reaction did not perform even at 20 
°C. Based on the experiments conducted for Z-12-phenyldodec-2-enoate 5, it seemed that NaH in 
DME was the best system for our substrates, and only reaction temperature and reagents equivalents 
were screened (see Table 3). The best results were obtained using 3.14 equivalents of NaH, 1.92 
equivalents of methyl P,P-bis(2,2,2-trifluoroethyl)phosphonoacetate at 65 °C for 18 h. Yet, Z-
selectivity was not obtained and even in the best case, both E- and Z-α,β-unsaturated esters were 
obtained in a roughly 1:1 mixture. 
 
Table 3: Conditions attempted for the synthesis of methyl (Z)-3-methyl-12-phenyldodec-2-enoate 13. 
Entry NaH Temperature Za
(13) 
Ea 
(11) 
 
1 
 
1.5 equiv. 
 
1.45 equiv. 
-78 °C for 3h, 
then 20 °C for 18h 
 
0% 
 
0% 
      
2 1.5 equiv. 1.45 equiv. 40 °C for 18h 7% 9% 
      
3 2 equiv. 1.98 equiv. 65 °C for 18h 12% 10% 
      
4 3.14 equiv. 1.92 equiv. 65 °C for 18h 27% 30% 
a Isolated yields after flash chromatography. 
 
The stereochemistry of the two esters could be determined from their 1H NMR spectra. It has been 
observed that β-methyl groups in α,β-unsaturated esters have characteristic shifts: β-methyl protons 
cis to an ester group has a slight downfield chemical shift at δ 2.1-2.2, while β-methyl protons trans 
to an ester resonates around δ 1.8-1.9.57 1H NMR spectra and the corresponding stereochemical 
assignments are in agreement with this observation: the chemical shift is δ 2.10-2.16 for the β-
methyl protons for the 3-methyl-E-ester (11) and δ 1.88 for the 3-methyl-Z-ester (13). 
Hydrolysis of the two esters 11 and 13 turned out to be challenging as well, and several conditions 
were attempted to get reasonable yields (see Table 4). The conditions described previously for the 
synthesis of the acids 4, 6, 8, and 10 were inefficient for the latest acids, applying heat to the 
mixture of ester 11 in EtOH and aqueous NaOH resulted in partial migration of the alkene to give 
the β-methylene-carboxylic acid (approximately 1:4 ratio between 3-methylene-12-
phenyldodecanoic acid and the desired acid), in a mixture that proved challenging to separate 
(Table 4, Entry 2).  
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Table 4: Experiments conducted for the hydrolysis of esters 11 and 13. 
Entry Ester Experimental conditions Outcome 
    
1 3-Methyl-E-ester (11) Aq. NaOH (3 equiv.), EtOH, 20 °C Very little conversion after 2 daysa 
 
 
   
2 3-Methyl-E-ester (11) Aq. NaOH (3 equiv.), EtOH, 40 °C, 
24 h 
Desired acid 12: 69 %b 
3-methylene-12-phenyldodecanoic 
acid: 20%b 
    
3 3-Methyl-E-ester (11) LiOH (3 equiv.), THF/H2O, 20 °C Less than 50 % conversion after 8 
daysa 
    
4 3-Methyl-Z-ester (13) LiOH (3 equiv.), THF/H2O, 20 °C Less than 50 % conversion after 8 
daysa 
    
5 3-Methyl-E-ester (11) Aq. NaOH (3 equiv.), tBuOH,  
20 °C 
Very little conversion after 5 daysa 
    
6 3-Methyl-Z-ester (13) Aq. NaOH (3 equiv.), tBuOH,  
20 °C 
Very little conversion after 5 daysa 
    
7 3-Methyl-E-ester (11) TMSOK (3 equiv.), anhydrous 
Et2O, 20 °C, 24 h 
Desired acid 12: 71 %b 
Z-Isomer 14: 6 %b 
 
8 3-Methyl-Z-ester (13) TMSOK (3 equiv.), anhydrous 
Et2O, 20 °C, 24 h 
Desired acid 14: 62 %b 
E-Isomer 12: 7 %b 
 
a Observed by TLC; bIsolated after flash chromatography. 
 
Mild conditions using TMSOK to convert esters into anhydrous acid salts were developed by 
Laganis et al.,58 and applied efficiently for methyl esters saponification by Fuwa et al.,59 and was 
attempted on our compounds too. Although the esters were converted faster than with the 
NaOH/EtOH hydrolysis conditions (entries 5 and 6, Table 4), these new conditions led to partial 
isomerisation of the olefin, and both E- and Z- isomers were isolated, yet in a lower extent than in 
the case of the olefin migration described above (see Table 4, entries 7 and 8). Eventually, the 
desired acids could be isolated in satisfying yields using TMSOK as reported by Fuwa et al.59, with 
71% and 62% yield for E-12-phenyldodec-2-enoic acid 12 and Z-12-phenyldodec-2-enoic acid 14, 
respectively. 
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1.2.2. Synthesis of 1,2-diacyl-sn-glycerol 
The acids above obtained were attached to the sn-2 position of a monoacyl glycerol. Thus, 1-
stearoyl-3-O-(para-methoxybenzyl)-sn-glycerol (19) was synthesised in 3 steps from 1,2-O-
isopropylidene-sn-glycerol (see Scheme 3), by PMB-protection in the sn-3 position followed by 
isopropylidene protecting group hydrolysis under acidic conditions, as reported by Lim et al.60 in 53 
% yield over the two steps (65 % reported in the referenced literature).60 Selective esterification of 
the sn-1 position via a Steglich esterification,61 afforded the desired monoacyl glycerol 19 in 70 % 
yield using stearic acid, DCC and catalytic amounts of DMAP at 0 °C, according to the procedure 
described by Greimel et al..62 
 
Scheme 3: Preparation of 1-stearoyl-3-O-(para-methoxybenzyl)-sn-glycerol 19.a 
 
a Reagents. (a): NaH, PMBCl, DMF, 0 – 20 °C; (b): 1M HCl, MeOH; (c): Stearic acid, DCC, DMAP, CH2Cl2, 0-20 °C. 
 
Christensen et al. observed that Steglich esterification of α,β-unsaturated carboxylic acids can result 
in E/Z isomerisation in some instances.63 It was observed that the isomerisation was mediated by 
DMAP and required a proton source64 and thus it was proposed that an excess of base (10 equiv. 
Et3N) could solve the issue.63 Hence, the optimized conditions described by Christensen et al.63 
were applied for the esterification in the sn-2 position of 1-stearoyl-3-O-(para-methoxybenzyl)-sn-
glycerol 19 with with E-12-phenyldodec-2-enoic acid 4. No E/Z isomerisation was observed, 
however, the desired 1-stearoyl-2-(E-12-phenyldodec-2-enoyl)-3-O-(para-methoxybenzyl)-sn-
glycerol (20) was isolated in 30% yield only, as a consequence of double bond migration occurring 
as side reaction (see Scheme 4). The esterification was also conducted with the more classical 
Steglich conditions, without Et3N, adapted from the experimental conditions reported by Kubiak et 
al.,65 this performed smoothly to afford 20 in 88% yield. Very little migration product was observed 
in the crude mixture, no E/Z-isomerisation took place and the desired product could be separated 
after flash chromatography. 
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Scheme 4: Synthesis of 1-stearoyl-2-(E-12-phenyldodec-2-enoyl)-3-O-(para-methoxybenzyl)-sn-glycerol (20) 
 
 
These observations led us to perform a small screening of acylation conditions and methods for 
some of our acids with the monoacylglycerol 19 or its enantiomer: 23: (see Table 5 and Table 6). 
 
It was observed that depending on the conditions applied, either the same kind of by-product as for 
coupling with E-12-phenyldodec-2-enoic acid 4, resulting from olefin migration, or the by-product 
described by Christensen et al.,63 and resulting from an E/Z isomerisation, was formed. It seems that 
the classical Steglich reaction61 was best for the reaction with 4 and the same procedure as for 
synthesis of 20 was tested for the acylation with E-3-methyl-12-phenyldodec-2-enoic acid 12, but 
disappointingly this resulted in partial isomerisation and a mixture of the desired E-α,β-unsaturated 
ester and the by-product Z-α,β-unsaturated ester in the sn-2 position in a 3:1 ratio, observation 
similar to the one reported previously for ATRA (Table 5 entry 8).63  
 
Estimating that the other acids would be as likely to undergo the E/Z isomerisation, the modified 
Steglich reaction conditions, adding 10 equivalents of Et3N was attempted for the coupling of Z-12-
phenyldodec-2-enoic acid 6, where a mixture of the desired diacylglycerol was observed together 
with two by-products resulting from E/Z isomerisation and from olefin migration respectively, in a 
3:3:1 ratio (see Figure 9 and Table 5, entry 3). The same conditions did not result in a clean reaction 
either for the coupling of E-2-methyl-12-phenyldodec-2-enoic acid 8, where two spots of similar 
intensity could be seen on TLC (Table 5, entry 6). It appears from these experiments as well as from 
the saponification reactions, where olefin migration was also observed during the course of the 
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configuration inherent in the Mitsunobu reaction the enantiomer of 19 had to be synthesised if the 
Mitsunobu reaction were to be used for synthesis of our substrates. 
 
Table 5: Reactions conducted for synthesis of the di-acyl-glycerols. 
Entry Acid and alcohol Reaction Conditions Outcome 
 
1 
 
alcohol: 19 
 
DCC, DMAP, CH2Cl2,  
10 equiv. Et3N 
 
Desired diacylglycerol 19: 30% a 
Olefin migration by-product b 
 
 
2  
alcohol: 19 
 
 
DCC, DMAP, CH2Cl2  
 
 
 
20: 88% a 
 
 
 
3 
 
 
 
alcohol: 19 
 
DCC, DMAP, CH2Cl2,  
10 equiv. Et3N 
 
Desired diacylglycerol, isomerized 
diacylglycerol and olefin migration by-
product in approx. 3:3:1 mixture c  
 
 
4 
 
alcohol: 19 
 
2,4,6-Trichlorobenzoyl 
chloride, DMAP, THF 
 
Complete isomerisation to the  
E-ester c 
 
 
5 
 
alcohol: 19 
 
2,4,6-Trichlorobenzoyl 
chloride, DMAP, THF, 10 
equiv. Et3N 
 
2 spots on TLC in about 1:1 mixture d 
 
 
6 
 
alcohol: 19 
 
DCC, DMAP, CH2Cl2,  
10 equiv. Et3N 
 
By-product and desired compound in 
about 1:1 mixture d 
 
 
7 
 
alcohol: 19. test reaction 
 
 
Ph3P, DIAD, THF 
 
 
Desired diacylglycerol, 92 % a 
 
8 
 
alcohol: 19: 
 
DCC, DMAP, CH2Cl2  
 
Desired diacylglycerol and E/Z 
isomerisation product in a 3:1 mixturec 
a isolated yield after flash chromatography; b isolated after flash chromatography; c estimation from crude 1H NMR. d 
estimated from TLC. 
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Table 6: Synthesis of the di-acyl-glycerols by the Mitsunobu reaction. 
Entry Acid and alcohol Reaction Conditions Outcome 
 
1 
 
alcohol: 23: 
 
Ph3P, DIAD, THF 
 
Desired diacylglycerol 24: 93 % a 
 
2 
 
alcohol: 23: 
 
Ph3P, DIAD, THF 
 
Desired diacylglycerol 25: 94 % a 
NB: olefin migrationoccurs upon long 
reaction times. 
 
3 
 
alcohol: 23: 
 
Ph3P, DIAD, THF 
 
Desired diacylglycerol 26: 76 % a 
 
 
4 
 
alcohol: 23: 
 
Ph3P, DIAD, THF 
 
Desired diacylglycerol 27: 68 % a 
 
 
5 
 
alcohol: 23: 
 
Ph3P, DIAD, THF 
 
Desired diacylglycerol 28 74 % a 
 
a isolated yield after flash chromatography; b isolated after flash chromatography; c estimation from crude 1H NMR. d 
estimated from TLC. 
 
Thus, 1-O-(para-methoxybenzyl)-3-stearoyl-sn-glycerol 23 was synthesised in 30% yield over three 
steps from 2,3-O-isopropylidene-sn-glycerol following the same procedure as for the synthesis of 
19. 
 
Scheme 5: Synthesis of 1-O-(para-methoxybenzyl)-3-stearoyl-sn-glycerol 23.a 
 
a Reagents. (a): NaH, PMBCl, DMF, 0 – 20 °C; (b): 1M HCl, MeOH; (c): Stearic acid, DCC, DMAP, CH2Cl2, 0-20 °C. 
 
The Mitsunobu reaction proved to be efficient for the synthesis of esters 24 to 28, affording the 
desired diacylglycerols in yields ranging from 68% to 94% (see Table 6 and Scheme 6). 
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Scheme 6: Synthesis of the di-acyl-glycerols by the Mitsunobu reaction.a 
 
a Reagents: Ph3P, DIAD, THF, acids 6, 8, 10, 12, 14 for the synthesis of 24, 25, 26, 27 and 28 respectively. 
 
For the reaction to afford satisfying yields, two equivalents of the acids were required. This was due 
to by-product formation, which also accounts for the lower yields observed for compounds 26, 27 
and 28. Indeed, an N- acylhydrazine dicarboxylate by-product has been reported in the literature 
(structure A Figure 10),68however, we did not observe this, but rather a related by-product, for 
which the 1H NMR spectrum is in agreement with either tetraacylhydrazine B or N-acylcarbamate C 
Figure 10.  
 
 
Figure 10: Formation of side products in the Mitsunobu reaction. A: side product reported in the literature;68 B 
and C: plausible structures for the by-product isolated in our reactions. 
 
1.2.3. Synthesis of glycerophospholipids 
With the 1-stearoyl-2-α,β-unsaturated-acyl-3-O-(para-methoxybenzyl)-sn-glycerol derivatives in 
hand, we could deprotect the sn-3 position and install the head groups. Removal of the PMB 
protecting group was accomplished with DDQ in a biphasic system of CH2Cl2 and phosphate buffer 
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(pH 7)69 in order to avoid any potential acyl migration to the sn-3 position (see Scheme 8). The 
deprotection proceeded in satisfying yields (77%, 80% and 80% respectively for compounds 24, 20 
and 26 respectively), although slightly lower yield were obtained for compounds 25, 27 and 28, 
with yields of 60%, 60% and 62% respectively (see Scheme 8). The lower yields were obtained for 
compounds that eluted very close to the anisaldehyde resulting from the oxidative cleavage of PMB 
on flash chromatography, resulting in more challenging purification of the desired compounds. 
A new route to access the PG lipids using 2,3-di-O-(tert-butyldimethylsilyl)-sn-glycero-2-
cyanoethyl-N,N-diisopropylphosphoramidite 32 was developed by Pedersen et al.,42 and 
successfully applied in the synthesis of several asymmetric diacyl phosphatidylglycerol 
phospholipids.70,71 The strategy was thus applied to our substrates, and the phosphoramidite 32 
precursor for the PG head group was synthesised from allyl alcohol in 70 % yield over 4 steps (see 
Scheme 7). The alcohol was protected with para-methoxybenzoyl chloride to give 29 in excellent 
yield. The resulting allyl ester was subjected to Sharpless asymmetric dihydroxylation,72,73 which 
performed in excellent yield and enantioselectivity (ee 97%, chiral HLPC) to afford 1-(para-
methoxybenzoyl)-sn-glycerol. The crude diol was protected with TBSCl to afford 30 in excellent 
yield and deprotection of the sn-1 position with diisobutylaluminium hydride (DIBAL-H) at -78 °C 
gave the primary alcohol 31. Finally, this was reacted with 2-cyanoethyl N,N-
diisopropylchlorophosphoramidite under basic conditions, to afford the phosphoramidite 32 as 1:1 
diastereoisomeric mixture, as described in the literature,42 however, the original characterization of 
the compound was incorrect, as the cyanoethyl protons were not reported. 
 
Scheme 7: Synthesis of the phosphoramidite 32, precursor for the PG head group.a 
 
aReagents: (a) para-Methoxybenzoyl chloride, Et3N, DMAP, CH2Cl2; (b) (i) K2OsO4·2H2O, (DHQD)2PHAL, 
K3Fe(CN)6, K2CO3, tBuOH, H2O; (ii) TBSCl, imidazole, DMF; (c) DIBAL-H, CH2Cl2; (d) 2-cyanoethyl N,N-
diisopropylchlorophosphoramidite, DIPEA, CH2Cl2. 
 
With the 1,2-diacyl-sn-glycerol derivatives and phosphoramidite 32 in hand, we could carry out the 
synthesis of the desired lipids. The reaction sequence described by Pedersen et al.42 was the 
inspiration for coupling of the PG head-group and the subsequent deprotections (see Scheme 8). 
The phosphoramidite coupling to the diacylglycerol was catalysed by tetrazole in CH2Cl2,74 and 
followed by oxidation of the phosphite to the phosphate by tBuOOH. The cyanoethyl protecting 
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group was removed with 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) in CH2Cl2, and the TBS 
groups were cleaved with 40% aq. HF in a mixture of CH2Cl2 and MeCN at 0 °C (see Scheme 8). 
The yields observed were generally consistent from substrate to substrate, except for the final HF-
mediated deprotection step: addition of HF was performed at 0 °C, but when the reaction mixture 
was allowed to reach 20 °C as proposed in the original literature,42 we observed hydrolysis of the 
phosphate head group, which was not the case when the reaction mixture was kept at 0 °C and this 
dramatically decreased the efficacy of the reaction (yields in the range of 30% were obtained for the 
last deprotection, while yields neighbouring 80% were generally obtained when the reaction 
mixture was kept at 0 °C). This explains the differences in yields obtained for the different lipids: 
lipids 40, 41 and 42 where reaction temperatures evolved from 0 to 20 °C, while lipids 39, 43, 44 
were kept at 0 °C during the final TBS-deprotection step. 
 
Scheme 8: Synthesis of phospholipids 39 to 44a 
 
a Reagents: (a): DDQ, buffer (pH 7), CH2Cl2; (b) (i): tetrazole, CH2Cl2, MeCN; (ii) tBuOOH; (iii) DBU, CH2Cl2; (iv) 
HF, H2O, CH2Cl2, MeCN. 
 
The synthesis of the fully saturated diacyl-glycerophospholipid was attempted by direct 
hydrogenation of the lipid 39 using activated palladium on charcoal (Pd/C) and H2 in EtOAc, after 
16 h, full conversion of 39 was observed, yet a crude NMR showed the presence of a by-product, 
which could not be separated by flash chromatography. Therefore it was decided to reduce the 
olefin in an earlier step. To this end, 1-stearoyl-2-(12-phenyldodecanoyl)-sn-glycero-3-phospho-(S)-
glycerol 45 was synthesised from the diacyl-glycerol 20 in 47% yield over 6 steps. The PMB group 
was first removed using DDQ in CH2Cl2/buffer (pH 7), then the PG-headgroup was installed in the 
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sn-3 position by reaction with 32 and tetrazole in CH2Cl2/MeCN, the phosphite was oxidised to the 
phosphate by tBuOOH and the labile cyanoethyl group was displaced by treatment with DBU. The 
resulting TBS-protected phosphatidylglycerol derivative was at that stage reacted with Pd/C and H2 
in EtOAc, a reaction that performed cleanly and quantitatively and was completed after 14h. 
Finally, 45 was obtained after treatment with 40% aq. HF in CH2Cl2/MeCN at 0 °C. 
 
Scheme 9: Synthesis of 1-Stearoyl-2-(12-phenyldodecanoyl)-sn-glycero-3-phospho-(S)-glycerol.a 
 
a Reagents: (a): DDQ, buffer (pH 7), CH2Cl2; (b) (i): (2,3-di-O-tert-butyldimethylsilyl)-sn-glycero-2-cyanoethyl-N,N-
diisopropylphosphoramidite 32, tetrazole, CH2Cl2, MeCN; (ii) tBuOOH; (iii) DBU, CH2Cl2; (iv) Pd/C, H2, EtOAc; (v): 
HF, H2O, CH2Cl2, MeCN. 
 
1.2.4. Synthesis of the lysolipid 
The lysolipid (48) was synthesised from the mono-acylated glycerol derivative 19 (see  
 
 
 
Scheme 10). The sn-2 position was first protected with TBSCl, via imidazole catalysis in DMF to 
give 46.75 TBS was chosen for protection of the sn-2 position for its stability to the conditions for 
PMB deprotection and head group attachment, but also for the convenient possibility to remove it 
and the TBS protection groups on the head group simultaneously. The following reactions have 
been performed as for the other lipids discussed above: The PMB group was removed with DDQ in 
CH2Cl2/buffer (pH 7) to give 47, addition of the protected PG head group was performed with (2,3-
di-O-tert-butyldimethylsilyl)-sn-glycero-2-cyanoethyl-N,N-diisopropylphosphoramidite 32, in 
CH2Cl2/MeCN and catalysed by tetrazole and the phosphite was oxidized to the phosphate by 
tBuOOH. The cyanoethyl group was cleaved by DBU in CH2Cl2, and the three TBS groups were 
removed simultaneously upon treatment with 40% aq. HF in CH2Cl2, MeCN at 0 °C, affording the 
desired lysolipid 1-stearoyl-sn-glycero-3-phospho-(S)-glycerol 48 in 52% yield over the last four 
steps. Lysolipid 48 was prepared as a reference compounds, since it is the product of sPLA2 
hydrolysis of all the substrates 39-45. 
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Scheme 10: Synthesis of 1-stearoyl-sn-glycero-3-phospho-(S)-glycerol.a 
 
a Reagents: (a): TBSCl, imidazole, DMF; (b): DDQ, buffer (pH 7), CH2Cl2; (c) (i): (2,3-di-O-tert-butyldimethylsilyl)-
sn-glycero-2-cyanoethyl-N,N-diisopropylphosphoramidite 32, tetrazole, CH2Cl2, MeCN; (ii) tBuOOH; (iii) DBU, 
CH2Cl2; (iv) ): HF, H2O, CH2Cl2, MeCN. 
 
1.3. Liposome formulation and enzyme activity 
The phospholipids 39 to 44 and 45 were first formulated as multilamellar vesicles in 4-(2-
hydroxyethyl)-piperazine-1-ethanesulfonic acid (HEPES) buffer by the dry lipid film technique:76 
the phospholipids were solubilized in CHCl3 and the solvent was evaporated in vacuo to form a dry 
lipid thin film. HEPES buffer was added in order to obtain 2 mM suspensions of the lipids, and the 
lipids were solubilized upon heating the mixture to 50 °C and periodically vortexed. This resulted in 
a milky suspension of multilamellar vesicles that was extruded through a 100 nm polycarbonate 
filter at 20 °C in order to obtain the desired monolamellar liposomes as a transparent solution. The 
thereby obtained particles sizes were measured by Dynamic Light Scattering (DLS), and we 
observed that all the phospholipids were forming particles of about 100 nm, which is the typical 
liposome size region and indicates formation of unilamellar vesicles, with a low polydispersity, 
which confirms the homogeneity of the vesicles constituents (see  Table 7). 
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 Table 7: DLS analysis of the formulated phospholipids 39 to 45 
Compound                         Particle size  
 Diameter (nm) PdIa 
39 
 
 
 
94 
 
 
0.253 
40 
 
116 0.070 
41 
 
84 0.139 
42 
 
96 0.295 
43 
 
109 0.113 
44 
 
106 0.077 
45 108 0.196 
aPdI = polydispersity index 
 
DSC scans (10–70 °C) of the phospholipid 39 to 45 displayed no phase transitions in the tested 
temperature range indicating that the phospholipid bilayers are in a fluid state at room temperature 
as well during the sPLA2 experiments conducted at 37 °C. This is not surprising since the phase 
transition temperatures decrease when the length of the aliphatic chains decreases (the phase 
transition temperatures of DSPG, DPPG and DMPG are 55 °C, 41 °C and 23 °C, respectively), and 
drastically decreases when unstauration is introduced in the aliphatic chains (the phase transition 
temperatures of POPG, DLPG and DOPG are -2 °C, -3 °C and -18 °C, respectively). The saturated 
lipid (45) was the most likely phospholipid to possess a phase transition temperature above 15 °C, 
but even that compound did not show any transition phase in the tested temperature range  
The ability of sPLA2 to degrade the synthesised lipids 39 to 45 was studied by incubating the 
formulated liposomes with human tears at 37 °C, and sampling was done after 1, 2, 4, 8, 24, 48 and 
96 h. The tear fluid was obtained after breathing of vapour of onions, and it has been shown that 
sPLA2 content in tears was amongst the highest in human secretions,77 being highest in the age-
group 20-29 years (81.6 ± 32.0 µg/mL),78,79 fitting with the age of the subject. The samples were 
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analysed by matrix-assisted laser desorption/ionization - time of flight - mass spectrometry 
(MALDI-TOF-MS), a method that proved very efficient, fast and sensitive for the detection of 
lipids.80,81,82 The matrix applied on the sample target consisted in 2,5-dihydroxybenzoic acid (DHB) 
and CF3COONa in methanol and an internal standard 1,2-dimyristoyl-sn-glycero-3-
phosphatidylglycerol (DMPG), that would not interfere with the masses of the synthetic lipids, was 
also added to the matrix. Since constant quantities of matrix and sample were applied on the 
MALDI target, we estimated that the average signal measured for the phospholipids could be 
normalised with the internal standard, and the normalised signals were compared to study the extent 
of hydrolysis on each potential substrate. This method has been efficiently used for similar purpose 
by Linderoth et al.83 and by Pedersen et al..42,70 
HPLC analysis was also considered as a potential tool to obtain a more quantitative picture of 
sPLA2 hydrolysis capacity of each potential substrate. This is the reason why a phenyl ring was 
introduced on the sn-2: we looked for a UV-active functionality that would not disturb the 
hydrophobic chains packing. Thus, a rather small phenyl ring was seen as the best compromise, any 
larger aromatic system (such as a naphthalene group) or a system of conjugated olefins would most 
probably influence the packing of the phospholipids and might hinder formulation into liposomes 
and/or change the electronics in the vicinity of the sn-2 position, thereby influencing the properties 
we wished to investigate. 
The MALDI-TOF hydrolysis profiles of the reference substrate (saturated lipid 45), a good sPLA2 
substrate (E-unsaturated lipid 39) and a poorly-hydrolysed lipid (43, with a (E)--methyl substituted 
sn-2 fatty acid) are shown in Figure 11. All results are summarized in Table 8 and it is evident from 
the data that while unsaturation is tolerated to some degree by sPLA2 (entry 2 and 3), α- or -methyl 
substitution of the sn-2 fatty acid affords poor (entries 5 and 7) or completely resistant (entries 4 
and 6) substrates for the enzyme.  
 
Table 8: Hydrolysis of phospholipids 39-45 by sPLA2 as monitored by MALDI-TOF MS. 
Entry Lipid Structure Ratioa Hydrolysis after 96 hb 
1 45 Saturated 0.04 96% 
2 39 (E)-unsaturated 0.04 96% 
3 40 (Z)-unsaturated 0.32 68% 
4 41 (E)-α-methyl -c -c, <1% after 48hd 
5 42 (Z)-α-methyl 0.85 15% 
6 43 (E)--methyl 1.04 <1% 
7 44 (Z)--methyl 0.72 28% 
a. The ratio between the MS signal from the sPLA2 treated liposome solution (average of two independent experiments) 
and the control of the same liposome without added enzyme after 96 h, after normalisation using the internal standard 
 (DMPG); b. 
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substituted sn-2 fatty acid). The signals were normalised to that of the internal standard (DMPG, m/z (M+H+) = 
689) to allow for comparison of the lipids signal intensities. 
 
1.4. Molecular dynamics simulations 
Previously, MD simulations have been used to study the behaviour of sPLA2 and rationalize 
experimental observations. This was also the case for the inability of the enzyme to hydrolyze the 
ATRA prodrug, which prompted our study of the influence of unsaturation and substitution at the 
sn-2 position.70 In order to better understand how well the computational method can predict and 
explain experimental observations, we have carried out similar MD simulations for the seven 
phospholipids 39-45. The MD simulations described in the following were carried out by Dr. 
Vijayakumar Vinodhkumar and Assoc. Prof. Günther H. Peters, DTU Chemistry. 
 
1.4.1. Molecular dynamics results 
The overall stability of the protein structure in the simulations was verified by calculating the time 
evolution of the root mean square deviation (rmsd) of the amino acid Cα atoms with respect to the 
protein structure after minimisation. In all simulations, the rmsd reached a constant average value of 
~2 Å within a few nanoseconds (<5 ns; data not shown). The rmsd data slightly varied between the 
different simulations performed for the same complex as well as for the different complexes. 
However, the variations amounted to only ±0.5 Å indicating that the protein structure is stable over 
the time course of the simulations. 
 
 
Figure 12: Representation of the active site in sPLA2 with hydrogen bonds and ionic interactions indicated with 
dashed bonds. Key protein residues are drawn in blue, the substrate in red, the calcium ion and the water 
molecule both in brown. The two grey circles indicate the H–S region, where the overlap in dark grey represents 
the water count region. Amino acid labels and atom types indicated in parentheses refer to the Protein Data 
Bank nomenclature. 
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At least two conditions have to be fulfilled for the enzyme-catalysed reaction to occur. Firstly, a 
stable Michaelis-Menten complex has to form, and secondly, water molecules have to reach the 
active site to perform the nucleophilic attack on the substrate. Previous work has shown that both 
criteria can be used successfully to predict from simulation if a phospholipid analogue is a potential 
substrate for sPLA2.84. In the previous study of the ATRA prodrug, two parameters were studied: 
the access of water to the catalytic site and the geometry of the enzyme-substrate complex. It was 
found from the simulations that the prodrug examined both had a distorted and thus non-productive 
Michaelis-Menten complex and that the relative water count was lower than for the simulations 
with the natural substrate (DPPG). Therefore, we apply the same strategy in the following study. 
We first recorded the entry of water molecules into the binding site. In particular, we were 
interested in those water molecules that reach the region between His 47(ND1) and the substrate 
carbonyl carbon S(C21) (Figure 12), since this is where a water molecule needs to be positioned for 
hydrolysis. The region between these two residues will hereafter be referred to as the H-S region. 
The relative water count at 3.5, 4.0 and 4.5 Å is plotted in Figure 13. The saturated lipid 45 is a 
good substrate for sPLA2 (vide supra) and its results will be used for comparison to the other lipids. 
The probability of observing a water molecule at a certain distance from H-S varies slightly 
between the ester lipids. As can be seen from Figure 13, water molecules were able to enter H-S, 
and the results for ester lipids 39–44 were comparable to 45. Ester lipids 39 and 43 showed a 
relative water count that is higher than for 45. From this, we conclude that both ester lipids should 
show a higher activity towards sPLA2 than 45. Since these results are not in agreement with the 
experimental data (39 is as good a substrate as 45, while 43 is not a substrate, see Table 8), we 
conclude that the criterion of water accessibility to the active site is not sensitive enough to 
distinguish between the ester lipids. This may be expected since the structural changes between the 
ester lipids are local and placed close to the carbonyl carbon in the sn-2 position and thus unlikely 
to affect the flux of water molecules.  
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Figure 13: Relative water count extracted from the MD simulations. Before calculating the averages, the data 
were normalised by the water count at 6 Å, since there were significant differences in the water count within a 
single series of simulations. Mean and standard deviations (SD) are based on a series of independent simulations 
of each complex. 
 
Since the water count data were not conclusive, we returned to the stability of the Michaelis-Menten 
complex and monitored the distances in the complex. We have chosen distances involving the 
cofactor calcium, the carbonyl group in the phospholipid analogue and selected atoms in amino acid 
residues that are in the vicinity of the substrate. Mean distances and standard deviations (SD) for the 
different phospholipids are shown in Figure 14. For simplicity, we report here only distances 
between calcium and S(O22), as well as the distances Asp 91(OD1)-Tyr 51(OH), His 47(HE2)-Asp 
91(OD1) and His 47(ND1)-S(C21). Atom types and S refer to the Protein Data Bank nomenclature 
and substrate, respectively, and those are displayed in Figure 12. As shown in Figure 14, there are 
relatively large deviations. Standard deviations > ~0.4 are observed in all four distances for the ester 
lipids 41, 42 and 43. More importantly, most of the ester lipids cause a distortion of the His 
47(ND1)-S(C21) distance (Figure 14D), where the distances ±SD for 41 and 42 lie clearly above 
the distance measured for 45 indicating that these lipids cannot be hydrolysed by sPLA2. Similarly, 
for 40, 43 and 44 the mean His 47(ND1)-S(C21) distance lay outside the variation of the distance 
for the saturated lipid 45. This is more pronounced for 43 than for 40 and 44 suggesting that 43 is 
not a substrate, whereas 40 and 44 could be substrates but should not be hydrolysed very efficiently 
by sPLA2. That 43 is not a substrate is further supported by the relatively large standard deviation 
observed for the Ca2+-S(O22) distance (Figure 14A). The Michaelis-Menten complexes resulting 
from the MD simulations are illustrated in Figure 15 for the saturated substrate 45 (A) and the 
resistant lipid 43 (B). 
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evaluate putative substrates. Furthermore, we have established that while α,β-unsaturation is 
tolerated either very well (for trans geometry) or somewhat (for cis geometry), substitution, even by 
a relatively small methyl group, is not. Taken together, the results described here will help guide the 
development of future prodrug substrates that rely on triggered release by sPLA2 in tumour tissue.   
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2. Synthesis of functionalized lipids for reactivity studies on liposome surfaces 
 
2.1. Surface modified liposomes as pharmaceutical carriers 
As mentioned in section 1.1, while liposomes are used as DDS, they also have potential application 
as imaging agent delivery systems.86 The main early issue related to the use of liposomes which 
hindered their clinical applications was their short blood lifetimes, due to elimination by the cells of 
the reticulo-endothelial system (RES) primarily in the liver, which also resulted in a poor selectivity 
for the tissues of interest. However, a number of improvements have aimed at and contributed to 
reducing these problems. Modification of the liposomes surface by grafting biocompatible polymers 
such at PEG, improved the liposomes circulation longevity and reduced uptake by the RES organs. 
Indeed, due to their flexibility and high mobility, the PEG chains grafted to the liposomes 
(generally 3-7% for optimal circulation longevity) mask the surface of the liposomes, and thereby 
reduce nonspecific interaction with various plasma components. Therefore, the PEG-grafted 
liposomes, often referred to as STEALTH liposomes in the literature, have extended half-lives in 
the bloodstream (≥48 h in humans), and their uptake by the liver is reduced.85 As a result of their 
extended blood circulation, and because of the disrupted vasculature found in certain pathological 
conditions, liposomes can accumulate in diseased tissues. This is the case for instance in inflamed 
tissues and in solid tumours, where larger gaps are found between endothelial cells to enable 
leukocytes and other signalling molecules to extravasate. Thus, contrary to healthy tissues with tight 
blood vessels, gaps between adjacent endothelial cells can be as large as 600 to 800 nm in 
angiogenic tissues, enabling small unilamellar vesicles as liposomes (100 nm to 200 nm diameter) 
to extravasate and localize in the tissue interstitial space. Moreover, the impaired lymphatic 
drainage, characteristic for tumours, allows accumulation of the liposomes. This passive 
concentration of long circulating liposomes in tumours taking advantage of diseased tissues biology 
is known as the enhanced permeability and retention (EPR) effect.4 
If long circulating liposomes can accumulate in a passive way via the EPR effect in inflamed tissues 
and solid tumours, the selectivity for the diseased tissues, even in those cases, is not complete. In 
order to obtain better selectivity, targeted liposomes have been suggested, that display on their 
surfaces ligands capable of recognizing cell surface receptors and binding to the cells of interest. To 
that end, the most widely used targeting moieties are immunoglobulins and their fragments, but 
other proteins, peptides, and small molecules such as folic acid or carbohydrates and vitamins have 
also been used. Because of the short blood stream half-lives and low systemic exposure of the early 
liposomes, ligand-mediated targeting has been for a long time an elusive goal. However, after the 
development of the long circulating PEG-modified liposomes, ligand mediated targeting gained 
interest and applicability.86,85 Ligand-targeted liposomes can be internalized into endosomes and 
deliver their content directly into the cell, which can result in a better drug efficiency, when they 
display ligands against an internalizing receptor. This is the case for the folate-modified 
liposomes.86 
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Because of that need for PEG-liposomes decorated with various ligands, several strategies have 
been devised for the development of surface-modified liposomes, these are depicted in Figure 16. 
Strategies consisting of introducing the ligand directly on the polar head-group of lipids later on 
formulated with PEG-liposomes have been described in the literature (see Figure 16A),87 but only 
display poor target binding because the highly flexible PEG-chains hide the ligand and result in a 
steric barrier between the ligand and the targeted receptor.85 Therefore it became more attractive to 
attach the ligand at the distal end of the PEG chains. Hence, a number of end group functionalized 
pegylated lipids have been developed. Incorporation of the ligand-bearing PEG-lipid in liposomes 
have been done in three different manners. In some instances, PEG-lipids with a reactive functional 
group at the distal end of the PEG chain were incorporated in the liposomal formulation, and then 
conjugated with the desired ligand to that reactive group on the formulated liposome, as in Figure 
16B. This strategy is more suitable for macromolecular ligands such as immunoglobulins. However, 
a drawback of this strategy lies in the obtention of ligand-bearing liposomes that still display 
unreacted functional end groups on the inner monolayer in any case, and also in the outer 
monolayer if the conjugation is not complete. The unreacted functional groups can then take part in 
side reactions with water or drug molecules. Moreover, there is a possibility of cross-linking 
through several potential reactive sites of a single ligand. Another approach consists in formulating 
the liposomes with lipids displaying the ligand of interest at the distal end of the PEG chain and 
other common lipids such as PC and cholesterol, as was performed by Gabizon et al. in their 
synthesis of folate receptor-targeted liposomes (see Figure 16C).88 This method is suited for low 
molecular weight ligands, e.g. peptides, oligosaccharides or vitamins. However, with this method, 
only a little over half (55-60%) of the ligands linked to the lipids will be on the outer layer and 
effective in binding to the targeted receptor, since the other half is situated on the inner layer of the 
liposome, and thus is entrapped in the core of the liposome. Finally, a methodology of insertion of 
ligand-PEG-DSPE into preformed liposomes, depicted in Figure 16D, has been developed. This is 
done by incubating the ligand-PEG-DSPE (1.2-1.5%) with the preformed liposomes containing 2-
3% PEG-DSPE at 37 °C, and results in positioning of the PEG-tethered ligands exclusively at the 
outer surface of the lipid bilayer, with similar external surface densities of ligand-derived lipids 
incorporation as in the lipid mixing followed by extrusion process. This method has been performed 
with oligosaccharides and peptides conjugates successfully, and overcomes the drawbacks of the 
two previously mentioned methods.85 
Various methods have also been developed for the coupling of ligands on functionalized liposomes 
(case B, Figure 16), employing different end-group functionalized PEG-lipids. Some of these 
methods are summarized in Figure 17. Click chemistry has also been exploited for that purpose, 
examples of such applications are presented in Figure 18 (section 2.3). 
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Figure 17: Overview of reported methods for the coupling of ligands on functionalized liposomes. A: direct 
coupling of an antibody to an activated ester at the distal end of a pegylated DPPE.89 B: formation of a 
maleimide functionalized lipid from an aminoterminated PEG-DPPE followed by 1,4-addition of the cysteine 
thiol of a cyclic peptide.90 C: synthesis of a pyridyldisulfide functionality that was reduced to the mercaptane and 
conjugated to a maleimide functionalised antibody.91,92 D: chloroacetylation of the distal amino group followed 
by nucleophilic attack of a peptidic cysteine.91 E: example of the formation of an activated carbamate, which was 
reacted with 3-aminopropane-1,2-diol and oxidized to afford an aldehyde-terminated lipid.91 F: direct 
conjugation of an N-Boc protected hydrazide to DSPE, followed by deprotection and hydrazone formation to 
attach a peptide through an oxidized N-terminal threonine residue.93,94 G: amidation with folic acid on an amino 
terminated DSPE-PEG lipid.95 H: formation of a cysteine lipid applied for native chemical ligation of a protein 
thioester.96 I: the application of a double activated PEG-carbonate to first functionalise DSPE followed by the 
non-specific attachment of a polycationic TAT peptide.97,98 
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Despite the number of methods reported thus far, very few (click chemistry, Staudinger ligation and 
native chemical ligation) are truly chemoselective, and coupling generally result in poor control of 
the site of reaction for instance when peptides are involved, hence the interest in investigating and 
developing other chemoselective (or more chemospecific) ways to couple ligands on functionalized 
liposomes. 
We intended to investigate the click reaction for the coupling of ligands with a functionalized PEG-
grafted liposome, and developed a new, selective method for ligand coupling using progargyl 
amines and isothiocyanate derivatives. The syntheses of the lipids for those two separate studies 
were based on the same strategy. Therefore the syntheses will be discussed together in the following 
section. The study on the click chemistry will be developed in section 2.3, while the new 
conjugation method by formation of iminothiazolidines will be discussed in section 2.4. 
 
2.2. Synthesis of the functionalised lipids of interest 
As described in paragraph 1.2, enantiomerically pure glycerolipids can be obtained from 1,2-O-
isopropylidene-sn-glycerol. Contrary to the previous project, we chose to work here with ether 
lipids, which requires new reaction conditions, but will also provide more stable target compounds. 
General synthetic routes to 1,2-di-O-alkyl-sn-glycerolipids have been well established99 also 
starting from 1,2-O-isopropylidene-sn-glycerol.100,101,102,103 We envisioned that ether bond 
formation would be more difficult on a 1,2-di-O-stearyl-sn-glycerol, where the sn-3 position can be 
“buried” in the aliphatic chains, and thereby hindered. Thus, we decided to install the tetraethylene 
glycol (TEG) at an early stage. Therefore, the commercially available TEG was protected at one 
end via monobenzylation, and activated at the other end by introduction of a methanesulfonate 
leaving group in excellent yield according to a procedure described by Kunze et al.,103 by treatment 
with methanesulfonyl chloride (MsCl) and Et3N in CH2Cl2 (see Scheme 11). Insertion of the 
benzyl-protected TEG to the sn-3 position of the 1,2-protected glycerol moiety also performed 
smoothly (see Scheme 11), after some improvement of the protocol reported by Kunze et al.103 
Indeed with the conditions described in the literature, 51 was isolated in 64% yield. It was 
attempted to add a slight excess of the mesylate, but this resulted in lower yield. On the contrary, 
using 1.5 equivalents of the protected glycerol resulted in an improvement, with 51 isolated in 76% 
yield.  
The enantiomer of 51, 1-O-(13-phenyl-3,6,9,12-tetraoxatridecanyl)-2,3-O-isopropylidene-sn-
glycerol was reported by Kunze et al.,103 with synthetic schemes and compound names being in 
accordance with the enantiomeric series. However, the isopropylidene glycerol reported as the 
starting material in the synthesis is drawn as the (R)-(–)-enantiomer, but reported in the 
experimental section to have an optical rotation of +15.0, consistent with the (S)-(+)-enantiomer. 
Consequently, the authors have in fact prepared the same series of compounds as seen in Scheme 
11, but reported them as the other antipodes. The characterization data confirms this, specifically, 
the optical rotations of the starting protected glycerol as well of compound 51 are both in agreement 
with the data reported by Kunze et al.103  
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Scheme 11: Synthesis of 1,2-O-isopropylidene-3-O-(13-phenyl-3,6,9,12-tetraoxatridecanyl)-sn-glycerol (51).a 
 
a Reagents: (a): NaH, BnBr, DMF; (b): MsCl, Et3N, CH2Cl2; (c): KOH, DMSO, 1,2-O-isopropylidene-sn-glycerol. 
 
Different methods were tested to perform the monobenzylation in good yield (see Table 9).The first 
method applied was to have a slight excess of the TEG (1.7 equivalents) compared to BnBr in THF, 
following a protocol described by Coppola et al.,104 but the yields obtained varied from one reaction 
to another, and could get as low as 51%. It was also attempted to obtain the monobenzylation upon 
phase transfer catalysis, using tetrabutylammonium hydrogen sulphate (TBAHS) in a biphasic 
system of aqueous NaOH (1.3M) and CH2Cl2, as reported by Csuk et al.,105 however whereas high 
yields were reported for the substrates in the original paper, only 20 to 25% were obtained on our 
system (see Table 9, entry 2). We finally decided to use a large excess of the TEG (5 equivalents) 
compared to the BnBr in DMF, which gave a much better result with the monobenzylated TEG 49 
was obtained in 92% yield. The excess reagent was not lost, since the unreacted TEG was recovered 
after purification by flash chromatography (see Table 9, entry 3). 
  
43 
 
Table 9: Conditions tested for monobenzylation of TEG. 
Entry Experimental conditions Outcome 
   
1 1.7 equiv. TEG, 1.7 equiv. NaH, 1 equiv. BnBr, THF, 20 °C 49: 51% to 76% yieldsa 
(not consistently reproducible) 
 
2 Phase transfer catalysis:1 equiv. TEG, aq. NaOH (1.3 M), 
0.2 equiv. TBAHS, CH2Cl2, 40 °C, 24h 
 
49: 20% to 25%a 
Only partial conversion of TEG 
3 5 equiv. TEG, 5 equiv. NaH, 1 equiv. BnBr, DMF, 20 °C 49: 92%a
Unreacted TEG recovered (68%) 
a Isolated yields after flash chromatography 
 
Once the protected TEG had been added to the sn-3 position, the isopropylidene was cleaved by 
hydrolysis, in the same way as for the synthesis of compounds 18 and 22 in excellent yield, and the 
octadecanyl chains were attached to the sn-1 and sn-2 positions in one step (see Scheme 12). 
 
Scheme 12: Synthesis of 1,2-di-O-octadecyl-3-O-(13-phenyl -3,6,9,12-tetraoxatridecyl)-sn-glycerol 53.a 
 
a Reagents: (a): HCl (1M in MeOH), MeOH; (b): bromooctadecane, KOH, DMSO. 
 
Several reactions were conducted for the alkylation of the sn-1 and sn-2 positions before effective 
and efficient experimental conditions could be found. Williamson ether syntheses were first 
attempted, using bromooctadecane, NaH (2.5 equivalents) as base in different solvents and 
temperatures (THF at 20 °C, THF at 66 °C, DME at 85 °C and DMF at 153 °C), but only small 
amounts of the desired product was isolated, and instead the main product resulted from elimination 
of bromide (see Table 10, entries 1-4). Neither the recourse to tetrabutylammonium iodide (TBAI) 
catalysis, nor to other base with crown ether (KH with 18-crown-6) improved the previous results 
(see Table 10, entries 5 and 6). The use of a stronger base system, KOH in DMSO revealed much 
more effective, both with bromooctadecane and with its tosyl counterpart (see Table 10, entries 7 
and 8), and reactions with both electrophiles gave comparable results. However, octadecyl para-
toluenesulfonate 54 had to be synthesised in one step from octadecanol according to the procedure 
described by Yang et al,106 and it was preferred to work further with the bromine derivative. 
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Table 10: Reaction conditions tested for the synthesis of 1,2-di-O-octadecyl-3-O-(13-phenyl-3,6,9,12-
tetraoxatridecanyl)-sn-glycerol 53. 
Entry Reaction condition Outcome 
 
1 
 
4 equiv. C18H37Br, 2.4 equiv. NaH, THF, 20 °C, 19h 
 
53: <10% isolated 
Mainly C16H33-CH=CH2 isolated a 
 
2 4 equiv. C18H37Br, 2.4 equiv. NaH, THF, 66 °C, 19h idem a
 
 
3 4 equiv. C18H37Br, 2.4 equiv. NaH, DME, 85 °C, 19h idem a
 
 
4 4 equiv. C18H37Br, 2.4 equiv. NaH, DMF,  
153 °C, 19h 
idem a
 
 
5 3 equiv. NaH, 3 equiv. C18H37Br, 5% equiv. TBAI, THF, 0 
to 20 °C, 19h 
idem a
 
 
6 3 equiv. KH, 10 equiv. 18-crown-6, 3 equiv. C18H37Br, 5% 
equiv. TBAI, THF, 0 to 20 °C, 19h 
 
idem a
 
7 3 equiv. C18H37OTsb, 5 equiv. KOH, DMSO, 20 °C, 14h 53: 65%a 
C16H33-CH=CH2 also isolated 
 
8 4 equiv. C18H37Br, 5 equiv KOH, DMSO, 20 °C, 22h 53: 60 to 68%a 
C16H33-CH=CH2 also isolated 
 
aIsolated after flash chromatography; bsynthesised from C18H37OH according to the procedure described by Yang et 
al.106 
 
With 1,2-di-O-octadecyl-3-O-(13-phenyl-3,6,9,12-tetraoxatridecanyl)-sn-glycerol 53 in hand, the 
desired functionalized lipids could be synthesised over 2 to 3 steps. The benzyl group was first 
cleaved by palladium catalysed hydrogenolysis to give 55, and the resulting alcohol was either 
reacted with 4-pentynoic acid, EDC·HCl and DMAP to give 1,2-di-O-octadecyl-3-O-(3,6,9,12-
tetraoxa-13-oxo-heptadec-16-yn-1-yl)-sn-glycerol 56 or with 5-azidopentanoic acid, EDC.HCl and 
DMAP to give 1,2-di-O-octadecyl-3-O-(17-azido-3,6,9,12-tetraoxa-13-oxo-heptadecan-1-yl)-sn-
glycerol 57.107 The Keck esterification performed in very satisfying yields to afford both lipids 56 
and 57 in 93% and 86%, respectively (see Scheme 13). 
1,2-Di-O-octadecyl-3-O-(12-aza-3,6,9,12-tetraoxa-pentadec-14-yn-1-yl)-sn-glycerol 59 was 
obtained after mesylation of 55 followed by mono-N-alkylation of propargylamine inspired by a 
procedure reported by Xiong et al.,108 in 63% yield over the two steps (see Scheme 13). It is to be 
noted that bis-alkylated progargyl amine was also isolated after flash chromatography upon longer 
reaction times, despite the fact that an excess propargylamine was reacted compared to the mesyl 
derivative, reducing the yield of the alkylation reaction down to 38% yield after 24 h reaction, 
instead of 79% yield when the reaction was stopped after 3.5 h.  
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Scheme 13: Synthesis of functionalized lipids 56, 57 and 59.a 
 
a Reagents: (a): Pd/C, H2, EtOAc; (b): 4-pentynoic acid, EDC.HCl, DMAP, CH2Cl2; (c): 5-azidopentanoic acid, 
EDC·HCl, DMAP, CH2Cl2; (d): Et3N, MsCl, CH2Cl2, (e): propargyl amine, Et3N, Bu4NI, THF. 
 
2.3. Study of the copper catalysed click reaction on functionalized lipids 
As described in section 2.1, a number of methods has been developed and used to modify liposome 
surfaces and attach targeting agents. However, most covalent anchoring methods used in the 
literature are not specific, and result in a lack of control in the formation of covalent bonds between 
the liposomes and the ligand of interest (generally peptides or polypeptides). On the contrary, the 
[3+2] cycloaddition between azides and alkynes offers several advantages in comparison with other 
coupling methods, especially since both the copper(I)-catalyzed reaction109,110 and the strain-
promoted cycloaddition111 have been reported to occur in aqueous media at room temperature. 
Furthermore, the chemoselectivity of the reaction and the unreactive nature of both alkynes and 
azides towards functionalities present in biomolecules prevent unwanted side reactions, or coupling 
at undesired residues. Therefore, the reaction has been increasingly used as a biocompatible tool to 
modify biomolecules, and liposomes have been functionalised by means of the [3+2] azide-alkyne 
cycloaddition. Examples are presented in Figure 18, and include functionalization of conventional 
(e.g. DOPE) (Figure 18, A), pegylated (Figure 18, B), or engineered (Figure 18, C) liposomes with 
a terminal alkyne with small molecules, PEG-carbohydrate conjugates or peptides displaying an 
azide functionality,112,114,115 but also reaction between two membrane-bound alkyne and azide 
moieties (Figure 18, D).116 The CuAAC reaction has also been performed on free lipids and 
phospholipids at various positions (head-group or lipophilic chains),113 but since our interest lies in 
the functionalization of formulated liposomes, this area is not further described. 
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Figure 18: Reported click reactions performed on liposomes bearing surface functionalities. A: Cavalli et al. 
monitor the CuAAC reaction on liposomes using FRET.112 B: Hassane et al. introduced azide-containing sugars 
onto alkyne-displaying liposomes via CuAAC.114 C: Cai et al. derivatized the surface of highly stable polymerized 
liposomes.115 D: Van Lengerich et al. observed DNA-mediated vesicle interactions between vesicles tethered to a 
supported lipid bilayer via CuAAC.116 
 
Despite those examples of liposomes functionalization by CuAAC, general optimization of the 
reaction on liposomes has not been investigated for these substrates, and in particular, the 
importance of the positioning of the two reactive functionalities has not been studied. Given that 
most conjugation reactions take place between a surface functionality (i.e. a modified lipid 
incorporated in a liposome) and a coupling partner (small molecule, peptide, etc.) in solution in the 
presence of a soluble catalyst, we found it prudent to investigate, whether the reaction is equally 
efficient with surface alkynes and soluble azides and with an inverted orientation of the functional 
groups. Therefore, we formulated liposomes containing the two functional lipids 56 and 57, 
presenting an alkyne and an azide, respectively, and investigated their reaction with the fluorescein 
conjugated azide and alkyne (Figure 19) as the coupling partners. 
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Figure 19: The coupling partners for the functionalised liposomes and the water soluble ligand added in some of 
the experiments. The fluorescein-alkyne conjugate is known117 and the azido containing derivative was 
synthesised from fluoresceinamine and 5-azidopentanoic acid. 
 
The functionalized lipid 56 or 57 (5%) was mixed with POPC (95%) and formulated as liposomes 
by extrusion in PBS buffer (c = 25 mM) using the dry lipid film technique, yielding milky solutions. 
The functionalized liposomes (c = 12.5 mM) were incubated with the corresponding coupling 
partner (the fluorescein-azide with 56 and the fluorescein-alkyne with 57) (0.20 mM; 0.65 equiv.), 
sodium ascorbate (0.56 mM) and copper sulfate (0.10 mM; 0.33 equiv.) in the absence or presence 
of a ligand for Cu (0.20 mM, 0.66 equiv.). Samples were taken for HPLC analysis after 0 (before 
addition of copper sulfate), 120, 480 and 1440 minutes. The time-course profile of the reaction can 
be seen in Figure 20. As can be seen, there was very little conversion in the coupling between the 
fluorescein-alkyne and the azide functionalised liposomes. When the reaction partners were 
reversed, approximately 50% of the fluorescein-azide was converted within the first two hours, but 
then the reaction stalled. 
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Figure 20: Time-course of the conjugation reactions. AUC for the fluorescein-alkyne (red) and the fluorescein-
azide (blue) when incubated with liposomes consisting of POPC and 56 or 57, respectively, from HPLC data at 
t=0, 120, 480 and 1440 min. 
 
When liposomes consisting of only POPC were subjected to the reaction conditions, no conversion 
of the coupling partners were observed and the same was the case in the absence of Cu (data not 
shown). As mentioned previously, we have observed earlier that the CuAAC reaction with liposome 
coupling partners is significantly more sluggish when the alkyne is in solution and the liposomes 
contain the azide functionality, compared to the reverse situation, which is confirmed by the 
observations made here. It has previously been reported that the CuAAC reaction of liposomal 
substrates perform better in the presence of ligands for copper114,115 but when the reactions were 
performed in the presence of the water-soluble Cu-ligand shown in Figure 19118 (two equiv. relative 
to copper), both combinations of coupling partners resulted in very poor conversion in 24 h (see 
Figure 20). It is also noteworthy that the very popular CuAAC reaction does not afford full 
conversion of the fluorescein-azide when reacted with the alkyne functionalised liposomes, despite 
the fact that the azide is the limiting reagent. Rather remarkably, the reaction appears to stall after 
about two hours and this phenomenon warrants further investigation.  
 
2.4. Study on the reaction of propargyl amines with isothiocyanates. 
Synthesis of 2-amino-4-methylene-thiazolines upon extended reaction of propargylamines with 
isothiocyanates at reflux in benzene was first reported by Eloy and Deryckere in 1973.119 A decade 
before, Easton et al. had also reported the isolation of similar compounds, in their attempt to 
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synthesise thioureas by reaction of secondary propargylamines with isothiocyanate.120 A later study 
on the synthesis of iminothiazolidines also reported the synthesis of the heterocycles upon reaction 
of propargyl amines with aryl isothiocyanates at reflux in dioxane.121 
 
Scheme 14: Reaction of isothiocyanate with propargyl amines: a) aminothiazolines and b) iminothiazolidines 
have been reported.119,121 
 
 
Earlier work carried out in the group showed that the above reactions, though only reported to occur 
under rather harsh conditions (several hours under reflux in dioxane121 or under reduced pressure 
above 80 °C120), could in fact be performed under very mild and biocompatible conditions, and a 
series of experiments had been carried out to investigate the applicability of the reaction under 
biocompatible conditions.122 The reaction with fluorescein isothiocyanate (FITC) and either primary 
or secondary propargyl amine (2-(prop-2-yn-1-ylamino)-ethanol) have been performed in a mixture 
of water and tert-butanol at 20 °C, to afford the desired thiazolidines in 81% and 78% yields 
respectively (see Scheme 15).122 
 
Scheme 15: Reaction of primary and secondary propargyl amines with fluorescein isothioscyanate.a 122 
 
a Conditions: 1: H2O/tBuOH, 20 °C, 6 h; 2: H2O/tBuOH, 20 °C, 2 h. 
The reaction was described to compete with formation of thiourea when internal propargyl amines 
are used, and the desired thiazolidine was isolated in 52% yield along with 34% of the thiourea,122 
(see Scheme 16). However, we identified a stepwise mechanism, in which the thiourea is an 
intermediate, and prolonged reaction times showed full conversion to the desired thiazolidine, 
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which was isolated in 82 % yield. The reaction scope is therefore extended to any propargyl amine, 
knowing that longer reaction times are necessary for internal propargyl amines. 
 
Scheme 16: Reaction of internal propargyl amine with fluorescein isothiocyanate after 4h.a 122 
a Conditions: H2O/tBuOH, 20 °C, 4 h. 
 
Finally, an experiment was performed to investigate the competition of a primary amine and a 
terminal propargyl amine in their reaction with FITC. It was observed that the propargyl amine 
reacted faster than the primary amine, to afford the desired thiazolidine along with the thiourea 
resulting from attack of the primary amine on FITC in a 10:1 mixture (respectively isolated in 78% 
and 8% yield after flash chromatography, see Scheme 17).122 Thus, the reaction is selective towards 
propargyl amines, which attests the relevance of the cyclization reaction in biological systems, since 
it is feasible to imagine using the reaction in the presence of other amino functionalities. 
 
Scheme 17: Competition reaction of a primary amine and a terminal propargyl amine with fluorescein 
isothiocyanate. a 122 
 
a Conditions: H2O/tBuOH, 20 °C, 2 h. 
The perspective of a new selective and biocompatible reaction provided by these interesting data 
prompted us to investigate the reaction on biological systems and possibly develop a new tool for 
functionalization of macromolecules in aqueous media. 
52 
 
2.4.1. Investigation of conjugation of fluorescein isothiocyanate with functionalised liposomes 
Functionalized liposomes bearing a terminal propargyl amine were chosen as test substrates, since 
these would validate if the reaction was useful for macromolecular constructs in water. We first 
wanted to investigate the conjugation reaction of liposomes containing lipid 59 (see section 2.2, 
Scheme 13) displaying a terminal propargyl amine with FITC, following and quantifying the 
reaction by fluorescence spectroscopy, the principle is outlined in Figure 21.  
 
 
Figure 21: Principle of conjugation quantification by fluorescence measurement; Liposomes containing lipid 59 
could be reacted with FITC, resulting in fluorescent liposomes. Measurement of the resulting fluorescent 
quantifies the conjugation. 
 
However, preliminary experiments on fluorescence measurement and purification of free FITC 
indicated issues with regard to quantification of the conjugation reaction. Indeed, in order to 
quantify the conjugation in the way described above, unreacted FITC has to be removed from the 
liposomal solution, without altering the liposomes, which is not straightforward. 
Two devices were investigated for the elimination of free FITC based on size exclusion: dialysis 
using Slide-A-Lyzer® dialysis cassettes (10.000 MW cut off), which is a well established method 
for dialysis of small volumes  and Amicon® Ultra-15 centrifugal filter devices (100.000 MW cut 
off), which has the advantage of the time efficiency (liposomal solutions have been cleaned in 
minutes to hours, while days are needed with the dialysis cassettes). Therefore, liposomomes were 
formulated with 1,2-distearoyl-sn-glycero-3-phosphatidylcholine (DSPC) and 1% fluorescent lipid 
1,2-dioleoyl-sn-glycero-3-phosphatidylethanolamine-N-(carboxyfluorescein) in phosphate buffered 
saline (PBS) solution at 65 °C, and fluorescein was attempted removed from a solution containing 
those liposomes (see structures in Figure 22).  
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Figure 22: Compounds used for the preliminary experiments. A: 1,2-Distearoyl-sn-glycero-3-
phosphatidylcholine (DSPC); B: Fluorescein; C: 1,2-dioleoyl-sn-glycero-3-phosphatidylethanolamine-N-
(carboxyfluorescein). 
 
During optimization of the centrifugation conditions using the centrifugal filter devices, we 
observed a considerable overall loss of fluorescence (i.e. the fluorescence measured in the filtrate 
and in the solution remaining in the device did not correspond to the initial fluorescence in the 
mother solution). The same outcome was observed in an additional centrifugation experiment with a 
solution containing only the fluorescent liposomes, indicating that the liposomes were most 
probably partly trapped in the filter of the device during centrifugation. For this reason, we 
discarded the initially attractive idea of a fast removal of FITC by centrifugation. 
The later observation prompted us to adjust the strategy for quantification of the conjugation 
reaction: Realising the difficulty to recover all the liposomes also from dialysis cassettes, either 
because some of the liposomes could also be trapped in the membrane of the dialysis cassettes, or 
because some liposomes might be lost when the dialysed solution is removed from the cassette, we 
decided to integrate a fluorescent phospholipid as an internal standard to the liposomes (see Figure 
23). 
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Figure 23: Conjugation quantification using an internal fluorescent standard. 1: The internal fluorophore 
contained in the lipid is excited with a wave length of 470 nm. 2: The internal fluorophore contained in the lipid 
emits fluorescence with a maximum at a wave length of 503 nm. 3: After reaction with the propargyl amine 
functionalities, the tetramethylrhodamine fluorophore is covalently linked to the liposomes, and can be excited at 
a wavelength of 520 nm. 4:.After excitation, the tetramethylrhodamine fluorophore emits fluorescence with a 
maximum at a wavelength of 572 nm. 
 
This allows us to measure the fluorescence due to the conjugation product and compare it to the 
intrinsic fluorescence of the lipid, using the ratio to quantify the progress of the conjugation 
reaction. However, in order to do so, the fluorescent lipid and the isothiocyanate-fluorophore 
reacting with the propargyl amine should have distinct excitation and emission spectra, and 
especially, the emission of one of the fluorophore should not overlap with the excitation spectrum 
of the second. 
Therefore, we chose to work with a lipid displaying 4,4-difluoro-1,3,5,7-tetramethyl-4-bora-3a,4a-
diaza-s-indacene, for which the excitation maximum is at 495 nm and the emission maximum is at 
503 nm, and tetramethylrhodamine ITC, for which the excitation maximum is at 544 nm and the 
excitation maximum is at 572 nm. The structures and emission spectra can be seen in Figure 24 B to 
E. 
Thus, liposomes containing 0.5% Bodipy® 495/503 lipid (Figure 24B) and 1% lipid 59 (Figure 
24A) with DSPC were formulated in PBS buffer at 65 °C, and liposomes containing only 0.5% of 
the Bodipy® lipid, but no lipid 59 were formulated in PBS buffer at 65 °C for control. As for the 
precedent project, the lipids were first formulated as multilamellar vesicles but this time in PBS 
buffer, by the dry lipid film technique:123 the phospholipids were solubilised in CHCl3 and the 
solvent was evaporated in vacuo to form a dry lipid thin film. PBS buffer was added in order to 
obtain 2 mM suspensions of the lipids, and the lipids were solubilised upon heating the mixture to 
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60 °C with periodic vortexing. This resulted in a milky suspension of multilamellar vesicles that 
was extruded through a 100 nm polycarbonate filter at 65 °C in order to obtain the desired 
monolamellar liposomes as a transparent solution.  
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Figure 24: Synthesised functionalised lipid 59 (A) and fluorescent dyes used for conjugation quantification. B: 
Bodipy® lipid 495/503. C: Excitation and emission spectra of Bodipy® lipid 495/503. D: Tetramethylrhodamine 
isothiocyanate. E: Excitation and emission spectra of tetramethylrhodamine isothiocyanate. 
 
Three sets of experiments were conducted to study the conjugation reaction on functionalised 
liposomes: In the first one, one equivalent (compared to the propargyl amine) of TRITC in MeOH 
(0.003M) was reacted with the liposomal solution containing 1% of 59 and 0.5 % of Bodipy® lipid, 
in the second one, ten equivalents (compared to the propargyl amine) of TRITC in MeOH (0.003M) 
was reacted with the liposomal solution containing 1% of 59 and 0.5 % of Bodipy® lipid, and in the 
third one, the same amounts as for ten equivalents of TRITC in MeOH (0.003M) was reacted with 
the liposomal solution containing only 0.5 % of Bodipy® lipid, but no propargyl amine lipid 59 as a 
control for passive diffusion of the tetramethylrhodamine dye into the liposomal membrane. 
Sampling was done after 2 h, 8 h, 24 h, 48 h and 96 h, and the resulting solutions were purified by 
 dialysis ov
Figure 25. 
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Figure 25 A and B shows the fluorescence spectrum of the control reaction with 20 equivalents 
TRITC compared to Bodipy® lipid (conducted on liposomes containing 0.5 % Bodipy® lipid only) 
with excitations at 470 nm and 520 nm respectively. From Figure 25 A, we can see fluorescence of 
the Bodipy® lipid, after 2 h, 8 h and 24 h, the maximum fluorescence at 503 nm is characteristic for 
the Bodipy lipid only, attesting that the TRITC was effectively cleared up by dialysis. However, a 
second emission at 572 nm increasing with time can be observed, which indicates that TRITC has 
been incorporated in some extent to the liposomes free of propargyl amine, probably by diffusion 
through the liposome membranes. This is further assessed by Figure 25 B, where excitation at 520 
nm also results in fluorescence at 572 nm increasing with time and especially powerful after 96 h. 
However, for reaction times below 24 h, diffusion of TRITC through the liposome membranes does 
not seem to be an issue. The fact that fluorescence characteristic for TRICT is observed in Figure 25 
A, where the sample was excited with a wavelength of 470 nm, also indicates that fluorescence 
resonance energy transfer (FRET) occurs. FRET is the mechanism through which energy is 
transfered between two chromophores in close proximity. A donor chromophore is excited at an 
initial wavelength, it is thus in its electronic excited state, and emits some of the absorbed energy by 
fluorescence, but can also transfer part of its energy to an acceptor fluorophore through non-
radiative dipole coupling. The acceptor fluorophore then enters its electronic excited state, loses 
some of the energy through internal conversion, and emits fluorescence at a higher wavelength (see 
Figure 26). The energy transfered from the donor to the acceptor fluorophore is inversely 
proportional to the sixth power of the distance, and thus only fluorophores in very close proximity 
can interact through FRET. 
 
 
Figure 26: Jablonski diagram showing fluorescence resonance energy transfer (FRET).  
 
Figure 25 C and D show the fluorescence resulting from excitation at 470 nm and 520 nm 
respectively of the samples from the test reaction (performed with one equivalent of TRITC 
compared to the propargyl amine in the liposomal solution containing 1% of 59 and 0.5 % of 
Bodipy® lipid). Figure 25 E and F show the fluorescence spectrum of the test reaction with 10 
equivalents TRITC (conducted on liposomes containing 0.5 % Bodipy® lipid and 1% lipid 59) with 
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excitations at 470 nm and 520 nm respectively. From graphs D and F and by comparison with 
graphs B and E, it is clear that the rhodamine derivative has been attached to the functionalised 
liposomes (containing the propargyl amine functionalised lipid 59) already with a single equivalent 
of TRITC (graph D), but to a larger extent when ten equivalents of TRITC are added (stronger 
fluorescence in graph F). Indeed, the fluorescence observed at 572 nm after excitation at 520 nm is 
characteristic for tetramethylrhodamine derivatives, and the fluorescence observed in Figure 25 D 
and F is significantly stronger than in Figure 25 B, which indicates that the passive diffusion of 
TRITC into the liposomes (observed in Figure 25B) does not account for all the fluorescence 
observed in Figure 25 D. However, Figure 25 C also shows that FRET occurs, which unfortunately 
limits the possibility for quantification of the reaction.  
Moreover, DLS analysis of the samples showed an increase in the size of the liposomes especially 
after 48 h and 96 h (see Table 11). This was thought to be due to liposome aggregation, possibly 
aggravated by the presence of TRITC. 
 
Table 11: DLS analysis of the lipids formulated with DSPC and 1% Bodipy (control) or DSPC, 1% Bodipy and 
0.5% 59 after reaction with TRITC. 
 
Liposome size control by DLS 
 
Sample Diameter (nm) PdIa 
Control   
2 h  254,2 0,316 
8 h 214,3 0,366 
24 h 383,2 0,390 
48 h 743,6 0,344 
96 h 
 
1103,5 0,355 
Reaction with 1 equiv. TRITC   
2 h 238,1 0,317 
8 h 248,9 0,370 
24 h 349 0,399 
48 h 7,2,2 0,392 
96 h 
 
1659,8 0,236 
Reaction with 10 equiv. TRITC   
2 h 256,8 0,366 
8 h 273,1 0,345 
24 h 503,2 0,409 
48 h 962,9 0,401 
96 h 
 
1521,7 0,345 
aPdI = polydispersity index 
 
In order to assess whether TRITC enhances liposome aggregation, test reactions have been 
performed, mixing different concentrations of TRITC (0%, 1%, 5% and 10%) with liposomes 
formulated with 100% DSPC in PBS, and measuring the liposome diameter after 2 h, 4 h, 24 h and 
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96 h, but no increase in liposome diameter was observed under those conditions. Thus, the 
aggregation of the liposomes seems to be mainly due to inhomogeneity in the liposome formulation. 
These results, even though the method shows limitations, were very encouraging, since the reaction 
described above seems to occur readily at 20 °C in PBS buffer.  
In order to circumvent the issues faced in the last set of experiments, we chose to perform the next 
set of experiement with POPC instead of DSPC. Since the conjuagation experiments are carried out 
at 20 °C, which is well above the Tm for POPC, it was expected that aggregation could be 
circumvented by this change in the major liposome component. Moreover, the liposomal solutions 
would be analysed by HPLC instead of fluorimetry, which would also bypass the quantification 
difficulties introduced by the undesired FRET phenomenon. Another advantage of following the 
reaction by HPLC is that introduction of the Bodipy ® lipid is no longer necessary, thus liposomes 
can be formulated with only POPC and lipid 59, increasing the homogeneity of the liposomes and 
hopefully their stability. 
The propargyl amine functionalized lipid 59 (1%) was mixed with POPC (99%) and formulated as 
liposomes by extrusion in PBS buffer using the dry lipid film technique, yielding clear solutions. 
The particle size of the formulated lipids was measured by DLS. The DLS analysis revealed that all 
of the lipids were able to form particles with a diameter between 120 and 180 nm and with a low 
polydispersity (mean: 145.2 nm, polydispersity: 0.245), indicating the formation of unilamellar 
vesicles. The functionalized liposomes (c = 12.5 mM) were incubated with FITC (31.25 µM; 0.5 
equiv.) and samples were taken for HPLC analysis after 5, 30, 60, 120, 240 and 1440 minutes. The 
analysis showed that after 5 min, more than 50% of the FITC (retention time (Rt): 6 min) had been 
converted to a major (Rt=18.6 min) and a minor (Rt=17 min) product. After 4 h, all the FITC had 
been converted to the two products and after 24 h, only the fast eluting (Rt 18 min) product was 
detected, see Figure 27. We performed the reaction between the propargyl amine functionalised 
lipid 59 and FITC in solution, which enabled us to identify the faster eluting compound (Rt=17 
min) as the desired product. HPLC-ESI-MS showed that both peaks had the same mass, 1198.8, 
which leads us to assign the peak at Rt=18.6 min as the intermediate thiourea.  
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Figure 27: Example of the monitoring of a conjugation reaction by HPLC over time at 254 nm. The decreasing 
peak with RT=6 min belongs to the free fluorescein isothiocyanate (FITC), while the peaks with RT=17 min and 
RT=18.6 min are the 2-imino-4-methylenethiazolidine and the intermediate thiourea, respectively. 
 
The time-course profile of the reaction can be seen in Figure 28. Already after 5 min, more than 
50% of the FITC has been converted to a mixture of the thiourea and the thiazolidine. After 2 h, the 
FITC is fully converted and after 4 h, the thiazolidine is the major product. After 24 h, only the 
product can be detected, demonstrating that the reaction has gone to completion. The integrity of 
the liposomes after 24 h incubation with FITC were verified by DLS and showed no significant 
change in the average size or polydispersity of the particles (diameter mean: 147.6 nm, 
polydispersity: 0.231). 
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Figure 28: Time-course of the conjugation reaction. AUC for FITC (blue), the intermediate thiourea (green) and 
the desired 2-imino-4-methylenethiazolidine (red), from HPLC data at t=5, 30, 60, 120, 240 and 1440 min. 
 
2.5. Conclusion 
We have devised a short and efficient synthesis of three functionalised lipids, 56, 57 and 59, starting 
from the commercially available 1,2-O-isopropylidene-sn-glycerol. The design is based on 
dietherlipids to confer stability and a short PEG chain in the sn-3 position to serve as the headgroup 
and can be viewed as a model for lipids useful for formulation of stealth liposomes with distal 
functionality (Figure 16 B). 
Lipids 56 and 57 enabled us to investigate the importance of positioning of the two functional 
groups involved in the copper catalysed azide-alkyne click reaction on either the surface of 
nanoparticles or in solution. We have previously found that the reaction performs best when 
liposomes display the alkyne coupling partner rather than the azide and the synthesis of 56 and 57 
for the first time allowed us to confirm this while comparing structurally similar lipids. The studies 
supported the hypothesis and interestingly also indicated that the presence of a ligand for copper 
was detrimental to the click reaction on liposome. 
Lipid 59 was used to benchmark a new conjugation reaction in aqueous media, the spontaneous 
reaction between an isothiocyanate and a secondary propargyl amine. Extensive experimentation 
went into identifying the best method to follow the reaction on the surface of liposomes and it was 
gratifying to observe that the reaction occurred cleanly to afford the desired product in high purity 
within 24 h, when monitored by HPLC. 
The results described here will be useful for future research in methodology for functionalising 
particle surfaces. We have chosen to study liposomes, but the conclusions reached about the click 
reaction and the novel conjugation method developed should be applicable to other nanoparticle 
systems. It is also noteworthy that our new conjugation reaction between propargyl amines and 
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isothiocyanates is superior to the widely used CuAAC “click” reaction, when compared directly on 
similar systems. The novel conjugation reaction does not require a catalyst and goes to completion 
in less than 24 hours, where the azide-alkyne coupling is significantly slower and even with 5% 
functionalised lipid on the liposome surface and applying 50% copper, the reaction stalled at around 
55% conversion.   
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3. Synthesis of 2-mono(10,16-dihydroxyhexadecanoyl)glycerol for investigation 
of cutin biosynthesis in plants 
 
3.1. Introduction 
Land plants are protected from desiccation and pathogens by the presence of a hydrophobic cuticle 
on their aerial epidermis. This cuticle consists of a polyester of hydroxy fatty acids, called cutin, 
surrounded by a variety of waxes.124 While the generic composition of the cutin polymer is known, 
the mechanism and site of cutin polymerization have remained longstanding question. Our 
collaborators had identified a candidate protein CD1 (and its coding gene) responsible for the 
formation of the cutin polymer, along with an expected substrate for the enzyme and precursor for 
the cutin polymer and they desired to test the activity of the enzyme on the putative substrate 2-
mono(10,16-dihydroxyhexadecanoyl)glycerol. However, the scarce availability and low purity of 
the compound in plants extracts prompted us to pursue a synthetic route to the compound. 
 
3.2. Synthesis of the proposed substrate for CD1 
 
 
Figure 29: Retrosynthetic analysis for 2-mono(10,16-dihydroxyhexadecanoyl)glycerol. 
 
2-Mono(10,16-dihydroxyhexadecanoyl)glycerol was first attempted synthesised by the route shown 
in Figure 29. Methyl 10-oxodecanoate 60 was synthesised by Swern oxidation43,44 from 
commercially available methyl 10-hydroxydecanoate.  
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Scheme 18: Attempted synthesis of methyl 16-(benzyloxy)-10-hydroxyhexadecanoate 61 by a Grignard reaction. 
 
 
Several attempts have been carried out in order to synthesise 16-(benzyloxy)-10-
hydroxyhexadecanoate 61. The classical Grignard reaction55 was attempted by first preparing (6-
(benzyloxy)hexyl)magnesium bromide. Formation of the organomagnesium compound was titrated 
by 1M HNO3 and phenolphthalein, and the Grignard reagent was calculated to be formed in about 
90% yield. However, following addition of a solution of the aldehyde 60 in anhydrous THF, after 4 
h the Grignard reagent had mainly been converted into its dimer and only 1,12-
bis(benzyloxy)dodecane and benzyl-hexyl-ether were isolated (see Scheme 18), even though the 
reaction was performed under argon, which has been reported to prevent the coupling products 
arising from a Wurtz-type reaction (Equation 3.1).125 Barbier conditions126 were also tested, but the 
same outcome was observed as with the Grignard reaction, and the desired product was not isolated. 
  
The strategy was then slightly changed, and we thought an alkyne could be easily deprotonated to 
attack the electrophilic aldehyde 60, the resulting ynol could then be hydrogenated in a later step. 
Therefore (6-tert-butyldimethylsilyloxy)-hex-1-yne 62 was synthesised in one step from hexyn-6-
ol. 
 
Scheme 19: Attempted synthesis of methyl 16-(tert-butyldimethylsilyloxy)-10-hydroxyhexadec-11-ynoate 63. 
 
 
Several attempts have again been carried out for the synthesis of ynol 63, but none of them proved 
successful. The first base used in this reaction was LHMDS, but with reaction temperatures ranging 
from – 78 °C to 20 °C, no conversion of 60 could be observed. Test reactions were then performed 
with nBuLi, tBuLi and LDA. In those cases, inseparable mixtures of by-products were obtained. 
Although TBS groups are typically compatible with strong bases under anhydrous conditions, , we 
speculated that some of the observed by-products might arise from partial deprotection of the TBS 
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group. Therefore, similar reactions were attempted using the O-benzyl-protected alkyne 64, 
synthesised in 1 step from hexyn-6-ol (see Scheme 20), however, the desired product 65 could not 
be isolated. 
 
Scheme 20: Attempted synthesis of methyl 16-(benzyloxy)-10-hydroxyhexadec-11-ynoate 65 
 
 
It was observed that for the main by-products that could be purified to some extent, no carbonyl 
signal could be seen in 13C NMR. Thus, we concluded that the problem observed in those reactions 
may arise from the ester functionality present in 60, and we decided to change the strategy and use a 
simpler aldehyde. 
The new synthetic route to 2-mono-(10,16-dihydroxyhexadecanoyl)glycerol is shown in Scheme 
21. Starting with decan-1,10-diol, one hydroxyl was protected by monobenzylation in excellent 
yield, inspired from the previous project, and the other hydroxyl was oxidized via Swern 
oxidation.43,44 The resulting aldehyde was reacted with (6-tert-butyldimethylsilyloxy)-hex-1-yne 62 
and tBuLi in THF. It was extremely gratifying to see that the reaction we could not perform 
successfully with methyl 10-oxodecanoate 60, now not only afforded the desired ynol 67 but also 
proceeded in a good yield (68%).  
The resulting secondary alcohol was TBS-protected with TBSCl and imidazole in DMF in excellent 
yield to give 68, and the benzyl protecting group was removed by palladium-catalysed 
hydrogenolysis with concomitant reduction of the alkyne in quantitative yield. The resulting alcohol 
was first oxidized to the carboxylic acid by use of PhI(OAc)2 and TEMPO in CH2Cl2 and H2O, and 
the glycerol moiety was only then introduced on the fatty acid in its 1,3-benzylidene-protected 
form, by Keck coupling of the fatty acid with cis-5-hydroxy-2-phenyl-1,3-dioxane, EDC·HCl and 
DMAP in CH2Cl2 to afford the fully protected dihydroxy acid ester 70 in 89% yield.  
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Scheme 21: Final synthetic route to 2-mono-(10,16-dihydroxyhexadecanoyl)glycerol.a 
 
aReagents: (a): NaH, DMF, BnBr; (b): i) DMSO, (ClCO)2,CH2Cl2, ii) Et3N, iii) (6-tertbutyldimethylsilyloxy)-hex-1-yne 
62, tBuLi, THF; (c): TBSCl, imidazole, DMF; (d): H2, Pd/C, EtOAc; (e): i) PhI(OAc)2, TEMPO,CH2Cl2, H2O, ii) cis-5-
hydroxy-2-phenyl-1,3-dioxane, EDC·HCl, DMAP, CH2Cl2; (f): 20 % aq. HF, MeCN; (g): H2, Pd(OH)2/C, THF. 
The TBS protecting groups were removed with HF in MeCN to afford the diol 71. For this 
deprotection step, milder conditions were at first attempted, using TBAF and HOAc in THF at 20 
°C, however, after 24 h only the terminal TBS group was cleaved using these conditions. Even 
applying a large excess of TBAF in THF for an extended time only resulted in trace amounts of the 
desired product. Therefore, we turned to acidic conditions for the removal of the TBS groups: using 
more concentrated (40%) aqueous HF in MeCN at temperatures ranging from 0 C to 20 C 
resulted in a mixture of the desired diol 71, the fully deprotected 2-MHG (72), and the isomer 
resulting from migration of the acyl moiety to one of the primary alcohols (see Scheme 22). 
 
Scheme 22: Attempted cleavage of the TBS protecting groups with 40% HF in MeCN at 0 °C to 20 °C. 
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Gratifyingly, we found that using 20% aq. HF and keeping the reaction temperature at 0 C for 
three hours cleanly afforded the desired diol in 84% yield. With the dioxane 71 in hands, the last 
step for the synthesis of 2-MHG was cleavage of the benzylidene group. This step had to be carried 
out with special care, because of the high propensity of the acyl group to migrate to one of the 
primary alcohols (as was observed in the attempted TBS-deprotection using 40% HF).  
We chose to use mild hydrogenation conditions with Pearlman´s catalyst127 in THF and obtained the 
desired lipid 72 in 83% yield after crystallization from ethyl acetate and heptane. The challenge of 
potential migration from the 2-position to one of the primary alcohols was avoided by the use of 
THF. Indeed other solvents do not give such good results as the one reported here: dissolving the 
pure lipid 72 in deuterated methanol resulted in acyl migration after 15 min, which could be 
monitored by 1H NMR. 
 
3.3. 2-MHG (72) is a substrate for CD1 
The CD1 protein is thought to acts as an acyl transferase, operating a transesterification from the 
glycerol of the 2-MHG to the primary hydroxyl group of another molecule of 2-MHG or of a 
growing oligomer, as shown in Scheme 23. The acyl donor is the 2-MHG monomer, which is 
transferred, either to another molecule of 2-MHG (n=1) to start the polymerisation or to the 
growing polyester chain. 
 
Scheme 23: Proposed mechanism for the synthesis of cutin catalysed by the enzyme CD1. 
 
 
In order to validate the theory, the synthesised 2-MHG 72 was tested as substrate for the 
recombinant CD1 protein in an in vitro polymerization assay. The products of the assay were 
analysed by MALDI-TOF-MS, which showed the presence of a series of oligomers with up to 
seven units of the 2-MHG linked to a glycerol end group (see Figure 30), which assesses both the 
role of the enzyme and the identity of its substrate.  
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Figure 30: MALDI-TOF positive-mode ion spectra of lipid products from in vitro assays with 2-MHG substrate 
72 and purified recombinant CD 1 enzyme. Oligomerisation up to DP 7 can be detected. 
 
3.4. Conclusion 
A concice synthesis of the cutin monomer 2-mono(10,16-dihydroxyhexadecanoyl)glycerol (2-
MHG, 72) has been devised. The route takes advantage of the efficient addition of an alkyne-
lithium reagent to an aldehyde, followed by protecting group manipulations, oxidation-esterification 
and finally careful deprotection to afford the sensitive product in its stable, crystalline form.  
With the proposed monomer for CD1 catalysed formation of cutin oligomers in hand, our 
collaborators were able to show that the enzyme does indeed accept 72 as a substrate and catalyse 
the formation of cutin oligomers. These findings constitute the first biochemical validation of the 
function of an enzyme involed in cutin biosynthesis in plants.128  
69 
 
4. Synthesis of a novel C3 symmetric phosphacyclophane as a putative ligand for 
transition metal catalysed reactions 
 
4.1. Introduction 
4.1.1. Phosphines and other mono-phosphorus ligands for transition metals 
Phosphines, PR3, are valuable ligands in organometallic chemistry. Their abilility to form very 
diverse complexes, to stabilize a variety of metals as their phosphine complexes (R3P)nM-L as well 
as different oxidation states of the metals, enables phosphine-metal complexes to promote a wide 
range of catalytic reactions.  
Not only electronic effects, but also to a considerable extend steric effects of ligands have been 
shown to influence the reactivity of complexes, by stabilizing or destabilizing different oxidation 
states and/or coordination numbers of the metal. This feature is of special interest in the case of 
phosphine ligands, for which changing the ligand sizes and electron-donor power can be achieved 
relatively easily and in a predictable manner by varying R. This fine tuning of steric and electronic 
properties allows eliciting desired properties from their complexes.129  
Phosphine ligands can donate their phosphorus lone pair, and are good sigma donors, they are also 
π-acids, which means that the empty σ* orbital of the P-R bond overlaps with the filled metal dπ 
orbital and accepts electrons from the metal. This effect is known as back bonding. The extent to 
which the empty σ* orbital accepts electron back donation depends on the nature of the R 
substituents: the more electronegative the atom attached to phosphorus, the better σ* acceptor from 
the metal. This effect affects the P-R bond, as well as the M-P bond length and stability. 
Electronic effects are defined by the changes in molecular properties as a result of transmission 
along chemical bond (for instance changing from an electron donating substituent on the 
phosphorus, such as P(p-C6H4OCH3)3, to an electron withdrawing substituent as in P(p- C6H4Cl)3). 
Steric affects are defined by the changes in molecular properties as a result of forces between parts 
of the molecules (for instance repulsions between bulky substituents). A schematic definition of 
these effects is depicted in Figure 31.130 The cone angle is a steric parameter introduced by Tolman, 
which allows an intuitive depiction of the steric effects, and which has been used to explain the 
influence of the steric bulk of phosphorus ligands in a variety of complexes. It is defined as the apex 
angle of the cylindrical cone centred 2.28 Å from the centre of the P atom, and tangent to the Van 
der Waals radii of the outmost atoms in the space filling model of the M(PR3) group, as shown in 
Figure 31. 
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the reactivity of organometallic complexes (depicted in Figure 35 A).129,130 Later, Casey and 
Whiteker introduced the notion of natural bite angle, which only considers the preferred chelation 
angle as dictated by the backbone constraints, and abstracts other constraints introduced by metal 
valence angle. Thus, the natural bite angle is determined by steric considerations solely. They also 
determined values of natural bite angles for a series of chelating diphosphine ligands by molecular 
mechanics calculations.139 Several diphosphines have been designed to adopt cis coordination sites 
in square planar and octahedral metal complexes, such as DIPHOS, bis-diphenylphosphinoethane, 
which forms cis-chelated complexes, with a bite angle close to 90° due to the rigid 5-membered 
metallacycle. On the other hand, diphosphines with a large bite angle have been designed with the 
aim of obtaining better selectivities and rates for a number of reactions. Therefore, Ito and co-
workers have developed the trans-chelating chiral diphosphine ligand TRAP 2, 2´´-bis[1-
(diphenylphosphino)ethyl]-1,1´´-biferrocene, efficient for asymmetric Michael addition of α-cyano-
carboxylates catalysed by ruthenium (see Figure 35C),140 and Van Leeuwen and co-workers 
developed and studied a series of ligands structurally close to Xantphos, some of them displaying 
increased rates and selectivities in reactions such as rhodium-catalysed hydroformylation or nickel 
catalysed hydrocyanation, and explained the rates and selectivities with steric and electronic 
arguments.141 
 
 
Figure 35: Bite angles of diphosphine ligands. A: Schematic definition of the bite angle for a chelate ligand.130 B: 
an example of diphosphine ligand with a large bite angle: Xantphos (natural bite angle: 111.4 °).141 C: other 
example of diphosphine ligand with a large bite angle: TRAP (bite angle: 164.4 °).140 
 
Indeed, as for monodentate phosphorus ligands, steric and electronic effects affect ligands 
properties and consequently determine the related complexes reactivities. The PMP bite angle has 
been shown to play a role in the rates and selectivities of several reactions, and is related to both the 
“steric bite angle effects”, involving interactions between ligands or between ligands and substrates, 
and the “electronic bite angle effects”, relating to electronic changes emerging when the bite angle 
is modified. The latter can be described as an orbital effect, in the sense that the bite angle 
influences the metal hybridisation, thereby influencing the metal orbitals energies and reactivities. 
Therefore different transition states can be stabilised or destabilised, which impacts the catalytic 
reaction outcome in terms of reactivity and selectivity.141  
A variety of diphosphine ligands displaying particular structural properties such as wide bite angle, 
chirality at the phosphorus center, chiral backbones, or planar chirality, has been synthesised and 
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showed attractive catalytic properties. Two examples are particularly worth mentioning, that 
illustrate the works of William S. Knowles and Ryoji Noyori, rewarded by the Nobel Prize in 2001 
"for their work on chirally catalysed hydrogenation reactions".142 Both researchers developed 
chiral ligands that effectively and efficiently introduced asymmetry in hydrogentation reactions. 
Knowles and Sabacky developed the first asymmetric hydrogenation using a rhodium complex and 
a chiral phosphine ligand, achieving modest enantiomeric excess, but which was a proof of 
principle that enantioselectivity could be achieved in reactions catalysed by organometallic 
complexes (see Figure 36 A).143,144 Further chiral monophosphines and diphosphines ligands have 
been developed until the synthesis of the diphosphine ligand DIPAMP (ethane-1,2-diylbis[(2-
methoxyphenyl)phenylphosphane]), achieving excellent enantioselectivity, and its industrial use in 
the synthesis of L-DOPA (L-3,4-dihydroxyphenylalanine). The stereoselective hydrogenation step 
performed on the L-DOPA precursor is presented in Figure 36 B.144,145 
 
 
Figure 36: Enantioselective hydrogenations developed by Knowles. A: First example of enantioselective 
hydrogenation catalysed by Rh complex displaying chiral phosphorus ligand.143,144 B: More efficient asymmetric 
catalysis of olefin hydrogenation by a Ru complex with DIPAMP ligand.144,145 
 
On the other hand, Noyori developed the asymmetric reduction of ketones catalysed by Ru-
complex. His original work focused on the reduction of β-keto-esters, for which he found that 
BINAP-Ru dihalide was a very efficient catalyst for the reaction (see Figure 37 A).146 Later, he 
extended the scope of the catalytic reduction to “simple ketones” (i.e. ketones with no requirements 
on the β-position) modifying his complex to a BINAP/diamine – ruthenium complex, this complex 
can reduce aromatic, heteroaromatic, and olefinic ketones enantioselectively (see Figure 37 B).147 
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Figure 37: Enantioselective reduction of ketones catalysed by Ru complexes developed by Noyori. A: asymmetric 
reduction of β-keto-esters catalysed by BINAP-Ru-complex.146 B: enlargement of the scope of the reaction by 
BINAP-diamine-Ru complex.147 
 
4.1.3. Ligands symmetry and enantioselective reactions 
If the importance of chiral diphosphine ligands in enantioselective reactions was already obvious in 
1968 with Knowles and Sabacky´s work143 and despite the early results of the application of 
monophosphines by e.g. Knowles, the latter gained popularity as alternatives to diphosphines in 
some enantioselective reactions only later, a milestone for this being the synthesis of the chiral 
monodentate phosphine ligands MOPs and their application in the synthesis of chiral alcohols 
published by Uozumi and Hayashi in 1991. In this work, chirality is introduced upon 
hydrosilylation reaction of prochiral terminal olefins with Markovnikov selectivity catalysed by 
palladium complexes, followed by Tamao-Fleming oxidation of the resulting chiral organosilane 
with retention of configuration to afford the alcohols in excellent yields and ee, as illustrated in 
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Scheme 24.148 Further chiral phosphine ligands based on a planar chiral ferrocene scaffold have 
been synthesised and investigated for the same process on styrene, achieving good 
stereoselectivity.149 
Scheme 24: Enantioselective hydrosilylation of prochiral alkenes followed by oxidation. A: As described by 
Uozumi and Hayashi,148 B: As described by Pedersen and Johannsen.149 
 
Other examples of atropisomery have been used to induce chirality on phosphorus ligands, as in the 
C2-symmetric BINAP ligand, mentioned in paragraph 4.1.2. In this case, consideration of symmetry 
is also important. Indeed, C2 symmetry reduces the number of transition states and/or intermediates 
in the catalytic reaction, and thereby increases the chance of a stereoselective outcome for the 
reaction. By definition, in the case of C2 symmetry, each rotation of the ligand 180° about the C2 
rotation axis results in an identical situation, while the two situations would be diastereomeric in the 
absence of symmetry. Along those lines, C3-symmetric ligands have gained interest, since C3-
symmetry results in identical situation for each 120° rotation. Thus, both achiral and chiral tripodal 
C3 symmetrical phosphines, shown in Figure 38A and B, have been synthesised that form 
complexes with metal ions in various oxidation states.150 Monophosphines having threefold 
rotational axis have also been synthesised with the aim to introduce a chirality axis that would be 
the same as the rotational axis. The design strategies were based on introducing aryl substituents on 
the phosphorus, taking advantage of non-bonding repulsive interactions between the rings, hoping 
to obtain propeller-like triarylphosphines and thereby introduce a helical chirality. However, low 
interconversion barrier and rapid racemisation, observed for the less complex ligand shown in 
Figure 38C, have limited its application. Thus, extremely encumbered substituents around the 
phosphorus (see Figure 38D) or more recently more complex designs, including peptidic bridging 
of aryl substituents as shown in Figure 38E were necessary to resolve such ligands. 
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symmetric propeller-shaped triarylphosphine oxides; 152 E: Propeller-shaped triphenylphosphine stabilized by a 
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More examples, depicted in Figure 39, show attempts to obtain stable chiral propeller shaped 
phosphine ligands based on bulky aryl substituents on the phosphorus, but X-ray analysis of those 
compounds illustrate the difficulty to obtain a true propeller-like triarylphosphine.154,155,156 
 
 
Figure 39: Examples of ligands that do not adopt perfect C3-symmetric conformation.154,155,156 
 
Ligands shown in Figure 39, even though they do not adopt a perfect C3-symmetric conformation, 
have been tested in asymmetric allylation reactions, and showed some degree of enantioselectivity, 
however, the observed ee were very substrate-dependant.156  
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4.2. Design of a new C3-symmetric phosphine ligand 
A first attempt to synthesize a novel C3-symmetric phosphacyclophane for enantioselective 
reactions was carried out by MSc student Louise Thorstholm.157 In the original design, shown in 
Figure 40A, the phosphine oxide did not carry any chiral center, but it was hoped that the bridging 
alkyl chains in the system would render it rigid enough to display a proper propeller shape and 
chirality around the phosphorus atom. However, the interconversion barrier was too low, and the 
compound could not be resolved. Nonetheless, the phosphine oxide was reduced in situ, tested as 
ligand in the palladium-catalysed hydrosilylation of styrene and shown to form an active complex 
for the reaction. Therefore, we decided to continue the project, introducing a chiral center in each of 
the six benzylic positions, aiming at increasing the energy barrier for interconversion and thereby 
achieving a stable propeller shaped triarylphosphine. Furthermore, the two propellers will be 
diastereoisomers due to the presence of the chiral centres, increasing the likelihood that one 
propeller will be energetically favoured over the other. The structure of our target phosphine ligand 
is shown in Figure 40 B.  
If the route for the synthesis of the first generation ligand was already a challenge, the introduction 
of the chiral centers changed the reactivity of the compounds, and none of the original procedures 
proved to be efficient for the synthesis of the latest phospine ligand. 
 
 
Figure 40: A: First generation phosphacyclophane synthesised by MSc student Louise Thorstholm;157 B: Second 
generation phosphacyclophane targeted in this project. The additional stereocenters are aimed at enhancing the 
structure rigidity through a relay of chirality from the remote stereocenters. 
 
4.3. Synthesis of the cyclophane 
3D structure of the target phosphacyclophane is shown in Figure 41 (A), along with a “flattened” 
structure (B) that should ultimately help the reader picturing the target compound. We wished to 
synthesised the phosphacyclophane by ring closing metathesis (RCM) of tris-(3,5-di((R)-1-
methoxybut-3-enyl)phenyl)-phosphine oxide. That step was envisioned to be the most challenging 
of the reactions sequence: three consecutive RCM should be performed on a system that becomes 
more and more strained when the rings are being closed. Moreover, phosphine oxides are known 
ligands for ruthenium, which might hamper the RCM. Tris-(3,5-di((R)-1-methoxybut-3-
enyl)phenyl)-phosphine oxide can be synthesised from 1-bromo-3,5-di((R)-1-methoxybut-3-
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enyl)benzene and an electrophilic phosphorus reagent such as PCl3, or P(OPh)3. Finally, the phenyl 
derivative can be synthesised from dimethyl 5-bromoisophthalate. 
 
Figure 41: Retrosynthetic analysis for the desired C3 symmetric phosphacyclophane. 
 
Selective reduction of esters to aldehydes can be achieved in different ways,158 the use of a 
controlled amount of DIBAL-H at low temperature,159,160 being the most widely used reagent for 
partial reduction of esters. Therefore, dimethyl 5-bromoisophthalate was attempted reduced to the 
dialdehyde 74 directly using 2 to 2.2 equivalents of DIBAL-H at -78 °C. However, only little 
conversion was observed by TLC at that temperature. The same reactions were also attempted at -
65 °C, but in that case only complex mixtures of the desired compound along with monoaldehyde, 
and products of reduction of the esters to the alchohols were obtained.i In the same way, Le et al.161 
reported a relatively low yield (45-55%) for the reduction of methyl benzoate to benzaldehyde using 
DIBAL-H, hence their decision to synthesise the aldehyde in a two steps-procedure, via full 
reduction to the alcohol followed by oxidation to the aldehyde, which route afforded the desired 
product in 84% yield over the two steps. Thus, to circumvent the issue of several reduction 
products, we decided to synthesise 74 via an intermediate, and dimethyl 5-bromoisophthalate was 
first reduced to the diol 73 with LiAlH4, as described by Brunner et al.,162 and oxidized to the 
dialdehyde via Swern oxidation43 performed in CH2Cl2/DMSO for solubility reasons in a second 
step, to afford 3,5-diformylbromobenzene in high purity and good yield (77% over the two steps). A 
selective reduction of dimethyl isophthalate using sodium bis(2-mothoxyethoxy)aluminium hydride 
(SMEAH) and N-methylpiperazine in toluene has also been reported to give isophthalaldehyde in 
66% yield,158 but the two-step synthesis was preferred due to its high yields and simple procedures. 
                                                 
i work carried out by MSc. stud. Jakob F. Kure 
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Scheme 25: Synthesis of 1-bromo-3,5-bis((R)-1-methoxybut-3-enyl)benzene 76.a 
 
a Reagents: (a): LiAlH4, THF; (b): i) (ClCO)2, DMSO, DMSO/CH2Cl2, ii)Et3N; (c): i) (+)-Ipc2BAll, THF, ii) MeOH, 3N 
NaOH, 30% H2O2; (d): NaH, MeI, DMF.  
 
A general method for asymmetric allylboration of dialdehydes with (-)-B-
allyldiisopinocampheylborane ((-)-Ipc2BAll) for the synthesis of aromatic C2-symmetric diols was 
reported by Brown and coworkers in 1997, that provided (1S,1'S)-1,1'-(1,3-phenylene)dibut-3-en-1-
ol from 1,3-benzenedialdehyde in 89% yield (88% de, ≥98% ee).163 Based on those reports, we 
chose to synthesise (1R,1'R)-1,1'-(5-bromo-1,3-phenylene)dibut-3-en-1-ol 75 via asymmetric 
allylboration of 74 with (+)-Ipc2BAll, inspired by procedures reported by Brown and co-
workers,163,164 which led to the preparation of 75 in excellent yield and with a de of 85% and ee of 
95-99% (determined by chiral HPLC). We found that for our substrate, carrying out the reaction at -
78 °C in THF instead of -100 °C, as described in the original literature163,164 still gave excellent ee, 
and we decided to perform the reaction at that temperature for convenience. Finally, methylation of 
the diol 75 afforded 76 in excellent yield.  
This reaction sequence (from 5-bromoisophthalate to 76) could be scaled up and performed on 
relatively large scales (20 g) without affecting the yields, and the products were stable when stored 
at 4 °C.  
The stereoselectivity can be explained by the interactions and steric repulsions in the transition 
state. Indeed, allylboration reactions have been reported to occur via a six-centred transition state to 
form rearranged homoallylic alcohols.165 The observed selectivity can be supported by the Traxler-
Zimmerman transition state model166 (see Scheme 26), however, it is difficult to understand why the 
attack of the allylborane occurs from the Re face of the aldehyde in this extent (98% ee was 
measured) and barely occurs from the Si face of the aldehyde. Nevertheless, the same observation 
was done when Brown and co-workers synthesised (1S,1'S)-1,1'-(1,3-phenylene)dibut-3-en-1-ol 
with ≥98% ee using (-)-Ipc2BAll,163 but to our knowledge, no mechanistic or transition state study 
has been reported to explain the outcome of these allylboration using (+)- nor (-)-Ipc2BAll. Brown 
and co-workers have mainly carried out studies of allylboration of benzaldehyde derivatives using 
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the (-)-Ipc2BAll to obtain (S)-homoallylic alcohols.163,164,167,168  Yet, (1R)-1-phenylbut-3-en-1-ol has 
been synthesised by treatment of benzaldehyde with (+)-Ipc2BAll at -100 °C in Et2O,169 which 
supports our hypothesis that (1R,1'R)-1,1'-(5-bromo-1,3-phenylene)dibut-3-en-1-ol would be 
obtained by asymmetric allylboration of 5-bromoisophthalaldehyde with (+)-Ipc2BAll. Moreover, a 
study carried out on reactions of heteroaromatic aldehydes with (+)-Ipc2BAll has also shown that 
(R)-homoallyllic alcohols were obtained as major products ,170 even though the yields and ee were 
not as high as described in the study of the reaction of (-)-Ipc2BAll with aromatic and 
heteroaromatic compounds described by Brown and co-workers,163 this being possibly explained by 
the basic pyridyl nitrogen atom, which complexes a boron atom easily, and thus reduces the 
reactivity of the allylborane.170 
 
Scheme 26: Mechanism and stereoselectivity of allylboration 
 
 
In order to verify that the dialdehyde 74 followed the trend of literature substrate to afford the 
(R,R)-product 75 upon reaction with (+)-Ipc2Ball, Mosher ester analysis was carried out. 
Mosher and co-workers developed a method to determine the ee and the absolute configuration of 
chiral compounds with a stereo center bearing a hydroxyl (or amino) group,171,172 which consists in 
coupling the chiral alcohol to a chiral carboxylic acid derivative in order to obtain diastereomeric 
esters. α-Methoxy-α-trifluoromethylphenylacetate (MTPA) esters were identified as derivatives that 
would allow determination of absolute configuration and ee, and this is probably the most widely 
used reagents for this purpose.173,174 The esters of both (R)- and (S)-MTPA have to be synthesised, 
which can be done by rather mild and fast reaction with the commercially available acid chlorides. 
It is worth mentioning that the configuration of the MTPA-Cl is inverted upon esterification of the 
chiral alcohol (i.e. the acid chloride of R configuration (R)-MTPA-Cl is converted to the MTPA 
ester of S configuration, according to the Cahn-Ingold-Prelog rules.175 The empirical determination 
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of the absolute configuration consists in measuring ΔδH=δS-δR: the chemical shift difference of any 
similar set of protons from the (S)- and (R)-MTPA ester respectively. The sign of the difference 
indicates the position of the considered set of protons relative to the MTPA phenyl and methoxy 
substituents.171,172,176 The argument assumes that the esters predominately adopt the most stable 
conformation shown in Figure 42, it follows that the chemical shift of the substituent protons on the 
carbinoli syn to the phenyl ring are shifted upfield compared to the similar protons syn to the 
methoxy group. In other words, any group of protons with a higher chemical shift in the (S)-MTPA 
ester compared to the (R)-MTBA ester (positive ΔδH) can be assigned to R2, and groups of protons 
with negative ΔδH can be assigned to R1.  
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Figure 42: Interactions with Mosher ester substituents and consequent NMR shift behaviour.171,174 
 
However, the 1H region of interest might be crowded and the spectra difficult to interpret. 
Especially, signals of the two diastereoisomers might overlap, hampering ee measurements. Thus, 
19F NMR has also been explored as a possible tool for absolute stereochemistry determination and 
ee measurement. A trend has been observed, which was rationalised by the deshielding of the CF3 
substituent when the latter is coplanar with the ester carbonyl group group (see Figure 43). This is 
however highly dependent on sterical interactions, and is only observed for marked differences in 
the sizes of the substituents R1 and R2 (see Figure 43).176 As a consequence, 19F NMR analysis has 
shown to be less reliable for determining absolute configuration compared to the 1H NMR Mosher 
ester method.172 
 
 
Figure 43: Configuration model for 19F NMR.176 Bond lengths have been exaggerated for the sake of clarity. 
                                                 
i Denomination used in the original literature.171,173,176 
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Therefore, 75 was reacted with (R)-(-)MTPA-Cl and (S)-(+)-MTPA-Cl in pyridine to obtain its 
Mosher ester derivatives 77 and 78 (see Scheme 27), for which both the crudes and the purified 
products were analysed by 1H NMR and 19F NMR. From the crude 1H NMR, and 19F the ee is at 
least 95%. For that purpose, the integrals of the methoxy signals were considered in the 1H NMR, 
due to signal crowding in the other regions of interest.  
 
Scheme 27: Synthesis of the Mosher ester derivatives of 75 for configuration analysis. 
 
 
In order to determine the absolute stereochemistry, NMR data from the purified products 77 and 78 
were analysed. As described above, the substituent shielded by the phenyl ring of the Mosher ester 
is shifted upfield, while the one on the same side as the methoxy group appears more downfield. In 
the 1H NMR spectra of 77 and 78, no change in chemical shift was observed for the methylene 
group, but the trend could be observed for the aromatic protons as well as for the vinylic protons 
(see Figure 44).  
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19F NMR of the two MTPA esters show a difference in chemical shift for the CF3 groups of about 
0.4 ppm, with the (S)-Mosher ester shifted upfield. This observation indicates that the CF3 group is 
rotated out-of-plane with the carbonyl group of the (S)-MTPA ester (see Figure 43) and thus that the 
large aromatic group can be assigned to R1, which supports the assignment of the stereocenter in 75 
as (R)-configured. 
 
Scheme 28: Synthesis of the phosphine oxide 79.a 
 
a Reagents: i) Mg, THF, ii) PCl3, iii) tBuOOH. 
 
Synthesis of the phosphine oxide 79 was challenging than expected and numerous experiments have 
been conducted before finding optimal conditions. We first sought to isolate the phosphine, but 
from the first attempts where traces of the compound were isolated, it was clear that the phosphine 
80 (see Scheme 29) was extremely sensitive, and readily oxidized to the phosphine oxide during 
work-up, the latter being isolated in larger amounts than the phosphine. Thus, very fast in the test 
experiments, work up was preceded by treatment with tBuOOH, to fully oxidize the phosphine to its 
oxide, so only the phosphine oxide would have to be isolated. 
 
Scheme 29: Attempted synthesis of tri-(3,5-bis((R)-1-methoxybut-3-enyl)phenyl)-phosphine 80. 
 
 
Working on test reactions and as a consequence on rather small scales, we hoped to turn 76 to a 
nucleophile via lithium-halogen exchange, and react the resulting lithium compound with an 
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electrophilic phosphorus derivative such as PCl3, such examples having been reported in the 
literature.177,178 This was successful once using tBuLi, PCl3 in THF at -78 °C, where 79 was isolated 
in 60% yield, but unfortunately this result could not be reproduced. Several attempts have been 
carried out to reproduce this result, and fine tuning of the conditions has been tried. Since mainly an 
unidentified by-product was isolated when the exchange was carried out at -78 °C, attempts have 
been carried out with reaction temperatures ranging from -90 °C to 0 °C, even though halogen-
metal exchange reactions are usually carried out at low temperatures (-60 °C to -120 °C). According 
to Burgess and co-workers in their synthesis of triarylphosphines with a similar strategy, strict 
control of the temperature and slow addition of the reagents had a dramatic influence on the yield of 
this step. However, the authors do not comment on the side reaction occurring in the case of poor 
temperature control. In the reported procedure, halogen-lithium exchange is carried out at -78 °C, 
and PCl3 addition is performed at temperatures ranging from -78 °C to -30 °C, depending on the 
substrate, to afford the desired phosphines in yields ranging from 40% to 64%.156 The same 
conditions have been attempted but were not satisfactory for our substrates, and less than 20% yield 
was obtained. This reaction presumably requires specific and time consuming optimization for each 
aryl bromine considered, since the same group had already reported the synthesis of some of their 
triarylphosphines three years earlier, performing the halogen-lithium exchange as well as PCl3 
addition at -30 C, for yields of 30-50%.155 Lithium-halogen exchange is generally an extremely 
fast reaction, the rate of lithium-halogen exchange exceeding sometimes the rate of proton 
transfer.179 However, on account of the poor yields attributed to a potential limited formation of the 
aryl lithium specie, reaction times for lithium-halogen exchange have been varied from one minute 
to one hour, without observed improvement. Burgess and co-workers report reaction times between 
30 min to 1 h for the lithium-halogen exchange.155,156 Performing extensive degassing by the freeze-
pump-thaw method has also been performed, but only yields below 20% were obtained in all those 
test reactions. One observation was interesting: TLC analysis already showed several products 
before addition of PCl3, and depending on the temperature and reaction time, the mixture would 
have different colours after tBuLi addition, ranging from clear yellow to dark red or green. It was 
also attempted to perform similar tests of reaction time and reaction temperature in Et2O, but the 
observations were quite similar in both solvents. nBuLi was also tested for the lithium-bromine 
exchange, but it appeared to be less reactive and very little product was isolated when using nBuLi. 
The effect of adding TMEDA to the reactions with nBuLi and tBuLi was also tested, but did not 
increase the yield of the reaction. Different electrophilic phosphorus compounds were also 
considered: similar reactions have been carried out using P(OPh)3 and PBr3 instead of PCl3, but 
with no improvement on the yield. 
A Grignard reaction55 was then attempted for the formation of the triarylphosphine oxide, inspired 
by literature examples to form a phosphorus-aryl bond,180 but several attempts were necessary to 
find optimal conditions to initiate the reaction and intensive activation of the magnesium turnings 
was required. Magnesium turning were dried by regular heating under high vacuum, and subjected 
to mechanical activation,181 by stirring the magnesium turnings with an olive-shaped stirring-bar 
overnight, which resulted in the magnesium being crushed into fine powder. The resulting finely 
grinded magnesium powder was covered with anhydrous THF and a crystal of iodine followed by 
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neat aryl bromide 76 were added to the magnesium powder in order to obtain a high concentration 
of 76 in close proximity to the magnesium. More dilute solutions of 76 in THF failed to initiate the 
reaction. Regular mild heating was then applied to the unstirred mixture until the reaction was 
started. Sometimes, addition of a small quantity of MeI was still necessary to initiate the reaction. 
When the reaction was started, the mixture was stirred gently, more uniform heating was applied by 
immersing the reaction flask into a warm oil bath (70 C) and a solution of 76 in THF was added 
dropwise. Activation by ultrasound was also considered,182 but failed to initiate the reaction. When 
the reaction could be initiated, 79 was obtained in very good and reproducible yields (typically 
about 80 % yield with best results of 84% for the formation of three bonds). This is a clear 
improvement over the lithium-halogen exchange, which seems to be extremely sensitive, not 
reproducible in our hands and was furthermore reported to afford a maximum of 40% yield on a 
similar substrate.156  
The final three ring closing metatheses (RCM) necessary for the synthesis of our target compounds 
82 were expected to be the most challenging step of the sequence (see Scheme 30).  
Many catalysts have been developed for RCM reactions, but none of them can be qualified of best 
or most efficient for all RCM reactions.183 For simple substrates, the most important factor is the 
catalyst activity, but for more challenging reactions, stability becomes an increasingly important 
factor. Standard catalysts performances have been compared, with regard to their reaction rates and 
stability. Even though the study was carried on simpler systems (formation of di- tri- and tetra-
substituted olefins in cyclopentenes), the study showed that although Grubbs’ catalysts 1st and 2nd 
generations as well as Hoveyda-Grubbs’ catalysts 1st and 2nd generations (see Figure 46) all were 
effective in catalyzing the reactions to completion for di- and tri-substituted cyclopentenes, the 1st 
generation catalysts required significantly longer reaction times for the synthesis of tri-substituted 
olefins mainly due to their lower reactivity. Finally, the more challenging formation of tetra-
substituted olefins could only be catalysed by the 2nd generation catalysts, Grubbs’ catalyst 2nd 
generation being the most efficient, yet low yields were reported in this study.183 Those catalysts 
appeared as a good starting point for the formation of the di-substituted olefins we intended to form, 
where sterics should not be an issue, but the strain in the rings system of the target compound 
probably slows the reaction and requires more stable catalysts. 
Large 13-membered rings, size of the rings we intended to form, have been accessed by RCM 
reaction using Grubbs’ catalysts 1st and 2nd generation in good yields (63 to 81 %) by Rao et al..184 
Depending on the substrates, various ratios of E and Z isomers were obtained, independently of the 
catalyst used, but in this study, remote heteroatoms have been described to interact with ruthenium, 
thereby influencing the transition state geometries and the stereochemical outcome of the RCM.184 
Unfortunately, no phosphorus heterocycle was considered in this study. However, the RCM 
reaction catalysed by Hoveyda-Grubbs’ catalyst 2nd generation and Grubbs’ catalyst 1st and 2nd 
generation tolerates a wide range of functional groups,185 and can be performed on highly and 
densely functionalised compounds such as carbohydrates. 186 Also, although Grubbs’ catalyst 1st 
generation was ineffective for the ring closure of diallyl phenyl phosphine, it was on the contrary 
effective for RCM of diallyl phenyl phosphine oxide and other phosphine oxide derivatives,187 and 
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Grubbs’ catalyst 2nd generation has been used for high yielding RCM of compounds containing 
phosphorus, such as phosphonates188 and phosphates.189 However, it is worth noting that treatment 
with triphenylphosphine oxide has been described as an efficient method for the removal of residual 
ruthenium from olefin metathesis products.190 It might follow that our substrates (in the open and/or 
in the cyclised form) forms a complex with Ru, and with the Ru-byproducts of the reaction, which 
would obviously hamper the isolation of the desired cyclised phosphine oxide. 
Macrocyclization, although commonly used,185 is often problematic because of the competition 
between the desired intramolecular reaction and intermolecular reactions giving rise to polymers. 
Therefore, high dilutions are generally required for the formation of large rings. Moreover, elevated 
temperatures and extended reaction times are required for difficult RCM of highly substituted or 
electron-deficient olefins, in which cases catalyst stability becomes a major issue.191 Except for 
these general considerations, it appears that numerous parameters influence metathesis reactions 
and no guideline for general conditions will guarantee the success of the process:185 each substrate 
requires fine tuning of the conditions.  
Because the precursor 76 could not be observed by LCMS, the first sets of reactions carried out was 
being followed by TLC. The starting material 79 has a distinct Rf from the products, but many by-
products were also formed during the reaction having similar Rf to the products of the RCM. The 
mixture were analysed by HPLC-MS, and luckily, the starting material 79 as well as the products of 
RCM could be observed by LC-MS. Thus, rapidly, test reactions were followed by LC-MS. 
 
Scheme 30: Synthesis of 82 
 
 
Initial test conditions included a small screening of solvent (toluene, CH2Cl2 and benzene), 
temperature effect (from 20 C to reflux of the above-mentioned solvents), catalyst (Grubbs’ 
catalyst 1st and 2nd generation,192,193 and Hoveyda-Grubbs’ catalyst 1st and 2nd generation (see 
Figure 46),194,195 as well as catalyst loading (4 mol % to 20 mol %) and concentration of the starting 
material 79 (0.01M and 0.001M). 
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Figure 46: Catalysts considered in the preliminary experiments. a) Grubbs’ catalyst 1st generation; b) Grubbs’ 
catalyst 2nd generation, c) Hoveyda-Grubbs’catalyst 1st generation; d) Hoveyda-Grubbs’ catalyst 2nd generation. 
 
From those first test experiments, it seemed that the Grubbs’ catalyst 2nd generation gave better 
results: more side products could be observed by TLC with the Hoveyda-Grubbs’ catalysts, and for 
equal reaction times, 79 was fully reacted with the 2nd generations of the Grubbs’ and Hoveyda-
Grubbs’ catalysts, but not for the 1st generation catalysts. However, even in the best cases, mixtures 
of one RCM and some two RCM products, compounds 83 and 84 respectively (see Scheme 31) 
were observed by LC-MS. 
 
Scheme 31: One RCM (83) and two RCM (84) products observed in the test reactions. 
 
 
A concentration of 0.01M of 79 was also chosen for the subsequent reactions, since the reaction was 
faster with that concentration, and it did not seem that cross-metathesis was efficiently avoided by 
the 10 times dilution. 
For the solvents, more by-products were formed (observed by TLC) in toluene, and benzene and 
CH2Cl2 seemed better choices. 
Interestingly, two peaks of m/z 727 (corresponding to the molecular weight of 84) were observed in 
LC-MS traces. This led us to think that conformational strain might already give rise to two 
conformers of 84, and that higher temperatures might be required for the last two alkene tethers to 
reach each other and thereby to allow the last RCM to occur. Thus, microwave heating was 
considered for the following reactions. Indeed, microwave heating under sealed vessel conditions, 
so-called “microwave flash heating”, provides an extremely fast and more homogeneous heating 
than more traditional external heat source (as oil bath used in the preliminary test reactions).196 This 
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rather modern heating method (the first reports of microwave heating to accelerate the rate of 
organic reactions were reported by Gedye et al. and by Giguere et al. in 1986197,198) has been 
successfully applied in RCM reactions and ene-yne metathesis, for which otherwise sluggish 
reactions were completed within minutes using microwave heating.199,200 The improved rates of 
RCM reactions were assigned to the rapid and uniform heating of the reaction mixture, as well as to 
the increased lifetime of the catalyst due to elimination of the wall effects.199,200 Even though 
CH2Cl2 has a low loss factor (tanδ = 0.042), it is not microwave transparent and heats up in 
microwave reactors. Finally, CH2Cl2 has been used effectively for RCM reactions at 100 °C under 
microwave hating.196,200 
Further attempts of optimization were thus performed under microwave heating. The reactions were 
monitored by LC-MS, for which the UV trace combined with the MS-data gave a clear picture of 
the reaction outcomes, such as whether the starting material was fully reacted as well as whether 
products with the expected mass were formed, but no quantitative data could be extracted. 
We first studied solvents effects, with benzene and CH2Cl2 (low microwave absorbing solvents), 
1,2-dichloroethane and chlorobenzene (two medium microwave absorbing solvents):196 it was 
expected that the difference in polarity of these solvents would have an effect on their heating using 
microwaves. Nevertheless, all four solvents could be heated to 120 °C, and the reactions were 
performed using Grubbs’ catalyst 2nd generation (2.5 mol %) for 30 min. Benzene and 
chlorobenzene gave the poorest results, where the starting material was not fully converted, 83 was 
the major peak and the peak corresponding 84 was also significant. Reactions performed in 1,2-
dichloroethane and CH2Cl2 had very similar outcomes, with a little less by-products in CH2Cl2. 
Gratifyingly, in those experiments, a peak for the formation of the three RCM (82, see Scheme 30) 
product was also observed yet along with a complex mixture containing the starting material, 83, 84 
and unidentified by-products. Thus, CH2Cl2 was chosen for the next experiments. 
Reaction time was briefly investigated: increasing the reaction time to 1h did not give better 
conversion, but decreasing the reaction time to 15 min gave similar conversion to the RCM 
products and less by-products. Further decreasing the reaction time to 5 min resulted in the 
formation of 84 mainly, in a cleaner reaction. This result interested us: we thought it could be easier 
to isolate 84 and try to perform the last RCM on the pure 84. Indeed, products of degradation of the 
catalyst might hamper its reactivity, which could be one reason why the last RCM seemed to be so 
difficult to carry out. We thus hoped to be able to form the desired product 82 from 84 having only 
the fresh batch of catalyst in the reaction vessel. 
Due to the equipment limitations, scaling up was not possible and the latest reaction (2.5 % equiv. 
Grubbs’ catalyst 2nd generation in CH2Cl2 at 120 °C for 5 min under microwave heating) was 
performed five times in order obtain enough material and try to isolate 84. From those reactions, 
performed with the exact same conditions and on the same batch of precursor and catalyst, it 
appeared that the microwave experiments were hardly reproducible: the UV traces were similar, but 
not identical, especially, for one of those reactions, the starting material had apparently fully 
reacted, a result that had not been observed before, and could not be reproduced The crude was 
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flashed repeatedly with different eluent systems (EtOAc and toluene/MeOH 8:2), but this was not 
sufficient to purify the desired product. Recrystallization was attempted, but with no success (also 
due to the small amounts isolated after the first purification by flash chromatography: about 50 mg). 
Furthermore, a by-product with m/z = 713 (m/z (84) -14) having a retention time close to 84 was 
observed and could not be separated by flash chromatography. This mass corresponds to a loss of 
methylene unit, such a by-product can be attributed to an isomerisation of the terminal olefin 
followed by a constructive RCM. Indeed, Grubbs’ catalysts 2nd generation has been reported to 
promote extensive olefin isomerisation201,202 and isomerisation followed by metathesis promoted by 
Grubbs’ catalyst 2nd generation was reported and studied.201 Moreover, by-products of isomerisation 
followed by RCM have been isolated with the unsaturated derivative of Grubbs’ catalyst 2nd 
generation (see Scheme 32). It has been reported that under RCM reaction conditions, isomerisation 
occurs when attempting to form large ring systems or when the precursors have conformations that 
are not germane to cyclisation, resulting in slow metathesis ring-closure events, which is the case 
with our substrate.  
 
Scheme 32 Example of olefin isomerisation followed by RCM with Ru catalyst. a) desired 21-membered ring; b) 
by-product resulting from the olefin isomerisation prior to RCM.203 
 
 
Reducing the temperature to 100 °C, 80 °C or 40 °C under microwave heating resulted in less by-
product, but did not suppress its formation, accordingly, isomerisations have been reported to occur 
readily at temperatures of 50-60 °C. 
However, Grubbs and co-workers have reported that high temperatures increase the formation of 
the isomerisation by-product, and suggest that benzoquinones can prevent isomerisation.204 
Therefore, we decided to pursue the investigation at 40 °C, and tested the efficiency of three 
quinones, namely 1,2-benzoquinone, 2,6-dichloro-1,4-benzoquinone and tetrafluoro-1,4-
benzoquinone, in the suppression of the by-product formation. Indeed, the two latter were reported 
to be the most effective inhibitors for the isomerisation side reaction.204 However, due to the scale 
limitation of the microwave equipment, and because we chose to decrease the reaction temperature 
to avoid isomerisation by-products, we chose to work on larger scales under conventional heating. 
Thus, the next set of test experiments were carried out in CH2Cl2 at reflux (with oil-bath heating), 
adding two portions of benzoquinone (2  5 mol %) followed by the catalyst (2  2.5 mol % 
Grubbs’ 2nd generation) over 2 h. Formation of the by-product was fully suppressed by 2,6-
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dichloro-1,4-benzoquinone as well as by tetrafluoro-1,4-benzoquinone. Moreover, after addition of 
the second batch of catalyst, 82 had been formed to some extent (LC-MS), the same reaction 
performed on 84, previously purified in some extent, did not lead to dramatically improved 
formation of 82. Consequently, the idea of isolating 84 in a first stage was abandoned, and we tried 
instead to push the reaction toward the desired final product 82.  
Therefore, regular addition of 2,6-dichloro-1,4-benzoquinone (20 mol %) followed by Grubbs’ 
catalyst 2nd generation (10 mol %) was performed every hour, and the reaction mixture analysed by 
LC-MS before and after each addition. After 4 h, the starting material was fully converted, and only 
traces of the product of one RCM 83 was observed, the desired compound 82 being the major 
product. 
One last screening of catalyst was performed under these reaction conditions: From the previous 
work, it seemed that the second generation of Grubbs’ catalyst and Hoveyda-Grubbs’ catalyst were 
fully converting the starting material in similar reaction times, even though Hoveyda-Grubbs’ 
catalyst seemed to give more side products. We tested both catalysts again under the last improved 
reaction conditions, and tested also two other catalysts very close in structure to the two previous 
ones, but a little less sterically hindered: dichloro[1,3-bis(2-methylphenyl)-2-
imidazolidinylidene](benzylidene)(tricyclohexylphosphine)ruthenium(II) and dichloro[1,3-bis(2-
methylphenyl)-2-imidazolidinylidene](2-isopropoxyphenylmethylene)ruthenium(II) (see Figure 
47). Five additions of 2,6-dichloro-1,4-benzoquinone (20 mol %) followed by Ru-catalyst (10 mol 
%) was performed every hour, and the reaction mixture analysed by LC-MS before and after each 
addition in CH2Cl2 at reflux.  
 
 
Figure 47: Catalysts tested in the latest experiments. a) Grubbs’ catalyst 2nd generation; b) Dichloro[1,3-bis(2-
methylphenyl)-2-imidazolidinylidene](benzylidene)(tricyclohexylphosphine)ruthenium(II), c) Hoveyda-Grubbs’ 
2nd generation; d) Dichloro[1,3-bis(2-methylphenyl)-2-imidazolidinylidene](2-isopropoxyphenylmethylene) 
ruthenium(II). 
 
From those experiments, better conversion to 82 were obtained with Grubbs’ catalyst 2nd generation 
and with Hoveyda-Grubbs’ catalyst 2nd generation. Thus the two latest experiments were performed 
on larger scales (500 mg of starting material 79). After the five additions, very little 83 was still 
present in the mixture and 84 was the major product, and the reaction was continued at reflux 
overnight, after which 83 had fully reacted, some 84 was left and 82 was formed in significant 
amounts (see Figure 48). The UV-trace obtained from the reaction performed with Grubbs’ catalyst 
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Figure 51: HMBC coupling pattern for 82.  
This non-equivalence results from the propeller shape taken by the aromatic rings: one side of the 
phenyl ring is above the surface created by the ring system, on the same side as the P=O bond, 
while the other side is below the surface, and the same is true for all set of protons. Taking for 
reference Figure 52, protons and methoxy-groups on the same side as the P=O bond are on the β-
face, and are pointing upwards (shown with a solid line), while the protons and methoxy groups on 
the face opposite to the P=O bond are pointing towards the cavity, which will be called the α-face 
(see Figure 52). The two ortho protons are not equivalent: one of them is on the α-face and the other 
on the β-face and have distinct chemical shifts. It is not possible with certainty to assign the signals 
from the protons on the the α- or on the β-face from the 1H NMR data, since both protons will be in 
the anisotropic shielding cone of the neighboring phenyl ring. The protons on the β-face will feel 
the shielding effect of the P=O bond, which the α-protons will not. Differential shielding can also 
arise from proximity to the the alkene π-system in the bridging carbon chains. 
 
 
 
Figure 52: Definition of α-face and β-face. 
 
In order to shed light on whether the phosphine oxide 82 was indeed locked in a preferred and 
stable propeller conformation, it was analysed by variable temperature 1H-NMR and circular 
dichroism (CD). 1H-NMR in dmso-d6 up to 150 C did not show any significant changes in the 
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spectra, indicating that either the structure is flexible at room temperature or the barrier to 
interconversion between the two diastereomeric conformations is very high. We then proceeded to 
low-temperature NMR, which was obtained by cooling a sample of 82 in CD2Cl2 to -100 C and 
heating it gradually to 25 C. The only region of the spectrum that displayed any dependence on the 
temperature is in the aromatic region and this can be seen in Figure 53. While the signals at 7.6 and 
7.5 ppm do not change appreciably, the last aromatic signal resonate at 7.0 ppm at room 
temperature, but moves upfield upon cooling, reaching 6.3 ppm at -100 C. There is significant 
signal broadening at intermediate temperatures, which indicates a dynamic process that is slowed 
down upon cooling. One possible explanation for the observed temperature dependence is that at 
room temperature there is significant flexibility and rapid rotation of the C-P bonds or movement of 
the bridging carbon chains, and the shielding is averaged out somewhat by this movement. Upon 
cooling, this process is slowed down (leading to signal broadening) and upon reaching -100 C 
(where the signals are sharp again), 82 is locked in a rigid conformation where the anisotropic 
shielding is maximized, leading to a chemical shift at 6.3 ppm. However, it cannot be ruled out that 
what is observed at room temperature is an average of the two diastereomeric conformations (a left-
hand propeller and a right-hand propeller), which would arise if there was rapid equilibration 
between them. But, considering the significant chemical shift difference (0.5 ppm) between the two 
ortho protons, it does appear unlikely, since their local environment would be very similar in the 
two propellers, where the only difference would be in the remote stereocenters.  
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Figure 53: Variable-temperature 1H-NMR of 82 in CD2Cl2. The aromatic region is shown. 
 
If one propeller conformation dominates at room temperature, one would expect this to be reflected 
in the CD spectrum, when this is compared to similar not-rigid molecules. Therefore, we obtained 
the CD spectra of 82 and the two precursors 76 (having only the two chiral centers) and 79 (a 
6.46.66.87.07.27.47.67.8 ppm
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triarylphosphine oxide expected to have a high degree of flexibility). The results can be seen in 
Figure 54 and the CD data does not support a rigid, single-propeller conformation for 82. 
 
 
Figure 54: Absorbance and CD spectra for compounds 76, 79 and 82 in acetonitrile solution. It can be expected 
that a rigid, propeller conformation for 82 would lead to a shift in the CD spectrum compared to the precursors 
76 and 79 and as can be seen, this is not the case. 
 
 
4.5. Conclusion 
A C3-symmetric triarylphosphine oxide was designed in order to investigate whether central chiral 
centers could act as a relay and stabilise a single diastereomeric propeller conformation of the 
molecule 82. The synthesis was executed after extensive optimisation of both the step to form the 
triarylphoshine 79 and the final one-pot three-RCM reaction, which eventually led to 82, which 
could be isolated in 2% yield, due to formation of several byproducts and great difficulties in 
separating the desired compound from these and ruthenium compounds. 
Initial structural studies of the solution conformation of 82 were performed using CD and variable 
temperature NMR. The results are inconclusive and further investigations will be needed to 
establish whether the relay strategy is successful.  
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5. Experimentals 
 
5.1. General experimental 
Starting materials, reagents, and solvents were purchased from Sigma-Aldrich Chemical Co. and 
used without further purification. CH2Cl2 was dried over 4 Å molecular sieves and THF was dried 
over sodium/benzophenone and distilled before use. Evaporation of solvents was done under 
reduced pressure (in vacuo). Thin layer chromatography (TLC) was performed on Merck aluminum 
sheets precoated with silica gel 60 F254. Compounds were visualized by UV irradiation at 254 nm 
and/or by charring after dipping in a solution of 6.25 g of (NH4)6Mo7O24 and 1.5 g of Ce(SO4)2 in 
250 mL of 10% aqueous H2SO4, in an ethanolic solution of phosphomolybdenic acid (48 g/L) or in 
a solution of 10 mL of p-anisaldehyde, 10 mL of a concentrated aqueous solution of H2SO4 and 250 
mL EtOH. Column chromatography was performed using Matrex 60 Å silica gel. The purity of the 
tested compounds was found to be >95% by HPLC. Normal-phase HPLC was performed on a 
Waters Alliance HPLC equipped with a diode array detector, using a LiChrospher Si 60 column and 
eluting with water/isopropanol/hexane mixtures or for chiral analysis a Chiralcel AS-H or OD-H 
column and eluting with hexane/2-propanol mixtures. RP-HPLC was obtained using a Shimadzu 
LC-2010C analytical HPLC by employing a XTerra RP8 5μm (4.6*150mm) column and eluting 
with water/acetonitrile mixtures containing 0.1% TFA. Analytical UPLC/MS (ESI) analysis was 
performed on a Waters AQUITY RP-UPLC system equipped with a diode array detector using an 
AQUITY UPLC BEH C-18 column (d 1.7 μm, 2.1 x 50 mm; column temp: 65 °C; flow: 0.6 
mL/min). Eluents A (0.1% HCO2H in water) and B (0.1% HCO2H in acetonitrile) were used in a 
linear gradient (5% B to 100% B) in a total run time of 5.2 min. The LC system was coupled to a 
SQD mass spectrometer. The LC system was coupled to a Micromass LCT orthogonal time-of-
flight mass spectrometer equipped with a Lock Mass probe operating in positive electrospray mode. 
NMR spectra were recorded using a Bruker AC 200 MHz spectrometer, a Varian Mercury 300 
MHz spectrometer, a Bruker Ascend 400 MHz spectrometer, a Varian Unity Inova 500 MHz 
spectrometer or a Bruker Ascend 500 MHz spectrometer. Chemical shifts were measured in ppm 
and coupling constants in Hz, and the field is indicated in each case. IR analysis was carried out on 
a Bruker Alpha FT-IR spectrometer and optical rotations were measured with a Perkin-Elmer 341 
polarimeter, units for ሾ∝ሿହ଼ଽଶ଴  are 10-1 deg cm2 g-1. CD was performed on a Jasco J-815 CD 
spectrometer equipped with a Jasco CDF-426 S/15 controller and a Julabo F12 temperature 
controller. HRMS was recorded on an Ionspec Ultima Fourier transform mass spectrometer. 
Melting points were measured by a Buch & Holm melting point apparatus and given in degrees 
Celsius (°C) uncorrected.  
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5.2. Procedures for biophysical and biological characterisation 
Liposome preparation, particle size determination and main phase transition temperature 
measurement 
The phospholipids were dissolved in CHCl3 in a test tube and dried under vacuum for 15 h to form 
a thin film. The (phospho)lipids (2 mM) were solubilized by addition of aqueous buffer (HEPES: 
0.15 M KCl, 30 μM CaCl2, 10 μM EDTA, 10 mM HEPES, pH 7.5 or PBS: 10 mM Na2HPO4, 2 
mM KH2PO4, 2.7 mM potassium chloride, 0.137 M sodium chloride, pH 7.4) and vortexed 
periodically over 1 h at 20 °C. Subsequently, the solutions were extruded through a 100 nm 
polycarbonate cutoff membrane (about 20 times) using a Hamilton syringe extruder (Avanti Polar 
Lipids, Birmingham, AL). The particle size distribution of the formulated lipids was measured by 
DLS. The DLS measurements were obtained using a Zetasizer Nano Particle Analyzer (ZS 
ZEN3600, Malvern Instrument, Westborough, MA) or a ZetaPALS zeta potential analyzer 
(Brookhaven Instruments Corporation, Holtsville, NY). DSC was performed from 10 to 70 °C using 
a MicroCal MC-2 (Northhampton, MA) on samples at a scan rate of 10 °C /h. A DSC scan was also 
performed on the HEPES buffer solution and was used to subtract a baseline from the thermograms 
of the measured samples. 
 
 
sPLA2 activity measurements monitored by MALDI-TOF-MS 
The formulated phospholipids (0.40 mL, 2 mM) were diluted in an aqueous buffer (2.1 mL, 0.15 M 
KCl, 30 μM CaCl2, 10 μM EDTA, 10 mM HEPES, pH 7.5) and the mixture was stirred at 37 °C in 
a test tube protected from light. The catalytic reaction was initiated by addition of human sPLA2 IIA 
(40 μL tear fluid). Sampling was done after 0, 1, 2, 4, 8, 24 and 48 and 96 h by collecting 100 μL of 
the reaction mixture and rapidly mixing it with a solution of CHCl3/MeOH/H2O/AcOH 4:8:1:1 (0.5 
mL) in order to stop the reaction. The mixture was washed with water (0.5 mL) and the organic 
phase (80 μL) was isolated by extraction and then concentrated in vacuo. For the MALDI-TOF-MS 
analysis the extract was mixed with 9 μL of DHB matrix (0.5 M DHB, 2 mM CF3COONa, 1 
mg/mL DMPG in MeOH), and 0.5 μL of this mixture was used for the MS analysis. Tear fluid was 
used as the source for human sPLA2 IIA. Tear fluid was collected from healthy subject exposed to 
onion vapor. Tear fluid has a high concentration of sPLA2 IIA and is the only prevalent sPLA2 
species found in tears. The sPLA2 IIA content in tears in healthy subjects (54.5 μg/ml) is one of the 
highest amounts of sPLA2 IIA content reported in human secretions.77,78,79 
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The CuAAC reaction on liposomes 
Lipids were dissolved in CH3Cl/MeOH (9:1) and mixed in the ratio 95:5 POPC/56 or POPC/57. 
The solvent was removed under a stream of nitrogen and the films placed under vacuum overnight 
to remove remaining traces of organic solvent. The obtained films were hydrated in a PBS buffer, at 
room temperature for 1 h by periodical vortexing, followed by extrusion at room temperature 
through a 100 nm polycarbonate filter using an Avanti Polar Lipids mini-extruder. Preformed 
functionalized liposomes (25 mM, 0.25 mL, 1 equiv.) were mixed with the corresponding coupling 
partner (fluorescein-azide for the liposomes containing 56 and fluorescein-alkyne for liposomes 
with 57) (0.95 mM; 107 μL, 0.65 equiv.), sodium ascorbate in PBS (5.6 mM, 50 μL, 1.67 equiv.), 
either ligand in PBS (2.24 mM, 50 μL, 0.66 equiv.) or PBS (50 μL) and copper sulfate (1.12 mM; 
50 μL, 0.33 equiv.) The reactions were shaken at room temperature and aliquots were taken for 
HPLC analysis after 0 (before addition of copper sulfate), 120, 480 and 1440 minutes (45 μL 
solution was removed, mixed with 45 μL PBS and 30 μL of this was injected for HPLC). A linear 
gradient was used from 100% A (water containing 0.1% TFA) to 100% B (MeCN containing 0.1% 
TFA) over 20 min with a flow rate of 1 mL/min. The AUC for the fluorescein derivatives was 
measured at 280 nm to monitor the conjugation efficiency. 
 
 
Reaction between propargyl amine functionalised liposomes and FITC 
Lipids were dissolved in CH3Cl/MeOH (9:1) and mixed in the ratio 99:1 POPC/59. The solvent was 
removed under a stream of nitrogen and the films placed under vacuum overnight to remove 
remaining traces of organic solvent. The obtained films were hydrated in a PBS buffer, at room 
temperature for 1 h; followed by 5 freeze−thaw cycles and extrusion at room temperature through a 
100 nm polycarbonate filter using an Avanti Polar Lipids mini-extruder. The size distribution of the 
liposomes was analyzed using dynamic light scattering, before and after the incubation with FITC. 
Preformed functionalized liposomes (25 mM, 0.25 mL, 1 equiv.) were mixed with the 
corresponding fluorescein isothiocyanate (0.15 mM, 107 μL, 0.5 equiv.) dissolved in PBS, then 
PBS was added to a final volume of 0.5 mL. The reactions were shaken (not stirred; to avoid 
foaming) at room temperature and aliquots (40 μL) removed for analysis by analytical HPLC. A 
linear gradient was used from 70% A (aqueous solution containing 5% MeCN and 0.1% TFA) to 
100% B (MeCN containing 0.1% TFA) over 20 min with a flow rate of 1 mL/min. The AUC for the 
free FITC was compared to the AUC of the phospholipid coupled products at 254 nm to monitor the 
conjugation efficiency. 
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Experimental data for compounds 
10-Phenyldecanal (2) 
In a flame-dried 100 mL three-necked round-bottomed flask, anhydrous Me2SO (14.1 mmol, 1 mL) 
in anhydrous CH2Cl2 (32 mL) under argon was cooled to -78 °C. A solution of (COCl)2 (7.05 
mmol, 597 µL) in anhydrous CH2Cl2 (1.5 mL) was added dropwise in order to keep the reaction 
temperature below -60 °C, and the misture was stirred at -78 °C for 10 min, after what a solution of 
10-phenyldecanol (6.41 mmol, 1.5 g) in CH2Cl2 (6 mL) was added dropwise (maintain the reaction 
temperature below -60 °C) and the reaction mixture was stirred for 45 min. Et3N (32.05 mmol, 4.5 
mL) was added dropwise at -78 °C, the mixture was stirred for 15 min at that temperature then 
allowed to reach 20 °C slowly. Water (40 mL) was added, the organic layer was separated and the 
aqueous layer was extracted with CH2Cl2 (3  40 mL). The organic phases were combined, washed 
with aq. 1% HCl (100 mL), water (100 mL), aq. 5% Na2CO3 (100 mL) and water (100 mL), dried 
over anhydrous Na2SO4, and concentrated in vacuo to give 1.485 mg of a clear oil. The crude 
product was used without further purification. Rf = 0.22 (hexane/EtOAC 19:1). 1H NMR (300 
MHz,CDCl3): δ 9.76 (t, J = 1.9 Hz, 1H, CHO), 7.30-7.25 (m, 2H, Ph-meta), 7.18-7.15 (m, 3H, Ph-
ortho and -para), 2.60 (t, J =7.5 Hz, 2H, CH2-Ph), 2.41 (td, J = 7.3, 1.9 Hz, 2H, CH2-CHO), 1.60 
(m, 4H, CH2-CH2-CHO and CH2-CH2-Ph), 1.29 (m, 10H, CH2-(CH2)5-CH2).214 13C NMR (75 MHz, 
CDCl3): δ 203.0, 142.9, 128.3 (2C), 128.2 (2C), 125.5, 45.6, 43.9, 36.0, 31.5, 29.4, 29.3, 29.2, 29.1, 
22.0.  
 
Methyl (E)-12-phenyldodec-2-enoate (3) 
In a flame-dried 100 mL round bottom flask, NaH ((60 % w/w) in mineral oil, 10.26 mmol, 410 
mg) was suspended in freshly distilled DME (25 mL) under argon, and methyl 
diethylphosphonoacetate (9.36 mmol, 1.7 mL) was added dropwise. The solution was stirred at 45 
°C for 1 h, 2 (6.41 mmol, 1.49 g) was added and the solution was stirred for 2 h at 50 °C. The crude 
mixture was then poured into ice-water, the organic layer was separated, and the aqueous layer was 
extracted with EtOAc (3  25 mL). The organic phases were combined, washed with ice-water 
(100 mL), brine (100 mL), dried over anhydrous Na2SO4 and concentrated in vacuo to give a yellow 
oil. Purification of the crude oil by flash chromatography (heptane/EtOAc 29:1) yielded 3 as a 
colourless oil (1.37 g, 74%). Rf = 0.33 (toluene/hexane 1:1). 1H NMR (300 MHz, CDCl3): δ 7.30-
7.27 (m, 2H, aromatic-meta), 7.20-7.18 (m, 3H, aromatic-ortho and -para), 6.99 (dt, J = 15.6, 7.1 
Hz, 1H CH=CH-COOMe), 5.83 (dt, J = 15.6, 1.5 Hz, 1H, CH=CH-COOMe), 3.73 (s, 3H, O-CH3), 
2.61 (t, J = 7.9 Hz, 2H, CH2-Ph), 2.2 (qd, J = 7.1, 1.5 Hz, 2H, CH2-CH=CH-COOMe), 1.67-1.57 
(m, 2H, CH2-CH2-Ph), 1.48-1.40 (m, 2H, Ph-CH2-CH2-(CH2)6-CH2-CH=CH=COOMe), 1.34-1.27 
(m, 10 H, Ph-CH2-CH2-(CH2)6-CH2-CH=CH=COOMe). 13C NMR (75 MHz, CDCl3): δ 167.1, 
149.7, 142.8, 128.3 (2C), 128.2 (2C), 125.5, 120.8, 51.3, 35.9, 32.1, 31.5, 29.4 (2C), 29.3, 29.2, 
29.0, 28.0. IR (neat): 3025, 2924, 2853, 1723, 1656, 1434, 1267, 1131, 1030, 979, 698 cm-1. HRMS 
(ESI +) C19H28O2, m/z [M+H+] 289.2168, found 289.2165. 
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(E)-12-Phenyldodec-2-enoic acid (4) 
In a 50 mL round-bottom flask, a solution of the ester 3 (2.98 mmol, 860 mg) and aq. 10% (w/w) 
NaOH (3.7 mL) in EtOH (16 mL) was stirred at 20 °C. After 2 h, 1% aq. HCl was added at 0 °C to 
reach pH≈4. A white precipitate was formed during HCl addition. The mixture was stored at 4 °C 
for 17 h, and the white precipitate was filtered off and recrystallised from EtOH/H2O to afford 750 
mg of 4 as white crystals (92 %). Rf = 0.18 (toluene/EtOAc 9:1). Mp.: 37.5 °C (lit. 40 °C).215 1H 
NMR (300 MHz, CDCl3): δ 9.8-9.5 (br s, 1H, COOH), 7.30-7.27 (m, 2H, aromatic -meta), 7.20-
7.18 (m, 3H, aromatic -orhto -para), 7.09 (dt, J = 15.5, 7.0 Hz, 1H, CH=CH-COOH), 5.83 (dt, J = 
15.5, 1.5 Hz, 1H, CH=CH-COOH), 2.61 (m, 2H, CH2-Ph), 2.23 (qd, J = 7.0, 1.5 Hz, 2H, CH2-
CH=CH), 1.65-1.57 (m, 2H, CH2-CH2-Ph), 1.49-1.42 (m, 2H, (CH2)6-CH2-CH=CH), 1.36-1.28 (m, 
10H, (CH2)6-CH2-CH=CH).215 13C NMR (75 MHz, CDCl3): δ 172.0, 152.4, 142.3, 128.4 (2C), 
128.2 (2C), 125.5, 120.7, 36.0, 32.3, 31.5, 29.4 (2C), 29.3 (2C), 29.1, 27.8. IR (neat): 3027, 2917, 
2849, 1691, 1648, 1496, 1468, 1420, 1289, 1219, 931, 710, 691 cm-1. HRMS (ESI +) C18H26O2, m/z 
[M+H+] 275.2011, found 275.2014.  
 
Methyl (Z)-12-phenyldodec-2-enoate (5) 
In a flame-dried 100 mL round bottom flask, NaH ((60 % w/w) in mineral oil, 1.83 mmol, 44 mg) 
was suspended in freshly distilled DME (35 mL) and anhydrous THF (7.5 mL) under argon, and the 
resulting suspension was cooled to - 78 °C. Methyl P,P-bis(2,2,2-trifluoroethyl)phosphonoacetate 
(1.77 mmol, 374 µL) was added dropwise at - 78 °C, and the reaction mixture was stirred at that 
temperature. After 30 min, freshly synthesized 2 (1.22 mmol, 283 mg) was added and the solution 
was stirred for 3 h at - 78 °C, then at 20 °C for 65 h. Sat. aq. NH4Cl was added at 0 °C, the organic 
layer was separated, and the aqueous layer was extracted with Et2O (3  40 mL). The organic 
phases were combined, dried over anhydrous MgSO4 and concentrated in vacuo to give a yellow 
oil. Purification of the crude oil by flash chromatography (toluene/hexane 1:1) yielded 5 as a 
colourless oil (250 mg, 71%). Rf = 0.35 (toluene/hexane 1:1). 1H NMR (300 MHz, CDCl3): δ 7.31 - 
7.16 (m, 5H), 6.24 (dt, J = 11.5, 7.6 Hz, 1H, CH=CH-COOMe), 5.78 (dt, J = 11.5, 1.7 Hz, 1H, 
CH=CH-COOMe), 3.70 (s, 3H, O-CH3), 2.70 – 2.58 (m, 4H, CH2-Ph and CH2-CH=CH-COOMe), 
1.64 - 1.57 (m, 2H, CH2-CH2-Ph), 1.47-1.30 (m, 12H, Ph-CH2-CH2-(CH2)6-CH2-
CH=CH=COOMe). 13C NMR (75 MHz, CDCl3): δ 166.8, 151.0, 142.9, 128.3 (2C), 128.1 (2C), 
125.5, 119.0, 50.9, 35.9, 31.5, 29.4 (2C), 29.3 (2C), 29.2, 28.9 (2C). IR (neat): 3027, 2924, 2853, 
1723, 1644, 1437, 1171 cm-1. HRMS (ESI +) C19H28O2, m/z [M+H+] 289.2168, found 289.2167. 
 
(Z)-12-Phenyldodec-2-enoic acid (6) 
In a 25 mL round-bottom flask, a solution of the ester 5 (0.69 mmol, 200 mg) and aq. 10% (w/w) 
NaOH (840 µL) in tBuOH 3.5 mL) was stirred at 20 °C. After 5 days, 1% aq. HCl was added at 0 
°C to reach pH≈4. A white precipitate was formed during HCl addition. The mixture was stored at 4 
°C for 17 h, and the white precipitate was filtered off, washed with H2O and recrystallised from 
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EtOH/H2O to afford 164 mg of 6 as white crystals (87 %). Rf = 0.26 (toluene/EtOAc 1:1). Mp.: 39 
°C. 1H NMR (300 MHz, CDCl3): δ 7.30-7.15 (m, 5H, C6H5), 6.36 (dt, J = 11.5, 7.6 Hz, 1H, 
CH=CH-COOH), 5.79 (dt, J = 11.5, 1.7 Hz, 1H, CH=CH-COOH), 2.70-2.58 (m, 4H, CH2-Ph and 
CH2-CH=CH), 1.66-1.58 (m, 2H, CH2-CH2-Ph), 1.47-1.29 (m, 12H, (CH2)6-CH2-CH=CH). 13C 
NMR (75 MHz, CDCl3): δ 172.2, 153.8, 143.1, 128.5 (2C), 128.3 (2C), 125.7, 119.1, 36.1, 31.7, 
29.6 (2C), 29.5, 29.46, 29.40, 29.36, 29.08. IR (neat): 3056, 2923, 2849, 1692, 1631, 1435, 1231, 
903, 708 cm-1. HRMS (ESI +) C18H26O2, m/z [M+H+] 275.2011, found 275.2006.  
 
Ethyl (E)-2-methyl-12-phenyldodec-2-enoate (7) 
To a suspension of NaH ((60 % w/w) in mineral oil, 6.03 mmol, 241 mg) in freshly distilled DME 
(8.5 mL) under argon, was added dropwise a solution of triethyl-2-phosphonopropionate (6.03 
mmol, 1.3 mL) in freshly distilled DME (1 mL). The mixture was stirred at 50 °C for 30 min, and a 
solution of freshly synthesized 2 (3.45 mmol, 800 mg) in freshly distilled DME was added and the 
solution was stirred for 18 h at 70 °C. The crude mixture was then poured in ice-water (10 mL), the 
organic layer was separated, and the aqueous layer was extracted with EtOAc (3  10 mL). The 
organic phases were combined, washed with brine (100 mL), dried over anhydrous MgSO4 and 
concentrated in vacuo. The crude oil was purified by flash chromatography (toluene/hexane 1:1) to 
give 7 as a colourless oil in 59 % isolated yield (641 mg). The isomer ethyl (Z)-2-methyl-12-
phenyldodec-2-enoate (9) was also isolated (89 mg, 8 %). Rf = 0.16 (toluene/hexane 1:1). 1H NMR 
(300 MHz, CDCl3): δ 7.30-7.14 (m, 5H, C6H5), 6.76 (tq, J = 7.5, 1.3 Hz, 1H, CH=C(CH3)-COOEt), 
4.19 (q, J = 7.1 Hz, 2H, COO-CH2-CH3), 2.62-2.59 (m, 2H, CH2-Ph), 2.15 (q, J = 7.5 Hz, 2H, CH2-
CH=C(CH3)-COOEt), 1.83 (d, J = 1.3 Hz, 3H, CH=C(CH3)-COOEt), 1.63-1.56 (m, 2H, CH2-CH2-
Ph), 1.45-1.27 (m, 15 H, Ph-CH2-CH2-C6H12-CH2-CH2 and CH2-CH3). 13C NMR (75 MHz, CDCl3): 
δ 168.5, 143.0, 142.6, 128.5 (2C), 128.3 (2C), 127.8, 125.7, 60.5, 36.1, 31.6, 29.6 (3C), 29.51, 29.4, 
28.3, 28.7, 14.4, 12.47. IR (neat): 3026, 2980, 2924, 2853, 1708, 1453, 1258 cm -1. HRMS (ESI +) 
C21H32O2, m/z [M+H+] 317.2481, found 317.2482. 
 
(E)-2-Methyl-12-phenyldodec-2-enoic acid (8) 
In a 50 mL round-bottom flask, a solution of the ester 7 (1.93 mmol, 590 mg) and aq. 10% (w/w) 
NaOH (2.5 mL) in EtOH (10 mL) was stirred at 20 °C. After 40 h, 1% aq. HCl was added at 0 °C to 
reach pH≈4. A white precipitate was formed during HCl addition. The mixture was stored at 4 °C 
for 17 h, and the white precipitate was filtered off, washed with water and recrystallised from 
EtOH/H2O to afford 494 mg of 8 as white crystals (89 %). Rf = 0.51 (toluene/EtOAc 3:1). Mp.: 41 
°C. 1H NMR (300 MHz, CDCl3): δ 7.30-7.14 (m, 5H, C6H5), 6.92 (t, J = 7.4 Hz, 1H, CH=C(CH3)-
COOH), 2.60 (m, 2H, CH2-Ph), 2.19 (q, J = 7.4 Hz, 2H, CH2-CH=CH), 1.83 (s, CH=C(CH3)COO), 
1.66-1.56 (m, 2H, CH2-CH2-Ph), 1.47-1.29 (m, 12H, (CH2)6-CH2-CH=C(CH3)). 13C NMR (75 
MHz, CDCl3): δ 173.6, 145.7, 143.1, 128.6 (2C), 128.4 (2C), 127.1, 125.7, 36.2, 31.8, 29.7 (2C), 
29.6 (2C), 29.5, 29.14, 28.6, 12.2. IR (neat): 2917, 2848, 2651, 2540, 1680, 1632, 1467, 1421, 1287 
cm-1. HRMS (ESI +) C19H28O2, m/z [M+Na+] 311.1987, found 311.1989.  
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Ethyl (Z)-2-methyl-12-phenyldodec-2-enoate (9) 
To a suspension of NaH ((60 % w/w) in mineral oil, 3.88 mmol, 155 mg) in freshly distilled DME 
(70 mL) and anhydrous THF (10 mL) cooled to -78 °C under argon, was added slowly ethyl-2-
[bis(2,2,2-trifluoroethyl)phosphono]propionate (3.75 mmol, 1.30 g), and the mixture was stirred at -
78 °C for 30 min. After that, freshly synthesized 2 (2.58 mmol, 600 mg) was added and the solution 
was stirred for 3 h at -78 °C and then at 20 °C for 18 h. The crude mixture was then poured in ice-
water (150 mL), the organic layer was separated, and the aqueous layer was extracted with EtOAc 
(3  100 mL). The organic phases were combined, washed with brine (100 mL), dried over 
anhydrous MgSO4 and concentrated in vacuo. The crude oil was purified by flash chromatography 
(toluene/hexane 1:1) to give 9 as colourless oil in 67 % isolated yield (550 mg). Rf = 0.22 
(toluene/hexane 1:1). 1H NMR (300 MHz, CDCl3): δ 7.30-7.15 (m, 5H, C6H5), 5.92 (t, J = 7.5 Hz, 
1H, CH=C(CH3)-COOEt), 4.20 (q, J = 7.1 Hz, 2H, COO-CH2-CH3), 2.62-2.57 (m, 2H, CH2-Ph), 
2.43 (q, J = 7.5 Hz, 2H, CH2-CH=C(CH3)-COOEt), 1.89 (s, 3H, CH=C(CH3)-COOEt), 1.66-1.58 
(m, 2H, CH2-CH2-Ph), 1.41-1.28 (m, 15 H, Ph-CH2-CH2-C6H12-CH2-CH2 and COOCH2-CH3). 13C 
NMR (75 MHz, CDCl3): δ 168.2, 143.1, 142.9, 128.4 (2C), 128.2 (2C), 127.0, 125.5, 60.0, 36.0, 
31.5, 29.6, 29.5 (3C), 29.4, 28.3 (2C), 20.7, 14.3. IR (neat): 3025, 2978, 2924, 2853, 1713, 1454, 
1229 cm -1. HRMS (ESI +) C21H32O2, m/z [M+Na+] 339.2300, found 339.2311.  
 
(Z)-2-Methyl-12-phenyldodec-2-enoic acid (10) 
In a 50 mL round-bottom flask, a solution of the ester 9 (2.09 mmol, 662 mg) and aq. 10% (w/w) 
NaOH (2.5 mL) in EtOH (11 mL) was stirred at 20 °C. After 7 days, 1% aq. HCl was added at 0 °C 
to reach pH≈4. A white precipitate was formed during HCl addition. The mixture was stored at 4 °C 
for 17 h, and the white precipitate was filtered off, washed with water and recrystallised from 
EtOH/H2O to afford 345 mg of 10 as white crystals (83 %). Rf = 0.55 (toluene/EtOAc 3:1). Mp.: 
60.9-61.0 °C. 1H NMR (300 MHz, CDCl3): δ 7.31-7.14 (m, 5H, C6H5), 6.10 (tq, J = 7.5, 1.4 Hz, 
1H, CH=C(CH3)-COOH), 2.63-2.58 (m, 2H, CH2-Ph), 2.52 (qq, J = 7.5, 1.4 Hz, 2H, CH2-
CH=C(CH3)), 1.92 (q, J = 1.4 Hz, 3H, CH=C(CH3)COO), 1.66-1.56 (m, 2H, CH2-CH2-Ph), 1.43-
1.29 (m, 12H, (CH2)6-CH2-CH=C(CH3)). 13C NMR (75 MHz, CDCl3): δ 173.6, 147.1, 142.9, 128.4 
(2C), 128.2 (2C), 125.9, 125.5, 36.0, 31.5, 29.8, 29.5 (2C), 29.4 (2C), 29.3(2C), 20.5. IR (neat): 
2922, 2849, 1687, 1669, 1625, 1460, 1354, 1253 cm-1. HRMS (ESI +) C19H28O2, m/z [M+Na+] 
311.1987, found 311.1978. 
 
Methyl (E)-3-methyl-12-phenyldodec-2-enoate (11) 
In a flame-dried 25 mL flask, NaH ((60 % w/w in mineral oil), 3.90 mmol, 170 mg) was suspended 
in freshly distilled DME (10 mL) under argon, and methyl diethylphosphonoacetate (3.80 mmol, 
690 µL) was added dropwise. The solution was stirred at 45 °C for 30 min, ketone 16 (1.30 mmol, 
320 mg) was added rapidly and the solution was stirred for 18 h at 65 °C. The solution was poured 
into ice-water (20 mL), the organic phase was separated, and the aqueous layer was washed with 
EtOAc (3  15 mL). The organic phases were combined, washed with ice-water, brine, dried over 
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Na2SO4 and concentrated in vacuo to give a yellow oil. The desired product 11 was isolated after 
purification by flash chromatography (toluene/hexane 1:1) as colourless oil (218 mg, 56 %). The 
other isomer, methyl (Z)-3-methyl-12-phenyldodec-2-enoat (13) was also isolated (62 mg, 16 %). 
Rf = 0.13 (toluene/heptane 1:1). 1H NMR (300 MHz, CDCl3): δ 7.30-7.14 (m, 5H, C6H5), 5.67-5.66 
(m, 1H, C(CH3)=CH-COO), 3.69 (s, 3H, COO-CH3), 2.63-2.58 (m, 2H, CH2-Ph), 2.16-2.10 (m, 5H, 
CH2-C(CH3)=CH-COO), 1.66-1.56 (m, 2H, CH2-CH2-Ph), 1.50-1.43 (m, 2H, CH2-CH2-
C(CH3)=CH-COO), 1.31-1.27 (m, 10H, Ph-CH2-CH2-C5H10). 13C NMR (75 MHz, CDCl3): δ 167.3, 
160.8, 142.9, 128.4 (2C), 128.2 (2C), 125.5, 114.9, 50.8, 40.9, 36.0, 31.5, 29.4 (3C), 29.3, 29.1, 
27.3, 18.7. IR (neat): 3025, 2925, 2853, 1718, 1649, 1433, 1356, 1220, 1145, 1030, 865, 697 cm-1. 
HRMS (ESI +) C20H30O2, m/z [M+H+] 303.2324, found 303.2317. 
 
(E)-3-Methyl-12-phenyldodec-2-enoic acid (12) 
To a solution of 11 (3.34 mmol, 1.01 g) in anhydrous Et2O (15 mL) under argon, was added 
TMSOK (10.03 mmol, 1.29 g) and the resulting mixture was stirred at 20 °C for 25 h. After that 
time, TLC showed full conversion of the starting material, the mixture was cooled to 0 °C and 1M 
HCl was added to reach pH≈3. The organic phase was separated, the aqueous phase was extracted 
with EtOAc (3  10 mL), the combined organic phases were washed with brine and dried over 
anhydrous MgSO4. 12 was isolated in 71 % yield (684 mg) as white crystals after concentration in 
vacuo and purification by flash chromatography (toluene/EtOAc 99:1). The isomer, acid 14 was 
also isolated (55 mg, 6 % yield). Rf = 0.3 (toluene/EtOAc 4:1). Mp.: 40.5-41 °C. 1H NMR (300 
MHz, CDCl3): δ 11.72 (br. s, 1H, COOH), 7.31-7.14 (m, 5H, C6H5), 5.69 (q, J = 1.1 Hz, 1H, 
C(CH3)=CH-COO), 2.63-2.58 (m, 2H, CH2-Ph), 2.18-2.13 (m, 5H, CH2-C(CH3)=CH-COO), 1.66-
1.57 (m, 2H, CH2-CH2-Ph), 1.52- 1.45 (m, 2H, CH2-CH2-C(CH3)=C), 1.35-1.28 (m, 10H, Ph-CH2-
CH2-C5H10). 13C NMR (75 MHz, CDCl3): δ 172.1, 163.7, 142.9, 128.4 (2C), 128.2 (2C), 125.5, 
114.9, 41.2, 36.0, 31.5, 29.4 (3C), 29.3, 29.1, 27.3, 19.1. IR (neat): 3023, 2919, 2850, 1686, 1635, 
1495, 1469, 1253, 1162, 938 cm-1. HRMS (ESI +) C19H28O2, m/z [M+Na+] 311.1987, found 
311.1984. 
 
Methyl (Z)-3-methyl-12-phenyldodec-2-enoate (13) 
In a flame-dried 250 mL flask, NaH ((60 % w/w in mineral oil), 15.88 mmol, 635 mg) was 
suspended in freshly distilled DME (160 mL) under argon, and methyl-2-[bis(2,2,2-
trifluoroethyl)phosphono]acetate (11.68 mmol, 3.716 g) was added dropwise. The solution was 
stirred at 45 °C for 30 min, 16 (5.90 mmol, 1.45 g) was added and the solution was stirred for 18 h 
at 65 °C. The solution was poured into ice-water (150 mL), the organic phase was separated, and 
the aqueous layer was washed with EtOAc (3  100 mL). The organic phases were combined, 
washed with brine, dried over MgSO4 and concentrated in vacuo to give a yellow oil. The desired 
product 13 was obtained after purification by flash chromatography (toluene/heptane 1:1) as 
colourless oil (480 mg, 27 %). The other isomer, methyl (E)-3-methyl-12-phenyldodec-2-enoat (11) 
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was also isolated (525 mg, 30 %). Rf = 0.19 (toluene/heptane 1:1). 1H NMR (300 MHz, CDCl3): δ 
7.30-7.14 (m, 5H, C6H5), 5.65 (m, 1H, C(CH3)=CH-COO), 3.67 (s, 3H, COO-CH3), 2.64-2.57 (m, 
4H, CH2-Ph and CH2-C(CH3)=CH-COO), 1.88 (d, J = 1.4 Hz, 3H, CH2-C(CH3)=CH-COO), 1.64-
1.56 (m, 2H, CH2-CH2-Ph), 1.48-1.41 (m, 2H, CH2-CH2-C(CH3)=CH-COO), 1.30 (m, 10H, Ph-
CH2-CH2-C5H10). 13C NMR (75 MHz, CDCl3): δ 166.8, 161.3, 142.9, 128.4 (2C), 128.2 (2C), 
125.5, 115.4, 50.1, 36.0, 33.4 31.5, 29.7, 29.5 (3C), 29.3, 28.2, 25.2. IR (neat): 3025, 2925, 2853, 
1718, 1649, 1433, 1356, 1220, 1145, 1030, 865, 697 cm-1. HRMS (ESI +) C20H30O2, m/z [M+H+] 
303.2324, found 303.2313.  
 
(Z)-3-Methyl-12-phenyldodec-2-enoic acid (14) 
To a solution of 13 (2.46 mmol, 744 mg) in anhydrous Et2O (10 mL) under argon, was added 
TMSOK (7.39 mmol, 948 mg) and the resulting mixture was stirred at 20 °C. After 23 h, another 
portion of TMSOK (1.95 mmol, 250 mg) was added and the mixture was stirred at 20 °C for 
additional 4 h. The mixture was then cooled to 0 °C and 1M HCl was added to reach pH≈3. The 
organic phase was separated, the aqueous phase was extracted with EtOAc (3  10 mL), the 
combined organic phases were washed with brine and dried over anhydrous MgSO4. 14 was 
isolated in 62 % yield (435 mg) as white crystals after concentration in vacuo and purification by 
flash chromatography (toluene/EtOAc 99:1). The isomer, acid 12 was also isolated (50 mg, 7 % 
yield). Rf = 0.38 (toluene/EtOAc 4:1). Mp.: 61.5-62.5 °C. 1H NMR (300 MHz, CDCl3): δ 11.32 (br 
s, 1H, COOH), 7.30-7.14 (m, 5H, C6H5), 5.68-5.67 (m, 1H, C(CH3)=CH-COO), 2.65-2.57 (m, 4H, 
CH2-Ph and CH2-C(CH3)=CH-COO), 1.91 (d, J = 1.3 Hz, 3H, CH2-C(CH3)=CH-COO), 1.66-1.56 
(m, 2H, CH2-CH2-Ph), 1.48-1.41 (m, 2H, CH2-CH2-C(CH3)=C), 1.33-1.28 (m, 10H, Ph-CH2-CH2-
C5H10). 13C NMR (75 MHz, CDCl3): δ 171.1, 164.2, 142.9, 128.4 (2C), 128.2 (2C), 125.5, 115.2, 
36.0, 33.5, 31.5, 29.6, 29.5 (2 C), 29.4, 29.3, 28.1, 25.5. IR (neat): 3026, 2924, 2853, 1690, 1639, 
1453, 1417, 1248 cm-1. HRMS (ESI +) C19H28O2, m/z [M+H+] 289.2168, found 289.2169. 
 
11-Phenylundecan-2-ol (15) 
In a flame-dried 250 mL 3-neck round bottom flask equipped with a condenser, were suspended Mg 
turnings (12.89 mmol, 313 mg) in anhydrous Et2O (38 mL) under argon, and MeI (11.17 mmol, 696 
µL) was added dropwise. The resulting mixture was stirred at 20 °C for 2.5 h, after what the 
magnesium turnings had fully reacted and a solution of freshly synthesized 2 (8.59 mmol, 1.99 g) in 
Et2O (10 mL) was added dropwise and the resulting mixture was stirred at 20 °C. After 2.5 h, the 
mixture was cooled to 0 °C, sat. aq. NH4Cl (25 mL) was added, the organic phase was separated, 
and the aqueous phase was washed with Et2O (3  25 mL). The combined organic layers were 
washed with water and with brine, dried over MgSO4, concentrated in vacuo and purified by flash 
chromatography (hexane/EtOAc 6:1) to afford 1.58 g of 15 as a clear oil (79 %). Rf = 0.44 
(hexane/EtOAc 1:1). 1H NMR (300 MHz, CDCl3): δ 7.40-7.32 (m, 2H, C5H6-meta), 7.27-7.22 (m, 
3H, C6H5 –ortho and -para), 3.86-3.84 (m, 1H, CH-OH), 2.67 (t, J = 7.6 Hz, CH2-Ph, 2H), 1.73-
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1.63 (m, 2H, CH2-CH2-Ph), 1.54-1.34 (m, 14H, C7H14-CH-OH), 1.25 (d, J = 6.2 Hz, 3H, CH-
CH3).56 13C NMR (75 MHz, CDCl3): δ 142.9, 128.4 (2C), 128.2 (2C), 125.5, 68.2, 39.3, 35.9, 31.5, 
29.6 (2C), 29.5 (2C), 29.3, 25.7, 23.5. IR (neat): 3349, 3026, 2923, 2852, 1603, 1453, 1123, 1029, 
477, 696 cm-1. HRMS (ESI +) C17H28O, m/z [M+Na+] 271.2038, found 271.2027. 
 
11-Phenylundecan-2-one (16) 
In a flame-dried 250 mL three-necked flask, a mixture of Me2SO (29.38 mmol, 2.1 mL) in 
anhydrous CH2Cl2 (66 mL) was cooled to -78 °C. A mixture of (COCl)2 (14.69 mmol, 1.2 mL) in 
anhydrous CH2Cl2 (3.5 mL) was added slowly in order to keep the reaction temperature below -60 
°C, and the mixture was stirred at -78 °C. After 30 min, a solution of 15 (13.35 mmol, 3.31 g) in 
CH2Cl2 (14 mL) was added dropwise in order to keep the reaction temperature below -60 °C and 
the reaction mixture was stirred at -78 °C for 1 h. Et3N (66.75 mmol, 9.3 mL) was added dropwise, 
the mixture stirred for additional 15 min at -78 °C and was then allowed to reach 20 °C. Water (80 
mL) was added, the organic layer was separated and the aqueous layer was washed with CH2Cl2 (3 
 50 mL). The organic phases were combined, washed with aq. 1% HCl (100 mL), water (100 
mL), aq. 5% Na2CO3 (100 mL) and brine (100 mL), dried over anhydrous MgSO4, and concentrated 
in vacuo to give a clear oil, yielding 93 % (3.04 g) of 16 as a clear oil after flash chromatography 
(heptane/EtOAc 19:1). Rf = 0.16 (heptane/EtOAc 19:1). 1H NMR (300 MHz, CDCl3): δ 7.31-7.14 
(m, 5, C6H5), 2.62-2.57 (m, 2H, CH2-Ph), 2.4 (t, J = 7.4 Hz, 2H, CH2-C=O), 2.13 (s, 3H,C=O-CH3), 
1.66-1.52 (m, 4H, CH2-CH2-Ph and CH2-CH2-C=O), 1.32-1.27 (m, 10H, Ph-CH2-CH2-C5H10-CH2). 
13C NMR (75 MHz, CDCl3): δ 209.3, 142.9, 128.4 (2C), 128.2 (2C), 125.5, 43.8, 35.9, 31.5, 29.8, 
29.4 (3C), 29.3, 29.1, 23.8. IR (neat): 3026, 2925, 2853, 1714, 1495, 1453, 1365, 1164, 745, 698 
cm-1. HRMS (ESI +) C17H26O, m/z [M+H+] 247.2062, found 247.2059.  
 
1,2-O-Isopropylidene-3-O-(para-methoxybenzyl)-sn-glycerol (17) 
PMBOH (7.25 mmol, 1 g) was dissolved in concentrated HCl (2.5 mL) and the solution was stirred 
at 20 °C. After 20 h, the solution had turned yellow, and TLC showed full conversion of the starting 
material. Water (2.5 mL) was then added, the mixture was extracted with CH2Cl2 (3  5 mL), dried 
over CaCl2 and concentrated in vacuo to give 1.08 g of a pink oil (crude yield = 95 %). The crude 
was analyzed by NMR, and used without further purification. Rf = 0.58 (hexane/EtOAc 1:1). 1H 
NMR (300 MHz, CDCl3): δ 7.32 and 6.89 (AA’XX’ pattern, J = 8.7 Hz, 4H, aromatic), 4.57 (s, 2H, 
CH2-Cl), 3.81 (s, 3H, Ph-CH3).60 13C NMR (75 MHz, CDCl3): δ 159.6, 130.0 (2C), 129.7, 114.1 
(2C), 55.3, 46.3. 
In a 25 mL flame-dried flask, was prepared a suspension of NaH (60 % (w/w) in mineral oil, 6.7 
mmol, 268 mg) in anhydrous DMF (3 mL) cooled to 0 °C under argon, to which was added 1,2-O-
isopropylidene-sn-glycerol (4.19 mmol, 553 mg) dropwise at 0 °C and the resulting mixture was 
stirred at 20 °C. After 1 h, the resulting green mixture was cooled to 0 °C, the freshly synthesised 
PMBCl (6.07 mmol, 950 mg) was added dropwise and the mixture was stirred at 20 °C for 20 h. 
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The reaction was quenched by addition of water (10 mL) at 0 °C, the organic phase was separated, 
and the aqueous phase was extracted with Et2O (3  10 mL). The organic phases were combined 
and washed with water (30 mL), brine (30 mL), dried over Na2SO4, and concentrated in vacuo. The 
crude oil thereby obtained was purified by flash chromatography (hexane/EtOAc 6:1) to afford the 
desired acetonide as a colourless oil in 79 % yield (830 mg). Rf = 0.15 (hexane/EtOAc 6:1). 1H 
NMR (300 MHz, CDCl3): δ 7.32 and 6.89 (AA’XX’ pattern, J = 8.7 Hz, 4H, aromatic), 4.53 (d, J = 
11.7 Hz, 1H, CH2-Ph), 4.47 (d, J = 11.7 Hz, 1H, CH2-Ph), 4.28 (qnt, J = 6.0 Hz, 1H, CH2-CH-CH2-
OPMB), 4.04 (dd, J = 8.2, 6.0 Hz, 1H, CH2-CH-CH2-OPMB), 3.80 (s, 3H, O-CH3), 3.72 (dd, J = 
8.2, 6.0 Hz, 1H, CH2-CH-CH2-OPMB), 3.52 (dd, J = 9.8, 6.0 Hz, 1H, CH2-CH-CH2-OPMB), 3.43 
(dd, J = 9.8, 6.0 Hz, 1H, CH2-CH-CH2-OPMB), 1.42 (s, 3H, C-CH3), 1.36 (s, 3H, C-CH3).60 13C 
NMR (75 MHz, CDCl3): δ 159.2, 129.4 (2C), 128.6, 113.8 (2C), 109.4, 74.4, 73.1, 70.7, 66.9, 55.3, 
26.6, 26.4. 
 
3-O-(para-Methoxybenzyl)-sn-glycerol (18) 
In a 25 mL flask, 17 (3.29 mmol, 830 mg) was dissolved in methanol (1.2 mL) and 1M HCl (0.7 
mL), and the mixture was stirred at 20 °C. After 3 h, NaHCO3 was added (2 mL), and the mixture 
was extracted with EtOAc (3  3 mL). The combined organic phases were washed with H2O and 
brine, dried over MgSO4, concentrated in vacuo and purified by flash chromatography 
(CH2Cl2/MeOH 10:1). The desired product was isolated in 68% yield (475 mg) as white powder. Rf 
= 0.39 (CH2Cl2/MeOH 9:1). Mp.: 42-43 °C. ሾ∝ሿ஽ଶ଴= -1.55° (c = 6.9, CHCl3). (lit. ሾ∝ሿ஽ଶ଴= -1.4° (c = 
6.9, CHCl3)39. 1H NMR (300 MHz, CDCl3): δ 7.23 and 6.80 (AA’XX’ pattern, J = 8.7 Hz, 4H, 
aromatic), 4.45 (s, 2H, CH2-Ph), 3.88-3.82 (m, 1 H, CH2-CH-CH2), 3.79 (s, 3H, O-CH3), 3.65 (dd, J 
= 11.5, 3.2 Hz, 1H, OH-CH2-CH-CH2), 3.56 (dd, J = 11.5, 5.8 Hz, 1H, OH-CH2-CH-CH2), 3.51-
3.42 (m, 2H, OH-CH2-CH-CH2), 2.3 (br s, 2H, 2OH).39 13C NMR (75 MHz, CDCl3): δ 159.3, 
129.7, 129.4 (2C), 113.8 (2C), 73.1, 71.3, 70.7, 64.0, 55.2.39 IR (neat): 3512, 2915, 2848, 1737, 
1712, 1613, 1514, 1366, 1171, 1116, 1078, 1031, 812, 718 cm-1. HRMS (ESI +) C11H16O4, m/z 
[M+Na+] 235.0946, found 235.0956.  
 
1-Stearoyl-3-O-(para-methoxybenzyl)-sn-glycerol (19) 
In a 250 mL flask, stearic acid (8.26 mmol, 2.34 g) was dissolved in anhydrous CH2Cl2 (80 mL). 
DCC (8.66 mmol, 1.78 g) and DMAP (2.36 mmol, 288 mg) were added, and the resulting mixture 
was stirred at 20 °C. After 30 min, the mixture was cooled to 0 °C and a solution of the 18 (7.87 
mmol, 1.67 g) in anhydrous CH2Cl2 (80 mL) was added slowly. The mixture was stirred at 0 °C for 
2.5 h, and then allowed to reach 20 °C. The mixture was concentrated in vacuo, the product was 
purified by flash chromatography (hexane/EtOAc 5:1) and obtained as a white solid in 70% yield 
(2.62 g). Rf = 0.15 (hexane/EtOAc 5:1). Mp.: 49.5-50 °C. ሾ∝ሿ஽ଶ଴= + 0.23° (c = 5.9, CHCl3). (lit. 
ሾ∝ሿ஽ଶ଴= + 0.1° (c = 5.9, CHCl3).39 1H NMR (300 MHz, CDCl3): δ 7.23 and 6.80 (AA’XX’ pattern, J 
= 8.7 Hz, 4H, aromatic), 4.49 (s, 2H, CH2-Ph), 4.20-4.09 (m, 2H, C18H35-COO-CH2-CH-CH2), 
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4.05-3.98 (m, 1H, C18H35-COO-CH2-CH-CH2), 3.81 (s, 3H, O-CH3), 3.52 (dd, J = 9.6, 4.3 Hz, 1H, 
C18H35-COO-CH2-CH-CH2), 3.45 (dd, J = 9.6, 6.1 Hz, 1H, C18H35-COO-CH2-CH-CH2), 2.50 (d, J 
= 4.8 Hz, 1H, OH), 2.31 (t, J = 7.5 Hz, 2H, CH2COO), 1.63-1.60 (m, 2H, CH2-CH2-COO), 1.32-
1.25 (m, 28H, CH3-C14H28-CH2-CH2-COO), 0.88 (t, J = 6.7 Hz, 3H, CH3).39 13C NMR (75 MHz, 
CDCl3): δ 173.9, 159.3, 129.7, 129.4 (2C), 113.8 (2C), 73.2, 70.5, 68.9, 65.3, 55.3, 34.1, 31.9, 29.7 
(7C), 29.6, 29.4, 29.3, 29.2, 29.1, 24.9, 22.7, 14.1.39 IR (neat): 3265, 2973, 2939, 2862, 1610, 1584, 
1461, 1241, 1206, 1175, 1020, 812, 711 cm-1. HRMS (ESI +) C29H50O6, m/z [M+Na+] 501.3556, 
found 501.3563.  
 
1-Stearoyl-2-((E)-12-phenyldodec-2-enoyl)-3-O-(para-methoxybenzyl)-sn-glycerol (20) 
In a 50 mL flask, 4 (0.547 mmol, 150 mg) and 19 (0.61 mmol, 290 mg) were dissolved in 
anhydrous CH2Cl2 (10 mL), DCC (0.852 mmol, 175 mg) and DMAP (0.547 mmol, 67 mg) were 
added, and the mixture was stirred at 20 °C. After 2 h, a second portion of 4 (0.547 mmol, 150 mg), 
DCC (0.852 mmol, 175 mg) and DMAP (0.547 mmol, 67 mg) was added and the solution was 
stirred for 1 h. The mixture was concentrated in vacuo and the product was purified by flash 
chromatography (hexane/EtOAc 10:1) and isolated as a white solid in 88% yield (392 mg). Rf = 1.6 
(hexane/EtOAc 10:1). Mp.: 51.9-52.1 °C. ሾ∝ሿ஽ଶ଴= +5.91° (c = 1.6, CHCl3). 1H NMR (300 MHz, 
CDCl3): δ 7.29-7.17 (m, 7H, C6H5 and CH-CH-C-OMe), 7.0 (dt, J = 15.6, 6.9 Hz, 1H, CH=CH-
COO), 6.89-6.85 (m, 2H, CH-CH-C-OMe), 5.83 (dt, J = 15.6, 1.3 Hz, 1H, CH=CH-COO), 5.30-
5.23 (m, 1H, CH2-CH-CH2), 4.50 (d, J = 11.7 Hz, 1H, CH2-Ph-OMe), 4.45 (d, J = 11.7 Hz, 1H, 
CH2-Ph-OMe), 4.34 (dd, J = 11.8, 3.9 Hz, 1H, C17H35-COOCH2), 4.25 (dd, J = 11.8, 6.3 Hz, 1H, 
C17H35-COOCH2), 3.80 (s, 3H, O-CH3), 3.59 (d, J = 5.9 Hz, 2H, CH2-OPMB), 2.61-2.59 (m, 2H, 
C8H16-CH2-Ph), 2.28 (t, J = 7.5 Hz, 2H, C16H33-CH2-COO), 2.19 (q, J = 6.9 Hz, 2H, CH2-CH=CH-
COO), 1.63-1.53 (m, 4H, C15H31-CH2-CH2-COO and CH2-CH2-Ph), 1.45-1.25 (m,40 H, C6H12-
CH2-CH=CH and CH3-C14H28-CH2), 0.88 (t, J = 6.6 Hz, 3H, CH3-C16H32-COO). 13C NMR (75 
MHz, CDCl3): δ 173.4, 165.9, 159.3, 150.6, 142.8, 129.8, 129.3 (2C), 128.3 (2C), 128.2 (2C), 
125.5, 120.7, 113.8 (2C), 72.9, 70.0, 67.8, 62.7, 55.2, 35.9, 34.1, 32.3, 31.9, 31.5, 29.7 (10C), 29.5 
(2C), 29.4, 29.3 (2C), 29.2, 29.1, 27.9, 24.9, 22.7, 14.1. IR (neat): 2957, 2914, 2848, 1725, 1511, 
1366, 1204, 1170, 1108, 1082, 1029 cm-1. HRMS (ESI +) C47H74O6, m/z [M+Na+] 757.5383, found 
757.5384. 
 
1-O-(para-Methoxybenzyl)-2,3-O-isopropylidene-sn-glycerol (21) 
The synthesis was performed following the same procedure as for 1,2-O-isopropylidene-3-(para-
methoxybenzyl)-sn-glycerol (17), starting from 2,3-O-isopropylidene-sn-glycerol (12.88 mmol, 1.7 
g), NaH (60 % (w/w) in mineral oil, 20.6 mmol, 825 mg), freshly synthesized PMBCl (18.68 mmol, 
2.92 g) and 30 mL DMF and affording 2.50 g of 1-O-(para-methoxybenzyl)-2,3-O-isopropylidene-
sn-glycerol (21) (77 % yield). Rf = 0.15 (hexane/EtOAc 6:1). 1H NMR (300 MHz, CDCl3): δ 7.32 
and 6.89 (AA’XX’ pattern, J = 8.7 Hz, 4H, aromatic), 4.53 (d, J = 11.7 Hz, 1H, CH2-Ph), 4.47 (d, J 
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= 11.7 Hz, 1H, CH2-Ph), 4.28 (qnt, J = 6.0 Hz, 1H, CH2-CH-CH2-OPMB), 4.04 (dd, J = 8.2, 6.0 
Hz, 1H, CH2-CH-CH2-OPMB), 3.80 (d, J = 1.9 Hz, 3H, O-CH3), 3.72 (dd, J = 8.2, 6.0 Hz, 1H, 
CH2-CH-CH2-OPMB), 3.52 (dd, J = 9.8, 6.0 Hz, 1H, CH2-CH-CH2-OPMB), 3.43 (dd, J = 9.8, 6.0 
Hz, 1H, CH2-CH-CH2-OPMB), 1.42 (s, 3H, C-CH3), 1.36 (s, 3H, C-CH3). 13C NMR (75 MHz, 
CDCl3): δ 159.2, 129.4 (2C), 128.6, 113.8 (2C), 109.4, 74.4, 73.1, 70.7, 66.9, 55.3, 26.6, 26.4. 
 
1-O-(para-Methoxybenzyl)-sn-glycerol (22) 
1-O-(para-Methoxybenzyl)-sn-glycerol was prepared by deprotection of 1-(para-methoxybenzyl)-
2,3-O-isopropylidene-sn-glycerol (21) (9.92 mmol, 2.50 g), as described for 18, in MeOH (3.5 mL) 
and HCl (2 mL), to afford 1.51 g of (22) as white powder (yield: 72 %). Rf = 0.39 (CH2Cl2/MeOH 
9:1). Mp.: 44 °C. ሾ∝ሿ஽ଶ଴= + 0.35° (c = 1.0, CHCl3). (lit. ሾ∝ሿ஽ଶ଴= + 1.2° (c = 3.5, CHCl3))39. 1H NMR 
(300 MHz, CDCl3): δ 7.23 and 6.80 (AA’XX’ pattern, J = 8.7 Hz, 4H, aromatic), 4.45 (s, 2H, CH2-
Ph), 3.88-3.82 (m, 1 H, CH2-CH-CH2), 3.79 (s, 3H, O-CH3), 3.65 (dd, J = 11.5, 3.2 Hz, 1H, HO-
CH2-CH-CH2), 3.56 (dd, J = 11.5, 5.8 Hz, 1H, HO-CH2-CH-CH2), 3.51-3.42 (m, 2H, HO-CH2-CH-
CH2), 2.3 (br s, 2H, 2OH).39 13C NMR (75 MHz, CDCl3): δ 159.3, 129.7, 129.4 (2C), 113.8 (2C), 
73.1, 71.3, 70.7, 64.0, 55.2.39 IR (neat): 3512, 2915, 2848, 1737, 1712, 1613, 1514, 1366, 1171, 
1116, 1078, 1031, 812, 718 cm-1. HRMS (ESI +) C11H16O4, m/z [M+Na+] 235.0946, found 
235.0942. 
 
1-O-(para-Methoxybenzyl)-3-stearoyl-sn-glycerol (23) 
1-O-(para-Methoxybenzyl)-3-stearoyl-sn-glycerol has been synthesized in 55 % yield (2.23 g), 
following the same procedure as for 19, starting from stearic acid (8.92 mmol, 2.532 g) in 
anhydrous CH2Cl2 (85 mL), DCC (9.34 mmol, 1.92 g), and DMAP (2.55 mmol, 311 mg) and 22 
(8.49 mmol, 1.77 g) in anhydrous CH2Cl2 (85 mL). Rf = 0.46 (hexane/EtOAc 1:1). Mp.: 50.1-50.9 
°C. ሾ∝ሿ஽ଶ଴= - 1.33° (c = 0.98, CHCl3). 1H NMR (300 MHz, CDCl3): δ 7.23 and 6.80 (AA’XX’ 
pattern, J = 8.7 Hz, 4H, aromatic), 4.49 (s, 2H, CH2-Ph), 4.20-4.09 (m, 2H, C18H35-COO-CH2-CH-
CH2), 4.05-3.98 (m, 1H, C18H35-COO-CH2-CH-CH2), 3.81 (s, 3H, O-CH3), 3.52 (dd, J = 9.6, 4.3 
Hz, 1H, C18H35-COO-CH2-CH-CH2), 3.45 (dd, J = 9.6, 6.1 Hz, 1H, C18H35-COO-CH2-CH-CH2), 
2.50 (d, J = 4.8 Hz, 1H, OH), 2.31 (t, J = 7.5 Hz, 2H, CH2COO), 1.62-1.60 (m, 2H, CH2-CH2-
COO), 1.32-1.23 (m, 28H, CH3-C14H28-CH2-CH2-COO), 0.88 (t, J = 6.7 Hz, 3H, CH3). 13C NMR 
(75 MHz, CDCl3): δ 173.9, 159.3, 129.7, 129.4 (2C), 113.8 (2C), 73.2, 70.5, 68.9, 65.3, 55.3, 34.1, 
31.9, 29.7 (7C), 29.6, 29.4, 29.3, 29.2, 29.1, 24.9, 22.7, 14.1. IR (neat): 3265, 2973, 2939, 2862, 
1610, 1584, 1461, 1241, 1206, 1175, 1020, 812, 711 cm-1. 
 
 
1-Stearoyl-2-((Z)-12-phenyldodec-2-enoyl)-3-O-(para-methoxybenzyl)-sn-glycerol (24) 
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In a flame-dried 25 mL flask, a solution of Ph3P (1.5 mmol, 394 mg) in anhydrous THF (8 mL) was 
cooled to 0 °C under argon and DIAD (0.75 mmol, 148 µL) was added, and the solution became 
white. After the mixture had been stirred for 10 min at 0 °C, 23 (0.63 mmol, 302 mg) was added 
(the mixture turned yellow), followed by 6 (0.75 mmol, 206 mg) (the mixture became clear again) 
and the mixture was stirred at 20 °C for 2 h. The mixture was cooled to 0 °C and a second portion 
of Ph3P (1.5 mmol, 394 mg) and DIAD (0.75 mmol, 148 µL) was added and the resulting mixture 
was stirred for 10 min at 0 °C. Compound 6 (0.75 mmol, 206 mg) was then added and the mixture 
was stirred at 20 °C for 5 h, after which TLC (toluene/EtOAc 98:2) showed full conversion of the 
starting material (23). The mixture was concentrated in vacuo and the product was purified by flash 
chromatography (toluene/EtOAc 99:1) to afford 1-stearoyl-2-((Z)-12-phenyldodec-2- enoyl)-3-O-
(para-methoxybenzyl)-sn-glycerol (24) as white crystals in 93 % yield (428 mg). Rf = 0.17 
(toluene/EtOAc 9:2). Mp: 32-33 °C. ሾ∝ሿ஽ଶ଴= + 5.48° (c = 1.46, CHCl3). 1H NMR (300 MHz, 
CDCl3): δ 7.29-7.17 (m, 7H, C6H5 and 2CH-CH-C-OMe), 6.89-6.84 (m, 2H, CH-CH-C-OMe), 
6.27 (dt, J = 11.5, 7.5 Hz, 1H, CH=CH-COO), 5.78 (dt, J = 11.5, 1.7 Hz, 1H, CH=CH-COO), 5.29-
5.22 (m, 1H, CH2-CH-CH2), 4.50 (d, J = 11.7 Hz, 1H, CH2-Ph-OMe), 4.45 (d, J = 11.7 Hz, 1H, 
CH2-Ph-OMe), 4.33 (dd, J = 11.8, 3.9 Hz, 1H, C17H35-COOCH2), 4.23 (dd, J = 11.8, 6.3 Hz, 1H, 
C17H35-COOCH2), 3.80 (s, 3H, O-CH3), 3.59 (d, J = 5.3 Hz, 2H, CH2-OPMB), 2.67-2.57 (m, 4H, 
C8H16-CH2-Ph and CH2-CH=CH-COO), 2.27 (t, J = 7.5 Hz, 2H, C16H33-CH2-COO), 1.65-1.53 (m, 
4H, C15H31-CH2-CH2-COO and CH2-CH2-Ph), 1.45-1.25 (m, 40 H, C6H12-CH2-CH=CH and CH3-
C14H28-CH2), 0.88 (t, J = 6.7 Hz, 3H, CH3-C16H32-COO). 13C NMR (75 MHz, CDCl3): δ 173.4, 
165.5, 159.2, 151.8, 142.9, 129.8, 129.3 (2C), 128.4 (2C), 128.2 (2C), 125.5, 119.1, 113.8 (2C), 
72.9, 69.6, 67.9, 62.7, 55.2, 35.9, 34.1, 31.9, 31.5, 29.7 (9C), 29.6, 29.5 (3C), 29.4, 29.3 (2C), 29.2, 
29.1, 29.0, 24.9, 22.7, 14.1. IR (neat): 3032, 2958, 2915, 2849, 1724, 1711, 1642, 1612, 1512, 1468, 
1454, 1442, 1419, 1245, 1233, 1185, 1170, 1148, 1108, 1082, 1029 cm-1. HRMS (ESI +) C47H74O6, 
m/z [M+H+] 735.5564, found 735.5556.  
 
1-Stearoyl-2-((E)-2-methyl-12-phenyldodec-2-enoyl)-3-O-(para-methoxybenzyl)-sn-glycerol 
(25)  
Following the same procedure as for the synthesis of 1-stearoyl-2-((Z)-12-phenyldodec-2-enoyl)-3-
O-(para-methoxybenzyl)-sn-glycerol (24), and starting from 23 (0.32 mmol, 153 mg) in anhydrous 
THF (4 mL), Ph3P (2  0.76 mmol, 2  200 mg), DIAD (2  0.38 mmol, 2  75 µL) and 8 (2  
0.38 mmol, 2  110 mg), 1-stearoyl-2-((E)-2-methyl-12-phenyldodec-2-enoyl)-3-O-(para-
methoxybenzyl)-sn-glycerol (25) was obtained in 94 % yield (224 mg) as colourless oil. Rf = 0.17 
(toluene). ሾ∝ሿ஽ଶ଴= + 6.4° (c = 1.98, CHCl3). 1H NMR (300 MHz, CDCl3): δ 7.30-7.14 (m, 7H, C6H5 
and CH-CH-C-OMe), 6.89-6.85 (m, 2H, CH-CH-C-OMe), 6.78 (t, J = 7.5, 1.0 Hz, 1H, 
CH=C(CH3)-COO), 5.30-5.23 (m, 1H, CH2-CH-CH2), 4.50 (d, J = 11.7 Hz, 1H, CH2-Ph-OMe), 
4.45 (d, J = 11.7 Hz, 1H, CH2-Ph-OMe), 4.35 (dd, J = 11.8, 3.9 Hz, 1H, C17H35-COOCH2), 4.26 
(dd, J = 11.8, 6.3 Hz, 1H, C17H35-COOCH2), 3.80 (s, 3H, O-CH3), 3.62 (dd, J = 10.5, 5.1 Hz, 1H, 
CH2-OPMB), 3.58 (dd, J = 10.5, 5.4 Hz, 1H, CH2-OPMB), 2.62-2.57 (m, 2H, C8H16-CH2-Ph), 2.27 
(t, J = 7.5 Hz, 2H, C16H33-CH2-COO), 2.16 (q, J = 7.5 Hz, 2H, CH2-CH=C(CH3)-COO), 1.82 (d, J 
115 
 
= 1.0 Hz, 3H, CH=C(CH3)COO), 1.66-1.53 (m, 4H, C15H31-CH2-CH2-COO and CH2-CH2-Ph), 
1.45-1.25 (m, 40 H, C6H12-CH2-CH=CH and CH3-C14H28-CH2), 0.88 (t, J = 6.7 Hz, 3H, CH3-
C16H32-COO). 13C NMR (75 MHz, CDCl3): δ 173.4, 167.4, 159.2, 143.5, 142.9, 129.8, 129.2 (2C), 
128.4 (2C), 128.2 (2C), 127.1, 125.5, 113.8 (2C), 72.9, 70.3, 67.8, 62.7, 55.2, 36.0, 34.2, 31.9, 31.5, 
29.7 (8C), 29.6, 29.5 (2C), 29.4 (3C), 29.3 (2C), 29.1, 28.8, 28.5, 24.9, 22.7, 14.1, 12.4. IR (neat): 
2922, 2852, 1741, 1713, 1612, 1513, 1463, 1455, 1246, 1172, 1093, 1036, 820, 744, 698 cm-1. 
HRMS (ESI +) C48H76O6, m/z [M+Na+] 771.5540, found 771.5543. 
 
1-Stearoyl-2-((Z)-2-methyl-12-phenyldodec-2-enoyl)-3-O-(para-methoxybenzyl)-sn-glycerol 
(26)  
Following the same procedure as for the synthesis of 1-stearoyl-2-((Z)-12-phenyldodec-2-enoyl)-3-
O-(para- methoxybenzyl)-sn-glycerol (24), and starting from 23 (0.78 mmol, 371 mg) in anhydrous 
THF (10 mL), Ph3P (2  1.85 mmol, 2  484 mg), DIAD (2  0.92 mmol, 2  181 µL) and 10 (2 
 0.92 mmol, 2  266 mg), 1-stearoyl-2-((Z)-2-methyl-12-phenyldodec-2-enoyl)-3-O-(para-
methoxybenzyl)-sn-glycerol (26) was obtained in 76 % yield (442 mg) as colourless oil. Rf = 0.1 
(toluene/EtOAc 99:1). ሾ∝ሿ஽ଶ଴= + 6.8° (c = 2.21, CHCl3). 1H NMR (300 MHz, CDCl3): δ 7.30-7.14 
(m, 7H, C6H5 and CH-CH-C-OMe), 6.88-6.85 (m, 2H, CH-CH-C-OMe), 5.92 (t, J = 7.4 Hz, 1H, 
CH=C(CH3)-COO), 5.31-5.22 (m, 1H, CH2-CH-CH2), 4.50 (d, J = 11.7 Hz, 1H, CH2-Ph-OMe), 
4.45 (d, J = 11.7 Hz, 1H, CH2-Ph-OMe), 4.36 (dd, J = 11.8, 3.8 Hz, 1H, C17H35-COOCH2), 4.24 
(dd, J = 11.8, 6.3 Hz, 1H, C17H35-COOCH2), 3.80 (s, 3H, O-CH3), 3.65-3.55 (m, 2H, CH2-OPMB), 
2.62-2.57 (m, 2H, C8H16-CH2-Ph), 2.43 (q, J = 7.4 Hz, 2H, CH2-CH=C(CH3)-COO), 2.27 (t, J = 7.5 
Hz, 2H, C16H33-CH2-COO), 1.89-1.88 (s, 3H, CH=C(CH3)COO), 1.63-1.57 (m, 4H, C15H31-CH2-
CH2-COO and CH2-CH2-Ph), 1.40-1.25 (m, 40 H, C6H12-CH2-CH=CH and CH3-C14H28-CH2), 0.88 
(t, J = 6.3 Hz, 3H, CH3-C16H32-COO). 13C NMR (75 MHz, CDCl3): δ 173.4, 167.2, 159.2, 144.3, 
142.9, 129.8, 129.2 (2C), 128.4 (2C), 128.2 (2C), 126.5, 125.5, 113.8 (2C), 72.9, 70.0, 67.9, 62.7, 
55.2, 36.0, 34.1, 31.9, 31.5, 29.7 (9C), 29.6, 29.5 (3C), 29.4(2C), 29.3 (2C), 29.1, 24.9, 22.7, 20.6, 
14.1, 12.4. IR (neat): 2922, 2852, 1741, 1713, 1612, 1513, 1463, 1455, 1246, 1172, 1093, 1036, 
820, 744, 698 cm-1. HRMS (ESI +) C48H76O6, m/z [M+H+] 749.5720, found 749.5722. 
 
1-Stearoyl-2-((E)-3-methyl-12-phenyldodec-2-enoyl)-3-O-(para-methoxybenzyl)-sn-glycerol 
(27)  
In a flame-dried 25 mL flask, a solution of Ph3P (1.74 mmol, 454 mg) in anhydrous THF (10 mL) 
was cooled to 0 °C under argon and DIAD (0.87 mmol, 171 µL) was added, and the solution 
became white. After the mixture had been stirred for 10 min at 0 °C, 23 (0.79 mmol, 377 mg) was 
added (the mixture turned yellow), followed by 12 (0.87 mmol, 250 mg) (the mixture became clear 
again) and the mixture was stirred at 20 °C for 2 h. The mixture was cooled to 0 °C and a second 
portion of Ph3P (1.74 mmol, 454 mg) and DIAD (0.87 mmol, 171 µL) was added and the resulting 
mixture was stirred for 10 min at 0 °C. Carboxylic acid 12 (0.87 mmol, 250 mg) was then added 
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and the mixture was stirred at 20 °C for 1.5 h, after which TLC (toluene/EtOAc 98:2) showed full 
conversion of the starting material (23). The mixture was concentrated in vacuo and the product was 
purified by flash chromatography (toluene/EtOAc 99:1) to afford 1-stearoyl-2-((E)-3-methyl-12-
phenyldodec-2-enoyl)-3-(para-methoxybenzyl)-sn-glycerol (27) as clear oil in 68 % yield (401 
mg). Rf = 0.59 (toluene/EtOAc 9:1). ሾ∝ሿ஽ଶ଴= + 5.7° (c = 1.13, CHCl3). 1H NMR (300 MHz, CDCl3): 
δ 7.30-7.14 (m, 7H, C6H5 and 2CH-CH-C-OMe), 6.89-6.84 (m, 2H, CH-CH-C-OMe), 5.68 (q, J 
= 1.1 Hz, 1H, C(CH3)=CH-COO), 5.28-5.21 (m, 1H, CH2-CH-CH2), 4.51 (d, J = 11.7 Hz, 1H, CH2-
Ph-OMe), 4.45 (d, J = 11.7 Hz, 1H, CH2-Ph-OMe), 4.32 (dd, J = 11.8, 4.0 Hz, 1H, C17H35-
COOCH2), 4.23 (dd, J = 11.8, 6.2 Hz, 1H, C17H35-COOCH2), 3.80 (s, 3H, O-CH3), 3.60 (dd, J = 
10.4, 5.1 Hz, 1H, CH2-OPMB), 3.56 (dd, J = 10.4, 5.3 Hz, 1H, CH2-OPMB), 2.63-2.57 (m, 2H, 
C8H16-CH2-Ph), 2.27 (t, J = 7.5 Hz, 2H, C16H33-CH2-COO), 2.15-2.10 (m, 5H, C(CH3)=CH-COO 
and CH2-C(CH3)=CH-COO), 1.66-1.53 (m, 4H, C15H31-CH2-CH2-COO and CH2-CH2-Ph), 1.51- 
1.42 (m, 2H, CH2-CH2-C(CH3)=C), 1.34-1.22 (m, 38 H, C5H10-CH2-C(CH3)=CH and CH3-C14H28-
CH2), 0.88 (t, J = 6.7 Hz, 3H, CH3-C16H32-COO). 13C NMR (75 MHz, CDCl3): δ 173.4, 165.8, 
161.8, 159.2, 142.9, 129.8, 129.3 (2C), 128.4 (2C), 128.2 (2C), 125.5, 114.9, 113.8 (2C), 72.9, 69.2, 
67.9, 62.8, 55.2, 41.1, 36.0, 34.1, 31.9, 29.7 (9C), 29.6, 29.5, 29.4 (3C), 29.3 (2C), 29.2, 29.1, 27.4, 
24.9, 22.7, 18.9, 14.1. IR (neat): 2922, 2852, 1740, 1719, 1513, 1456, 1247, 1217, 1139, 1096 cm-1. 
HRMS (ESI +) C48H76O6, m/z [M+H+] 749.5720, found 749.5722. 
 
1-Stearoyl-2-((Z)-3-methyl-12-phenyldodec-2-enoyl)-3-O-(para-methoxybenzyl)-sn-glycerol 
(28)  
In a flame-dried 25 mL flask, a solution of Ph3P (1.39 mmol, 364 mg) in anhydrous THF (8 mL) 
was cooled to 0 °C under argon and DIAD (0.69 mmol, 137 µL) was added, and the solution 
became white. After the mixture had been stirred for 10 min at 0 °C, 23 (0.63 mmol, 301 mg) was 
added (the mixture turned yellow), followed by 14 (0.69 mmol, 200 mg) (the mixture became clear 
again) and the mixture was stirred at 20 °C for 2 h. The mixture had taken a yellow colour over the 
2 h and was cooled to 0 °C again. A second portion of Ph3P (1.39 mmol, 364 mg) and DIAD (0.69 
mmol, 137 µL) was added and the resulting mixture was stirred for 10 min at 0 °C. Carboxylic acid 
14 (0.69 mmol, 200 mg) was then added and the mixture was stirred at 20 °C for 1.5 h, after which 
TLC (toluene/EtOAc 98:2) showed full conversion of the starting material (23). The mixture was 
concentrated in vacuo and the product was purified by flash chromatography (toluene/EtOAc 99:1) 
to afford 1-stearoyl-2-((Z)-3-methyl-12-phenyldodec-2-enoyl)-3-(para-methoxybenzyl)-sn-glycerol 
(28) as clear oil in 74 % yield (351 mg). Rf = 0.71 (toluene/EtOAc 9:1). ሾ∝ሿ஽ଶ଴= + 6.0° (c = 1.1, 
CHCl3). 1H NMR (500 MHz, CDCl3): δ 7.28-7.15 (m, 7H, C6H5 and 2CH-CH-C-OMe), 6.87-
6.85 (m, 2H, CH-CH-C-OMe), 5.66 (m, 1H, C(CH3)=CH-COO), 5.25-5.21 (m, 1H, CH2-CH-CH2), 
4.49 (d, J = 11.7 Hz, 1H, CH2-Ph-OMe), 4.44 (d, J = 11.7 Hz, 1H, CH2-Ph-OMe), 4.31 (dd, J = 
11.8, 3.9 Hz, 1H, C17H35-COOCH2), 4.21 (dd, J = 11.8, 6.3 Hz, 1H, C17H35-COOCH2), 3.79 (s, 3H, 
O-CH3), 3.58 (dd, J = 10.5, 5.1 Hz, 1H, CH2-OPMB), 3.56 (dd, J = 10.5, 5.2 Hz, 1H, CH2-OPMB), 
2.61-2.58 (m, 4H, C8H16-CH2-Ph and CH2-C(CH3)=CH-COO), 2.27 (t, J = 7.6 Hz, 2H, C16H33-CH2-
COO), 1.88 (s, 3H, C(CH3)=CH-COO), 1.63-1.55 (m, 4H, C15H31-CH2-CH2-COO and CH2-CH2-
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Ph), 1.47-1.41 (m, 2H, CH2-CH2-C(CH3)=C), 1.30-1.23 (m, 38 H, C5H10-CH2-C(CH3)=CH and 
CH3-C14H28-CH2), 0.88 (t, J = 7.0 Hz, 3H, CH3-C16H32-COO). 13C NMR (75 MHz, CDCl3): δ 
173.5, 165.3, 162.2, 159.2, 142.9, 129.8, 129.3 (2C), 128.4 (2C), 128.2 (2C), 125.5, 115.5, 113.7 
(2C), 72.9, 69.2, 67.9, 62.8, 55.2, 36.0, 34.1, 33.6, 31.9, 31.5, 29.8, 29.7 (8C), 29.5 (4C), 29.4, 29.3 
(2C), 29.1, 28.2, 25.3, 24.9, 22.7, 14.1. IR (neat): 2922, 2852, 1741, 1721, 1513, 1455, 1246, 1172, 
1140, 1095, 1037 cm-1. HRMS (ESI +) C48H76O6, m/z [M+H+] 749.5720, found 749.5727. 
 
Allyl para-methoxybenzoate (29)42 
Allyl alcohol (73.5 mmol, 5.0 mL), Et3N (110.3 mmol, 15.4 mL) and DMAP (3.7 mmol, 0.45 g) 
were dissolved in CH2Cl2 (250 mL). para-Methoxybenzoyl chloride (88.2 mmol, 11.9 mL) was 
added dropwise and the reaction mixture was stirred at 20 °C for 2 h. After that H2O (200 mL) was 
added, the organic layer was separated and the aqueous layer was washed with CH2Cl2 (3  300 
mL), and the combined organic layers were dried over MgSO4 and concentrated in vacuo to afford 
14.0 g (99%) of 29 as colourless oil. Rf = 0.77 (heptane/EtOAc 1:1). 1H NMR (300 MHz, CDCl3): 
δ 8.03 (d, J = 9.0 Hz, 2H, CH-C-OMe), 6.93 (d, J = 9.0 Hz, 2H, CH-C-COO), 6.05 (ddt, J = 17.2, 
10.5, 5.6 Hz, 1H, CH=CH2), 5.41 (dd, J = 17.2, 1.6 Hz, 1H, CH=CH2), 5.31– 5.26 (m, 1H, 
CH=CH2), 4.81 (dt, J = 5.6, 1.4 Hz, 2H, CH2-CH=CH2), 3.78 (s, 3H, O-CH3). 
 
1-(para-Methoxybenzoyl)-2,3-di-O-(tert-butyldimethylsilyl)-sn-glycerol (30)42 
K2OsO4·2H2O (0.74 mmol, 271 mg), (DHQD)2PHAL (0.88 mmol, 687 mg), K3Fe(CN)6 (220.6 
mmol, 72.6 g) and K2CO3 (220.6 mmol, 30.5 g) were dissolved in a mixture of tBuOH (370 mL) 
and H2O (370 mL) and stirred at 20 °C for 15 min. 29 (73.5 mmol, 14.1 g) was then added, and the 
resulting mixture was stirred at 20 °C for 2 h and excess reagent was quenched by addition of 
Na2SO3 (0.88 mol, 111 g). The organic layer was separated and the aqueous layer was washed with 
EtOAc (3  500 mL). Toluene (200 mL) was added to the combined organic phases and 
concentration in vacuo afforded (S)-1-O-(para-methoxybenzoyl)-glycerol as a white solid, 1H NMR 
was in agreement with literature data,216 and estimated to be pure enough to proceed with the crude 
product. Enantiomeric excess (>97%) was determined by chiral HPLC. HPLC (chiral) Chiralpak 
AS-H at 20 °C, λ= 254 nm, hexane/2-propanol 75:25, retention times 17.8 min (S), 23.4 min (R) at 
0.4 mL/min flow rate. The hplc separation of the enantiomers was verified by performing the 
reaction in the absence of a chiral ligand to obtain the racemic diol. The crude product of (S)-1-O-
(para-methoxybenzoyl)-glycerol and imidazole (235.3 mmol, 16.0 g) were dissolved in DMF (78 
mL) and heated to 60 °C, TBSCl (220.6 mmol, 33.2 g) was added and the mixture was stirred at 
that temperature. After 4 h another portion of TBSCl (36.5 mmol, 5.5 g) and imidazole (36.7 mmol, 
2.5 g) were added, and the reaction mixture was stirred for additional 4h. H2O (50 mL) and Et2O 
(150 mL) were then added and the organic layer was separated, and the aqueous layer was washed 
with Et2O (3  150 mL). The combined organic phases were washed with a saturated aqueous 
solution of NaHCO3 (100 mL). Toluene (200 mL) was added to the combined organic layers and 
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concentration in vacuo gave a colourless oil that afforded 30 as clear oil in 99 % yield (32.6 g) after 
purification by flash chromatography (heptane/EtOAc 8:1). Rf = 0.28 (heptane/EtOAc 10:1). 1H 
NMR (300 MHz, CDCl3): δ 8.01 (d, J = 8.8 Hz, 2H, CH-C-OMe), 6.93 (d, J = 8.8 Hz, 2H, CH-C-
COO), 4.41 (dd, J = 11.3, 4.0 Hz, 1H, CH2-O-C=O), 4.25 (dd, J = 11.3, 6.1 Hz, 1H, CH2-O-C=O), 
4.06-4.00 (m, 1H,CH2-OTBS), 3.89 (s, 3H, O-CH3), 3.65-3.63 (m, 2H, CH2-CH-OTBSand CH2-
OTBS), 0.90 (s, 9H, Si-C-(CH3)3), 0.88 (s, 9H, Si-C-(CH3)3), 0.10-0.07 (m, 12H, 2Si-(CH3)2). 13C 
NMR (75 MHz, CDCl3): δ 166.4, 163.4, 131.8 (2C), 122.9, 113.7 (2C), 71.5, 66.5, 65.0, 55.5, 26.1 
(3C), 25.9 (3C), 18.5, 18.2, -4.4, -4.6, -5.2, -5.3. IR (neat) 2955, 2857, 1718, 1607, 1512, 1472, 
1256, 1102, 840, 774 cm-1. 
 
2,3-Di-O-(tert-butyldimethylsilyl)-sn-glycerol (31)42 
To a solution of 1-(para-methoxybenzoyl)-2,3-di-O-(tert-butyldimethylsilyl)-sn-glycerol (30) 
(19.79 mmol, 9 g) in anhydrous CH2Cl2 (70 mL) cooled to -78 °C under argon, was added dropwise 
1M in hexane DIBAL-H (40 mmol, 40 mL) over 25 min, and the resulting mixture was stirred at -
78 °C. Two other portions of 1M in hexane DIBAL-H (20 mmol, 20 mL) were added dropwise at -
78 °C after 2 h and after 3 h respectively, and after 4.5 h, MeOH (6 mL) was added dropwise at -78 
°C to quench excess DIBAL-H, and the mixture was stirred at -78 °C for 15 min. A sat. aq. Solution 
of Rochelle’s salt (20 mL) was then added at -78 °C, and the reaction mixture was allowed to reach 
20 °C over 1 h. H2O (100 mL) was added, the organic layer was extracted, and the aqueous layer 
was washed with EtOAc (3  100 mL). The combined organic layers were dried over Na2SO4, 
concentrated in vacuo and the resulting crude oil was purified by flash chromatography (CH2Cl2) to 
afford the desired 31 as clear oil in 79 % yield (5 g). Rf = 0.45 (CH2Cl2). ሾ∝ሿ஽ଶ଴= + 17.9 ° (c = 0.6, 
CHCl3). (lit. ሾ∝ሿ஽ଶ଴= + 18.5 ° (c = 0.6, CHCl3)). 1H NMR (300 MHz, CDCl3): δ 3.80-3.73 (m, 1H, 
CH2-CH-CH2), 3.66-3.52 (m, 4H, CH2-CH-CH2), 2.13 (t, J = 6.1 Hz, 1H, OH), 0.89 (s, 18 H, Si-C-
(CH3)3), 0.09 (s, 6H, Si-(CH3)2), 0.06 (s, 6H, Si-(CH3)2). 13C: NMR (75 MHz, CDCl3): δ 72.7, 65.0, 
64.9, 26.0 (3C), 18.4, 18.2, -4.4, -4.7, -5.3, -5.4. 
 
2,3-Di-O-(tert-butyldimethylsilyl)-sn-glycero-2-cyanoethyl-N,N-diisopropylphosphoramidite 
(32)42 
To a solution of 2,3-di-O-(tert-butyldimethylsilyl)-sn-glycerol (31) (2.82 mmol, 904 mg), and 
diisopropylethylamine (5.92 mmol, 765 mg) in anhydrous CH2Cl2 under argon, was added dropwise 
2-cyanoethyl-N,N-diisopropylchlorophosphoramidite (4.22 mmol, 1 g), and the mixture was stirred 
at 20 °C for 1.5 h. EtOAc (20 mL) was then added, followed by sat. aq. NaHCO3 (50 mL). The 
organic layer was separated, and the aqueous layer was extracted with EtOAc (3  50 mL), the 
combined organic layers were dried over MgSO4, concentrated in vacuo and the desired 
phosphoramidite 32 was obtained in 90 % yield (1.31 g) as a clear oil after purification by flash 
chromatography (EtOAc). Rf = 1.0 (EtOAc). 1H NMR (300 MHz, CDCl3, two diastereoisomers): δ 
3.89-3.44 (m, 7H, CH2-CH-CH2 and CH2-CH2-CN), 2.62 (t, J = 6.7 Hz,  2H, CH2-CN, main isomer, 
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2.63, t, J = 6.7 Hz, CH2-CN,2nd isomer), 1.19-1.16 (m (2  d from the 2 isomers), 12H, 2(CH3)2-
CH-N), 0.89 (s, 9H, Si-C-(CH3)3), 0.88 (s, 9H, Si-C-(CH3)3), 0.08-0.05 (m, 12H, 2(Si-CH3)2). 13C 
NMR (75 MHz, CDCl3, two diastereoisomers): δ 117.8 (0.5 C), 117.7 (0.5 C), 73.3 (d, J = 7.3 Hz, 
0.5 C), 73.2 (d, J = 8.3 Hz, 0.5 C), 65.1 (d, J = 15.2 Hz, 0.5 C), 65.0 (0.5 C), 64.9 (0.5 C), 64.8 (d, J 
= 15.7 Hz, 0.5 C), 58.7 (d, J = 11.9 Hz, 0.5 C), 58.4 (d, J = 12.5 Hz, 0.5 C), 43.2 (d, J = 4.7 Hz), 
43.1(d, J = 4.6 Hz), 26.1 (3C), 26.0 (3C), 24.8, 24.7 (2C), 24.6, 20.6 (0.5 C), 20.5 (0.5C), 18.5, 
18.3, -4.3 (0.5 C), -4.4 (0.5 C), -4.5, -5.2, -5.3. 31P NMR (202 MHz, CDCl3): δ 149.0, 148.4. 
 
1-Stearoyl-2-((E)-12-phenyldodec-2-enoyl)-sn-glycerol (33) 
20 (0.71 mmol, 522 mg) was dissolved in a mixture of CH2Cl2 (10 mL) and phosphate buffer 
(pH=7) (0.5 mL), and DDQ (1.26 mmol, 284 mg) was added in two portions over 45 min. The two-
phase mixture was stirred vigorously at 20 °C for 1.5 h, and ice-cold sat. aq. NaHCO3 (15 mL) and 
CH2Cl2 (10 mL) were added at 0 °C. The organic phase was separated, and the aqueous layer was 
extracted with CH2Cl2 (3  15 mL) and the combined organic layers were washed with cold brine 
(15 mL), dried over Na2SO4 and concentrated in vacuo. The product was purified by flash 
chromatography (heptane/EtOAc 7:1) and obtained as clear oil in 80% yield (349 mg). Rf = 0.18 
(heptane/EtOAc 3:1). ሾ∝ሿ஽ଶ଴= -1.13 ° (c = 1.06, CHCl3). 1H NMR (300 MHz, CDCl3): δ 7.30-7.25 
(m, 2H, Ph-meta), 7.19-7.16 (m, 3H, Ph -ortho and -para), 7.00 (dt, J = 15.6, 7.0 Hz, 1H, CH=CH-
COO), 5.84 (d, J = 15.6 Hz, 1H, CH=CH-COO), 5.14-5.12 (m, 1H, CH2-CH-CH2), 4.32-4.28 (m, 
2H, C17H35COO-CH2), 3.78-3.74 (m, 2H, CH2-CH-CH2-OH), 2.61-2.59 (m, CH2-Ph), 2.32 (t, J = 
7.5 Hz, 2 H, C16H33-CH2-COO), 2.20 (q, J = 7.0 Hz, 2H, CH2-CH=CH-COO), 1.62-1.58 (m, 4H, 
C15H31-CH2-CH2-COO and CH2-CH2-Ph), 1.25 (m, 40H, CH3-C14H28-CH2-CH2-COO and Ph-CH2-
CH2-C6H12-CH2-CH=CH), 0.88 (t, J = 6.7 Hz, 3H, CH3-C16H32-COO). 13C NMR (75 MHz, CDCl3): 
δ 173.8, 166.2, 151.1, 142.9, 128.4 (2C), 128.2 (2C), 125.5, 120.4, 72.2, 62.0, 61.6, 35.9, 34.1, 32.3, 
31.9, 31.5, 29.7 (8C), 29.6, 29.5, 29.4 (2C), 29.3 (2C), 29.2, 29.1, 27.9, 24.9, 22.7, 14.1. IR (neat): 
3530 (br.), 2922, 2852, 1723, 1508, 14632, 1248, 1174, 1151, 1034, 827, 698 cm-1.HRMS (ESI +) 
C39H66O5, m/z [M+Na+] 637.4808, found 637.4812.  
 
1-Stearoyl-2-((Z)-12-phenyldodec-2-enoyl)-sn-glycerol (34) 
Following the general procedure described for the synthesis of compound 33, and starting from 24 
(0.567 mmol, 416 mg) in CH2Cl2 (8 mL) and phosphate buffer (pH=7, 0.4 mL), and from DDQ (1.0 
mmol, 226 mg), 34 was obtained in 77 % yield (268 mg) as white crystals. Rf = 0.09 
(heptane/EtOAc 6:1). Mp.: 32.0-31.2 °C. ሾ∝ሿ஽ଶ଴= -8.33 ° (c = 1.26, CHCl3). 1H NMR (300 MHz, 
CDCl3): δ 7.29-7.13 (m, 5H, C6H5), 6.29 (dt, J = 11.5, 7.5 Hz, 1H, CH=CH-COO), 5.79 (dt, J = 
11.5, 1.7 Hz, 1H, CH=CH-COO), 5.11 (m, 1H, CH2-CH-CH2), 4.32 (dd, J = 11.2, 4.0 Hz, 1H, 
C17H35COO-CH2), 4.27 (dd, J = 11.2, 4.9 Hz, 1H, C17H35COO-CH2), 3.75 (dd, J = 6.3, 5.1 Hz, 2H, 
CH2-CH-CH2-OH), 2.68-2.57 (m, 4H, C8H16-CH2-Ph and CH2-CH=CH-COO), 2.34-2.26 (m, 3 H, 
C16H33-CH2-COO and OH), 1.63-1.56 (m, 4H, C15H31-CH2-CH2-COO and CH2-CH2-Ph), 1.46-1.26 
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(m, 40H, CH3-C14H28-CH2-CH2-COO and Ph-CH2-CH2-C6H12-CH2-CH=CH), 0.88 (t, J = 6.7 Hz, 
3H, CH3-C16H32-COO). 13C NMR (75 MHz, CDCl3): δ 173.8, 165.7, 152.4, 142.8, 128.3 (2C), 
128.1 (2C), 125.5, 118.8, 71.7, 62.0, 61.5, 35.9, 34.1, 32.3, 31.9, 31.5, 29.7 (7C), 29.6 (2C), 29.4 
(2C), 29.3 (3C), 29.2 (2C), 29.1, 28.9, 24.9, 22.7, 14.1. IR (neat): 3533 (br.), 2919, 2851, 1724, 
1496, 1166, 1049 cm-1. HRMS (ESI +) C39H66O5, m/z [M+Na+] 637.4808, found 637.4826.  
 
1-Stearoyl-2-((E)-2-methyl-12-phenyldodec-2-enoyl)-sn-glycerol (35) 
Following the same procedure as described for the synthesis of compound 33, starting from 25 
(0.36 mmol, 270 mg) in CH2Cl2 (5 mL) and phosphate buffer (pH = 7, 250 µL) and DDQ (2  0.32 
mmol, 2  72 mg), to give 35 in 60 % yield (121 mg) as white solid. Mp.: 27.3-28.1 °C. Rf = 0.13 
(hexane/EtOAc 6:1). ሾ∝ሿ஽ଶ଴= + 3.07 ° (c = 1.79, CHCl3). 1H NMR (300 MHz, CDCl3): δ 7.30-7.14 
(m, 5H, C6H5), 6.81 (tq, J = 7.5, 1.4 Hz, 1H, CH=C(CH3)-COO), 5.12 (m, 1H, CH2-CH-CH2), 4.36-
4.29 (m, 2H, C17H35COO-CH2), 3.77 (t, J = 5.6 Hz, 2H, CH2-CH-CH2-OH), 2.60 (m, 2H, CH2-Ph), 
2.32 (t, J = 7.5 Hz, 2H, C16H33-CH2-COO), 2.31 (br. s, 1H, OH),  2.17 (q, J = 7.5 Hz, 2H, CH2-
CH=C(CH3)-COO), 1.83 (d, J = 1.4 Hz, 3H, CH=C(CH3)COO), 1.63-1.56 (m, 4H, C15H31-CH2-
CH2-COO and CH2-CH2-Ph), 1.45-1.26 (m, 40H, CH3-C14H28-CH2-CH2-COO and Ph-CH2-CH2-
C6H12-CH2-CH=CH), 0.88 (t, J = 6.7 Hz, 3H, CH3-C16H32-COO). 13C NMR (75 MHz, CDCl3): δ 
173.8, 167.7, 144.0, 142.8, 128.3 (2C), 128.2 (2C), 127.0, 125.5, 72.5, 62.0, 61.7, 35.9, 34.1, 31.9, 
31.5, 29.7 (8C), 29.6 (2C), 29.5, 29.4 (2C), 29.3 (2C), 29.2, 29.1, 28.8, 28.5, 24.9, 22.7, 14.1, 12.3. 
IR (neat): 3522 (br.), 2918, 2949, 1741, 1713, 1688, 1463, 1272, 1253, 1169, 1147, 1099, 1056 cm-
1. HRMS (ESI +) C40H68O5, m/z [M+H+] 629.5145, found 629.5154. 
 
1-Stearoyl-2-((Z)-2-methyl-12-phenyldodec-2-enoyl)-sn-glycerol (36) 
Following the same procedure as described for the synthesis of compound 33, starting from 26 
(0.58 mmol, 433 mg) in CH2Cl2 (8 mL) and phosphate buffer (pH = 7, 0.4 mL) and DDQ (2  0.51 
mmol, 2  116 mg), to give 36 as white crystals in 80 % yield (290 mg). Rf = 0.13 (hexane/EtOAc 
6:1). Mp.: 30.8-31.1 °C. ሾ∝ሿ஽ଶ଴= -2.4 ° (c = 1.37, CHCl3). 1H NMR (300 MHz, CDCl3): δ 7.31-7.14 
(m, 5H, C6H5), 6.00 (tq, J = 7.5, 1.4 Hz, 1H, CH=C(CH3)-COO), 5.15 (m, 1H, CH2-CH-CH2), 4.36 
(dd, J = 11.9, 4.5 Hz, 1H, C17H35COO-CH2), 4.30 (dd, J = 11.9, 5.5 Hz, 1H, C17H35COO-CH2), 3.77 
(dd, J = 6.3, 5.2 Hz, 2H, CH2-CH-CH2-OH), 2.63-2.58 (m, 2H, CH2-Ph), 2.45 (q, J = 7.5 Hz, 2H, 
CH2-CH=C(CH3)-COO), 2.32 (t, J = 7.5 Hz, 3H, C16H33-CH2-COO and OH), 1.90 (d, J = 1.4 Hz, 
3H, CH=C(CH3)COO), 1.64-1.57 (m, 4H, C15H31-CH2-CH2-COO and CH2-CH2-Ph), 1.43-1.26 (m, 
40H, CH3-C14H28-CH2-CH2-COO and Ph-CH2-CH2-C6H12-CH2-CH=CH), 0.89 (t, J = 6.7 Hz, 3H, 
CH3-C16H32-COO). 13C NMR (75 MHz, CDCl3): δ 173.7, 167.4, 144.9, 142.8, 128.3 (2C), 128.1 
(2C), 126.2, 125.5, 72.1, 62.1, 61.5, 35.9, 34.1, 31.9, 31.5, 29.7 (9C), 29.6 (2C), 29.5 (2C), 29.4 
(2C), 29.3 (2C), 29.2, 29.1, 24.9, 22.7, 20.57, 14.1. IR (neat): 3527 (br.), 2922, 2852, 1742, 1719, 
1455, 1154, 1095, 1048 cm-1. HRMS (ESI +) C40H68O5, m/z [M+H+] 629.5145, found 629.5138.  
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1-Stearoyl-2-((E)-3-methyl-12-phenyldodec-2-enoyl)-sn-glycerol (37) 
Following the same procedure as described for the synthesis of compound 33, starting from 27 
(0.35 mmol, 260 mg) in CH2Cl2 (5 mL) and phosphate buffer (pH = 7, 270 µL) and DDQ (2  0.31 
mmol, 2  69 mg), to give 37 as white solid in 60 % yield (130 mg). Rf = 0.39 (heptane/EtOAc 
3:1). Mp.: 37.7-39.1 °C. ሾ∝ሿ஽ଶ଴= -2.63 ° (c = 1.71, CHCl3). 1H NMR (300 MHz, CDCl3): δ 7.30-7.14 
(m, 5H, C6H5), 5.69 (q, J = 1.1 Hz, 1H, C(CH3)=CH-COO), 5.13-5.07 (m, 1H, CH2-CH-CH2), 4.32 
(dd, J = 12.0, 4.9 Hz, 1H, C17H35COO-CH2), 4.27 (dd, J = 12.0, 5.6 Hz, 1H, C17H35COO-CH2), 
3.76-3.73 (m, 2H, CH2-CH-CH2-OH), 2.63-2.57 (m, 2H, CH2-Ph), 2.32 (t, J = 7.5 Hz, 2H, C16H33-
CH2-COO), 2.21-2.11 (m, 5H, CH2-C(CH3)=CH-COO), 1.64-1.56 (m, 4H, C15H31-CH2-CH2-COO 
and CH2-CH2-Ph), 1.50-1.42 (m, 2H, CH2-CH2-C(CH3)=CH), 1.35-1.26 (m, 38H, CH3-C14H28-CH2-
CH2-COO and Ph-CH2-CH2-C5H10-CH2-CH2-CH=CH), 0.88 (t, J = 6.7 Hz, 3H, CH3-C16H32-COO). 
13C NMR (75 MHz, CDCl3): δ 173.8, 166.1, 162.6, 142.9, 128.4 (2C), 128.2 (2C), 125.5, 114.6, 
71.4, 62.1, 61.7, 41.1, 36.0, 34.1, 31.9, 31.5, 29.7 (7C), 29.6, 29.5 (2C), 29.4 (3C), 29.3 (2C), 29.2, 
29.1, 27.4, 24.9, 22.7, 19.0, 14.1. IR (neat): 3524 (br.), 2922, 2852, 1741, 1719, 1645, 1464, 1455, 
1218, 1142, 1051 cm-1. HRMS (ESI +) C40H68O5, m/z [M+H+] 629.5145, found 629.5133.  
 
1-Stearoyl-2-((Z)-3-methyl-12-phenyldodec-2-enoyl)-sn-glycerol (38) 
Following the same procedure as described for the synthesis of compound 33, starting from 28 
(0.33 mmol, 249 mg) in CH2Cl2 (4.5 mL) and phosphate buffer (pH = 7, 256 µL) and DDQ (2  
0.29 mmol, 2  67 mg), to give 38 as white amorphous solid in 62 % yield (130 mg). Rf = 0.25 
(heptane/EtOAc 3:1). ሾ∝ሿ஽ଶ଴= -6.46 ° (c = 1.78, CHCl3). 1H NMR (300 MHz, CDCl3): δ 7.30-7.14 
(m, 5H, C6H5), 5.68 (m, 1H, C(CH3)=CH-COO), 5.12-5.06 (m, 1H, CH2-CH-CH2), 4.31 (dd, J = 
11.9, 4.9 Hz, 1H, C17H35COO-CH2), 4.26 (dd, J = 11.9, 5.4 Hz, 1H, C17H35COO-CH2), 3.74 (m, 2H, 
CH2-CH-CH2-OH), 2.63-2.57 (m, 4H, CH2-Ph and CH2-C(CH3)=CH-COO), 2.32 (t, J = 7.5 Hz, 
2H, C16H33-CH2-COO), 2.8 (t, J = 6.5, 1H, OH), 1.90 (d, J = 1.3 Hz, 3H, C(CH3)=CH-COO), 1.65-
1.56 (m, 4H, C15H31-CH2-CH2-COO and CH2-CH2-Ph), 1.48-1.40 (m, 2H, CH2-CH2-C(CH3)=CH), 
1.35-1.26 (m, 38H, CH3-C14H28-CH2-CH2-COO and Ph-CH2-CH2-C5H10-CH2-CH2-CH=CH), 0.88 
(t, J = 6.7 Hz, 3H, CH3-C16H32-COO). 13C NMR (75 MHz, CDCl3): δ 173.8, 165.6, 163.0, 142.9, 
128.4 (2C), 128.2 (2C), 125.5, 115.1, 71.3, 62.1, 61.7, 36.0, 34.1, 33.6, 31.9, 31.5, 29.8, 29.7 (8C), 
29.6(2C), 29.5 (2C), 29.4, 29.3 (2C), 29.1, 28.2, 25.3, 24.9, 22.7, 14.1. IR (neat): 3492 (br.), 2922, 
2852, 1741, 1720, 1645, 1456, 1377, 1226, 1142, 1051 cm-1. HRMS (ESI +) C40H68O5, m/z [M+H+] 
629.5145, found 629.5130. 
 
 
1-Stearoyl-2-((E)-12-phenyldodec-2-enoyl)-sn-glycero-3-phospho-(S)-glycerol (39) 
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To a solution of 33 (0.49 mmol, 302 mg) and 2,3-di-O-(tert-butyldimethylsilyl)-sn-glycero-2-
cyanoethyl-N,N-diisopropylphosphoramidite (32) (0.66 mmol, 345 mg) in anhydrous CH2Cl2 (4 
mL) was added 0.45 M tetrazole in MeCN (0.66 mmol, 1.47 mL), and the mixture was stirred at 20 
°C. After 45 min, a solution of tBuOOH 5.5 M in nonane (0.68 mmol, 0.123 mL) was added, and 
the mixture was stirred at 20 °C for 1 h before concentration in vacuo. The residue was purified by 
flash chromatography (hexane/EtOAc 5:1) to give 390 mg of a clear oil that was dissolved in 
CH2Cl2 (3 mL). DBU (0.39 mmol, 58 µL) was added and the mixture was stirred at 20 °C for 1 h. 
After that time, the mixture was concentrated in vacuo and the crude mixture was purified by flash 
chromatography (CH2Cl2/MeOH 9:1) to give 330 mg of the intermediate compound. This was then 
dissolved in CH2Cl2 (12 mL) and MeCN (32 mL) and the solution was cooled to 0 °C, treated with 
40 % w/w aqueous HF (1.3 mL), and the mixture was stirred vigorously at 0 °C for 3 h. The excess 
reagent was quenched by addition of MeOSiMe3 (12 mL) at 0 °C, the mixture was stirred for 30 
min at 20 °C, and NaHCO3 (3.26 mmol, 274 mg) was added to the reaction mixture. The desired 
phospholipid was isolated in 46% yield (177 mg) after flash chromatography (CH2Cl2/MeOH/H2O 
9:1:0 to 65:25:4) as white amorphous solid. Rf = 0.15 (CH2Cl2/MeOH 9:1). 1H NMR (500 MHz, 
CDCl3/CD3OD 4:1): δ 7.28-7.25 (m, 2H, Ph -meta), 7.18-7.15 (m, 3H, Ph –ortho and -para), 7.01 
(dt, J = 15.5, 7.0 Hz, 1H, CH=CH-COO), 5.81 (d, J = 15.5 Hz, 1H, CH=CH-COO), 5.29-5.26 (m, 
1H, C17H35-COO-CH2-CH-CH2), 4.38 (dd, J = 11.9, 2.8 Hz, 1H, C17H35-COO-CH2), 4.28-4.20 (1H, 
C17H35-COO-CH2, under HDO signal), 4.02 (t, J = 5.6 Hz, 2H, C17H35-COO-CH2-CH-CH2), 3.97-
3.89 (m, 2H, P-O-CH2-CH-CH2-OH), 3.84-3.80 (m, 1H, P-O-CH2-CH-CH2-OH), 3.65 (dd, J = 
11.4, 4.8 Hz, 1H, P-O-CH2-CH-CH2-OH), 3.61 (dd, J = 11.4, 5.0 Hz, 1H, P-O-CH2-CH-CH2-OH), 
2.61-2.58 (m, 2H, CH2-Ph), 2.30 (t, J = 7.5 Hz, 2H, C16H33-CH2-COO), 2.20 (q, J = 7.0 Hz, 2H, 
CH2-CH=CH-COO), 1.62-1.57 (m, 4H, CH2-CH2-Ph and CH2-CH2-COO), 1.46-1.40 (m, 2H, CH2-
CH2-CH=CH), 1.34-1.22 (m, 38H, CH3-C14H28-CH2-CH2-COO and Ph-CH2-CH2-C5H10-CH2-CH2-
CH=CH), 0.88 (t, J = 6.8 Hz, 3H, CH3-C16H32-COO). 13C NMR (75 MHz, CDCl3/CD3OD 4:1): δ 
174.1, 166.3, 151.1, 142.9, 128.4 (2C), 128.3 (2C), 125.6, 120.4, 70.9 (d, J = 3.8 Hz), 70.5 (d, J = 
9.1 Hz), 66.5 (d, J = 5.1 Hz), 63.8 (d, J = 4.2 Hz), 62.7, 62.2, 36.1, 34.1, 32.5, 32.0, 31.6, 29.8 
(13C), 29.6, 29.5, 29.4 (2C), 28.1, 25.0, 22.8, 14.1. 31P NMR (202 MHz, CDCl3/CD3OD 4:1): δ -
1.362. IR (neat): 3341, 2916, 2819, 1737, 1717, 1456, 1255, 1236, 1129, 1094, 1056, 1012, 874, 
843, 814, 695 cm-1. HRMS (ESI -) C42H72O10PNa [M – Na]- 767.4863, found 767.4877. 
 
1-Stearoyl-2-((Z)-12-phenyldodec-2-enoyl)-sn-glycero-3-phospho-(S)-glycerol (40) 
To a solution of 34 (0.40 mmol, 245 mg) and 2,3-di-O-(tert-butyldimethylsilyl)-sn-glycero-2-
cyanoethyl-N,N-diisopropylphosphoramidite (32) (0.54 mmol, 281 mg) in anhydrous CH2Cl2 (3 
mL) was added 0.45 M tetrazole in MeCN (0.54 mmol,1.2 mL), and the mixture was stirred at 20 
°C. After 45 min, a solution of tBuOOH 5.5 M in nonane (0.55 mmol, 0.1 mL) was added, and the 
mixture was stirred at 20 °C for 1 h before concentration in vacuo. The residue was purified by 
flash chromatography (hexane/EtOAc 5:1) to give 258 mg of a clear oil that was dissolved in 
CH2Cl2 (2 mL). DBU (0.36 mmol, 63 µL) was added and the mixture was stirred at 20 °C for 1 h. 
After that time, the mixture was concentrated in vacuo and the crude mixture was purified by flash 
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chromatography (CH2Cl2/MeOH 9:1) to give 226 mg of the intermediate compound. This was then 
dissolved in CH2Cl2 (9 mL) and MeCN (26 mL) and the solution was cooled to 0 °C, treated with 
40 % w/w aqueous HF (880 µL), and the mixture was stirred vigorously and allowed to reach 
slowly 20 °C over 3 h. The excess reagent was quenched by addition of MeOSiMe3 (9 mL) at 0 °C, 
the mixture was stirred for 30 min at 20 °C, and NaHCO3 (2.21 mmol, 186 mg) was added to the 
reaction mixture. The desired phospholipid was isolated in 17% yield (55 mg) after flash 
chromatography (CH2Cl2/MeOH/H2O 9:1:=0 to 65:25:4) as white amorphous solid. Rf = 0.15 
(CH2Cl2/MeOH 4:1). 1H NMR (300 MHz, CDCl3/CD3OD 4:1): δ 7.30-7.13 (m, 5H, C6H5), 6.31 (dt, 
J = 11.5, 7.5 Hz, 1H, CH=CH-COO), 5.76 (dt, J = 11.5, 1.6 Hz, 1H, CH=CH-COO), 5.30-5.24 (m, 
1H, C17H35-COO-CH2-CH-CH2), 4.35-4.42 (1H, C17H35-COO-CH2, under HDO signal), 4.22 (dd, J 
= 12.0, 6.9 Hz, 1H, C17H35-COO-CH2), 4.02 (m, 2H, C17H35-COO-CH2-CH-CH2), 3.97-3.90 (m, 
2H, P-O-CH2-CH-CH2-OH), 3.85-3.78 (m, 1H, P-O-CH2-CH-CH2-OH), 3.67-3.58 (m, 2H, P-O-
CH2-CH-CH2-OH), 2.75-2.51 (m, 4H, CH2-Ph and CH2-CH=CH-COO), 2.31 (t, J = 7.6 Hz, 2H, 
C16H33-CH2-COO), 1.66-1.54 (m, 4H, CH2-CH2-Ph and CH2-CH2-COO), 1.48-1.40 (m, 2H, CH2-
CH2-CH=CH), 1.36-1.22 (m, 38H, CH3-C14H28-CH2-CH2-COO and Ph-CH2-CH2-C5H10-CH2-CH2-
CH=CH), 0.88 (t, J = 6.8 Hz, 3H, CH3-C16H32-COO). 13C NMR (75 MHz, CDCl3/CD3OD 4:1): δ 
174.2, 165.8, 152.7, 143.0, 128.5 (2C), 128.3 (2C), 125.7, 118.8, 71.0 (d, J = 5.4 Hz), 70.0 (d, J = 
8.6 Hz), 66.5 (d, J = 5.6 Hz), 63.9 (d, J = 4.2 Hz), 62.8, 62.3, 36.1, 34.2, 32.1, 31.7, 29.8 (11C), 
29.7 (2C), 29.5 (3C), 29.3 (2C), 29.1, 25.0, 22.8, 14.1. 31P NMR (202 MHz, CDCl3/CD3OD 4:1): δ 
-1.659. IR (neat): 3500 (br.), 2919, 2850, 1722, 1237, 1183, 1106, 1070 cm-1. HRMS (ESI -) 
C42H72NaO10P, m/z [M-Na]- 767.4863, found 767.4880. 
 
1-Stearoyl-2-((E)-2-methyl-12-phenyldodec-2-enoyl)-sn-glycero-3-phospho-(S)-glycerol (41) 
To a solution of 35 (0.16 mmol, 100 mg) and 2,3-di-O-(tert-butyldimethylsilyl)-sn-glycero-2-
cyanoethyl-N,N-diisopropylphosphoramidite (32) (0.22 mmol, 112 mg) in anhydrous CH2Cl2 (1.5 
mL) was added 0.45 M tetrazole in MeCN (0.22 mmol, 478 µL), and the mixture was stirred at 20 
°C. After 45 min, a solution of tBuOOH 5.5 M in nonane (0.22 mmol, 40 µL) was added, and the 
mixture was stirred at 20 °C for 1 h before concentration in vacuo. The residue was purified by 
flash chromatography (hexane/EtOAc 5:1) to give 103 mg of a clear oil that was dissolved in 
CH2Cl2 (0.7 mL). DBU (0.10 mmol, 15 µL) was added and the mixture was stirred at 20 °C for 1 h. 
After that time, the mixture was concentrated in vacuo and the crude mixture was purified by flash 
chromatography (CH2Cl2/MeOH 9:1) to give 70 mg of the intermediate compound. This was then 
dissolved in CH2Cl2 (3 mL) and MeCN (8.2 mL) and the solution was cooled to 0 °C, treated with 
40 % w/w aqueous HF (276 µL), and the mixture was stirred vigorously and allowed to reach 
slowly 20 °C over 3 h. The excess reagent was quenched by addition of MeOSiMe3 (3 mL) at 0 °C, 
the mixture was stirred for 30 min at 20 °C, and NaHCO3 (0.70 mmol, 58 mg) was added to the 
reaction mixture. The desired phospholipid was isolated in 17 % yield (22 mg) after flash 
chromatography (CH2Cl2/MeOH/H2O 9:1:=0 to 65:25:4) as white amorphous solid. Rf = 0.15 
(CH2Cl2/MeOH 4:1). 1H NMR (300 MHz, CDCl3/CD3OD 4:1): δ 7.30-7.13 (m, 5H, C6H5), 6.79 (tq, 
J = 7.5, 1.1 Hz, 1H, CH=C(CH3)-COO), 5.30-5.23 (m, 1H, C17H35-COO-CH2-CH-CH2), 4.40 (dd, J 
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= 12.0, 3.2 Hz, 1H, C17H35-COO-CH2), 4.30-4.23 (1H, C17H35-COO-CH2, under HDO signal), 4.06-
3.98 (m, 2H, C17H35-COO-CH2-CH-CH2), 3.96-3.90 (m, 2H, P-O-CH2-CH-CH2-OH), 3.84-3.78 (m, 
1H, P-O-CH2-CH-CH2-OH), 3.65 (dd, J = 13.1, 4.8 Hz, 1H, P-O-CH2-CH-CH2-OH), 3.61 (dd, J = 
13.1, 5.1 Hz, 1H, P-O-CH2-CH-CH2-OH), 2.62 (m, 2H, CH2-Ph), 2.31 (t, J = 7.6 Hz, 2H, C16H33-
CH2-COO), 2.17 (q, J = 7.5 Hz, CH2-CH=C(CH3)-COO), 1.81 (d, J = 1.1 Hz, 3H, CH=C(CH3)-
COO), 1.66-1.52 (m, 4H, CH2-CH2-Ph and CH2-CH2-COO), 1.46-1.22 (m, 40H, CH3-C14H28-CH2-
CH2-COO and Ph-CH2-CH2-C6H12-CH2-CH=C(CH3)), 0.88 (t, J = 6.7 Hz, 3H, CH3-C16H32-COO). 
13C NMR (75 MHz, CDCl3/CD3OD 4:1): δ 174.1, 167.9, 144.5, 143.0, 128.5 (2C), 128.3 (2C), 
127.0, 125.7, 71.0 (d, J = 4.9 Hz), 70.8 (d, J = 9.2 Hz), 66.5 (d, J = 5.1 Hz), 63.8 (d, J = 4.3 Hz), 
62.7, 62.3, 36.1, 34.2, 32.1, 31.7, 29.8 (10C), 29.6 (3C), 29.5 (2C), 29.4, 29.3, 29.0, 28.7, 25.0, 
22.8, 14.1, 12.2. 31P NMR (202 MHz, CDCl3/CD3OD 4:1): δ -1.636. IR (neat): 3500 (br.), 2918, 
2850, 1736, 1713, 1466, 1275, 1255, 1228, 1174, 1095, 1076, 1030 cm-1. HRMS (ESI -) 
C43H74O10PNa [M – Na]- 781.5020, found 781.5037.  
 
1-Stearoyl-2-((Z)-2-methyl-12-phenyldodec-2-enoyl)-sn-glycero-3-phospho-(S)-glycerol (42) 
To a solution of 36 (0.42 mmol, 266 mg) and 2,3-di-O-(tert-butyldimethylsilyl)-sn-glycero-2-
cyanoethyl-N,N-diisopropylphosphoramidite (32) (0.57 mmol, 298 mg) in anhydrous CH2Cl2 (3.3 
mL) was added 0.45 M tetrazole in MeCN (0.57 mmol, 130 µL), and the mixture was stirred at 20 
°C. After 45 min, a solution of tBuOOH 5.5 M in nonane (0.58 mmol, 100 µL) was added, and the 
mixture was stirred at 20 °C for 1 h before concentration in vacuo. The residue was purified by 
flash chromatography (hexane/EtOAc 5:1) to give 274 mg of a clear oil that was dissolved in 
CH2Cl2 (2 mL). DBU (0.270 mmol, 41µL) was added and the mixture was stirred at 20 °C for 1 h. 
After that time, the mixture was concentrated in vacuo and the crude mixture was purified by flash 
chromatography (CH2Cl2/MeOH 9:1) to give 245 mg of the intermediate compound. This was then 
dissolved in CH2Cl2 (9.5 mL) and MeCN (27 mL) and the solution was cooled to 0 °C, treated with 
40 % w/w aqueous HF (940 µL), and the mixture was stirred vigorously and allowed to reach 
slowly 20 °C over 3 h. The excess reagent was quenched by addition of MeOSiMe3 (9.5 mL) at 0 
°C, the mixture was stirred for 30 min at 20 °C, and NaHCO3 (2.37 mmol, 100 mg) was added to 
the reaction mixture. The desired phospholipid was isolated in 17% yield (57 mg) after flash 
chromatography (CH2Cl2/MeOH/H2O 9:1:0 to 65:25:4) as white amorphous solid. Rf = 0.19 
(CH2Cl2/MeOH 4:1). 1H NMR (300 MHz, CDCl3/CD3OD 4:1): δ 7.30-7.13 (m, 5H, C6H5), 6.01 (tq, 
J = 7.3, 1.3 Hz, 1H, CH=C(CH3)-COO), 5.34-5.26 (m, 1H, C17H35-COO-CH2-CH-CH2), 4.42 (dd, J 
= 12.0, 2.9 Hz, 1H, C17H35-COO-CH2), 4.30-4.20 (1H, C17H35-COO-CH2, under HDO signal), 4.10-
3.98 (m, 2H, C17H35-COO-CH2-CH-CH2), 3.98-3.88 (m, 2H, P-O-CH2-CH-CH2-OH), 3.86-3.78 (m, 
1H, P-O-CH2-CH-CH2-OH), 3.668-3.58 (m, 2H, P-O-CH2-CH-CH2-OH), 2.62-2.57 (m, 2H, CH2-
Ph), 2.43 (q, J = 7.3 Hz, CH2-CH=C(CH3)-COO), 2.30 (t, J = 7.6 Hz, 2H, C16H33-CH2-COO), 1.88 
(d, J = 1.3 Hz, 3H, CH=C(CH3)-COO), 1.68-1.54 (m, 4H, CH2-CH2-Ph and CH2-CH2-COO), 1.42-
1.22 (m, 40H, CH3-C14H28-CH2-CH2-COO and Ph-CH2-CH2-C6H12-CH2-CH=C(CH3)), 0.88 (t, J = 
6.6 Hz, 3H, CH3-C16H32-COO). 13C NMR (75 MHz, CDCl3/CD3OD 4:1): δ 174.1, 167.5, 145.4, 
143.0, 128.5 (2C), 128.3 (2C), 126.3, 125.6, 71.0 (d, J = 5.7 Hz), 70.4 (d, J = 7.4 Hz), 66.5 (d, J = 
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3.7 Hz), 63.8 (d, J = 4.1 Hz), 62.8, 62.3, 36.1, 34.2, 32.0, 31.7, 29.9, 29.8 (10C), 29.7 (3C), 29.6 
(2C), 29.5 (2C), 29.3, 25.0, 22.8, 20.5, 14.1. 31P NMR (202 MHz, CDCl3/CD3OD 4:1): δ -1.659. IR 
(neat): 3500 (br.), 2918, 2849, 1734, 1709, 1466, 1455, 1387, 1221, 1135, 1098, 1072 cm-1. HRMS 
(ESI -) C43H74O10PNa [M – Na]- 781.5020, found 781.5024.  
 
1-Stearoyl-2-((E)-3-methyl-12-phenyldodec-2-enoyl)-sn-glycero-3-phospho-(S)-glycerol (43) 
To a solution of 37 (0.165 mmol, 104 mg) and 2,3-di-O-(tert-butyldimethylsilyl)-sn-glycero-2-
cyanoethyl-N,N-diisopropylphosphoramidite (32) (0.223 mmol, 116 mg) in anhydrous CH2Cl2 (1.3 
mL) was added 0.45 M tetrazole in MeCN (0.223 mmol, 500 µL), and the mixture was stirred at 20 
°C. After 45 min, a solution of tBuOOH 5.5 M in nonane (0.228 mmol, 41 µL) was added, and the 
mixture was stirred at 20 °C for 1 h before concentration in vacuo. The residue was purified by 
flash chromatography (hexane/EtOAc 5:1) to give 108 mg of a clear oil that was dissolved in 
CH2Cl2 (780 µL), DBU (0.106 mmol, 16 µL) was added and the mixture was stirred at 20 °C for 1 
h. After that time, the mixture was concentrated in vacuo and the crude mixture was purified by 
flash chromatography (CH2Cl2/MeOH 9:1) to give 95 mg of the intermediate compound. This was 
then dissolved in CH2Cl2 (3.7 mL) and MeCN (10 mL) and the solution was cooled to 0 °C, treated 
with 40 % w/w aqueous HF (365 µL), and the mixture was stirred vigorously and kept at 0 °C for 3 
h. The excess reagent was quenched by addition of MeOSiMe3 (3.7 mL) at 0 °C, the mixture was 
stirred for 30 min at 20 °C, and NaHCO3 (0.919 mmol, 77 mg) was added to the reaction mixture. 
The desired phospholipid was isolated in 45 % yield (59 mg) after flash chromatography 
(CH2Cl2/MeOH/H2O 9:1:0 to 65:25:4) as white amorphous solid. Rf = 0.13 (CH2Cl2/MeOH 9:1). 1H 
NMR (300 MHz, CDCl3/CD3OD 4:1): δ 7.31-7.11 (m, 5H, C6H5), 5.66 (q, J = 1.1 Hz, 1H, 
C(CH3)=CH-COO), 5.31-5.19 (m, 1H, C17H35-COO-CH2-CH-CH2), 4.41-4.39 (m, 1H, C17H35-
COO-CH2, under HDO signal), 4.23 (dd, J = 11.9, 6.5 Hz, 1H, C17H35-COO-CH2,), 4.10-3.89 (m, 
4H, C17H35-COO-CH2-CH-CH2, and P-O-CH2-CH-CH2-OH), 3.86-3.78 (m, 1H, P-O-CH2-CH-
CH2-OH), 3.69-3.56 (m, 2H, P-O-CH2-CH-CH2-OH), 2.60 (m, 2H, CH2-Ph), 2.32 (t, J = 7.5 Hz, 
2H, C16H33-CH2-COO), 2.18-2.11 (m, 5H, CH2-C(CH3)=CH-COO), 1.66-1.54 (m, 4H, CH2-CH2-Ph 
and CH2-CH2-COO), 1.50-1.20 (m, 40H, CH3-C14H28-CH2-CH2-COO and Ph-CH2-CH2-C6H12-
CH2-C(CH3)=CH), 0.88 (t, J = 6.8 Hz, 3H, CH3-C16H32-COO). 13C NMR (50 MHz, CDCl3/CD3OD 
4:1): δ 174.2, 166.3, 162.9, 143.0, 128.5 (2C), 128.3 (2C), 125.7, 114.7, 71.1, 69.7 (d, J = 7.4 Hz), 
66.5, 63.9, 62.9, 62.3, 41.3, 36.1, 34.2, 32.0, 31.6, 29.8 (10C), 29.6 (4C), 29.5 (2C), 29.3, 27.6, 
25.0, 22.8, 19.0, 14.1. 31P NMR (202 MHz, CDCl3/CD3OD 4:1): δ -3.009 IR (neat): 3500 (br.), 
2919, 2850, 1739, 1719, 1651, 1466, 1454, 1216, 1138, 1093, 1074, 1052 cm-1. HRMS (ESI -) 
C43H74O10PNa [M – Na]- 781.5020, found 781.5031.  
 
 
1-Stearoyl-2-((Z)-3-methyl-12-phenyldodec-2-enoyl)-sn-glycero-3-phospho-(S)-glycerol (44) 
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To a solution of 38 (0.165 mmol, 104 mg) and 2,3-di-O-(tert-butyldimethylsilyl)-sn-glycero-2-
cyanoethyl-N,N-diisopropylphosphoramidite (32) (0.223 mmol, 116 mg) in anhydrous CH2Cl2 (1.3 
mL) was added 0.45 M tetrazole in MeCN (0.223 mmol, 500 µL), and the mixture was stirred at 20 
°C. After 45 min, a solution of tBuOOH 5.5 M in nonane (0.228 mmol, 41 µL) was added, and the 
mixture was stirred at 20 °C for 1 h before concentration in vacuo. The residue was purified by 
flash chromatography (hexane/EtOAc 5:1) to give 113 mg of a clear oil that was dissolved in 
CH2Cl2 (1 mL). DBU (0.112 mmol, 17 µL) was added and the mixture was stirred at 20 °C for 1.5 
h. After that time, the mixture was concentrated in vacuo and the crude mixture was purified by 
flash chromatography (CH2Cl2/MeOH 9:1) to give 75 mg of the intermediate compound. This was 
then dissolved in CH2Cl2 (2.8 mL) and MeCN (8 mL) and the solution was cooled to 0 °C, treated 
with 40 % w/w aqueous HF (277 µL), and the mixture was stirred vigorously and kept at 0 °C for 3 
h. The excess reagent was quenched by addition of MeOSiMe3 (2.7 mL) at 0 °C, the mixture was 
stirred for 30 min at 20 °C, and NaHCO3 (0.697 mmol, 58 mg) was added to the reaction mixture. 
The desired phospholipid was isolated in 35 % yield (43 mg) after flash chromatography 
(CH2Cl2/MeOH/H2O 9:1:=0 to 65:25:4) as white amorphous solid. Rf = 0.13 (CH2Cl2/MeOH 9:1). 
1H NMR (300 MHz, CDCl3/CD3OD 4:1): δ 7.30-7.13 (m, 5H, C6H5), 5.65-5.63 (m, 1H, 
C(CH3)=CH-COO), 5.26-5.19 (m, 1H, C17H35-COO-CH2-CH-CH2), 4.36 (dd, J = 12.0, 3.3 Hz, 1H, 
C17H35-COO-CH2),  4.24-4.15 (1H, C17H35-COO-CH2, under HDO signal), 4.04-3.89 (m, 4H, 
C17H35-COO-CH2-CH-CH2 and P-O-CH2-CH-CH2-OH), 3.84-3.76 (m, 1H, P-O-CH2-CH-CH2-
OH), 3.68-3.59 (m, 2H, P-O-CH2-CH-CH2-OH), 2.74-2.46 (m, 4H, CH2-Ph and CH2-C(CH3)=CH-
COO), 2.30 (t, J = 7.6 Hz, 2H, C16H33-CH2-COO), 1.90 (d, J = 1.1 Hz, 3H, C(CH3)=CH-COO), 
1.66-1.54 (m, 4H, CH2-CH2-Ph and CH2-CH2-COO), 1.50-1.22 (m, 40H, CH3-C14H28-CH2-CH2-
COO and Ph-CH2-CH2-C6H12-CH2-C(CH3)=CH), 0.88 (t, J = 6.7 Hz, 3H, CH3-C16H32-COO). 13C 
NMR (50 MHz, CDCl3/CD3OD 4:1): δ 174.2, 165.6, 163.4, 143.0, 128.5 (2C), 128.3 (2C), 125.7, 
115.2, 71.0, 69.5 (d, J = 7.8 Hz), 66.5, 64.0, 62.9, 62.3, 36.1, 34.2, 33.7, 32.0, 31.7, 29.8 (10C), 
29.7 (3C), 29.5 (2C), 29.3, 28.4, 25.3, 25.0, 22.8, 18.9, 14.1. 31P NMR (202 MHz, CDCl3/CD3OD 
4:1): δ -2.986. IR (neat): 3500 (br.), 2921, 2852, 1719, 1645, 1455, 1227, 1141,1103, 1065 cm-1. 
HRMS (ESI -) C43H74O10PNa [M – Na]- 781.5020, found 781.5032.  
 
1-Stearoyl-2-(12-phenyldodecanoyl)-sn-glycero-3-phospho-(S)-glycerol (45) 
To a solution of 33 (0.16 mmol, 99 mg) and 2,3-di-O-(tert-butyldimethylsilyl)-sn-glycero-2-
cyanoethyl-N,N-diisopropylphosphoramidite (32) (0.22 mmol, 113 mg) in anhydrous CH2Cl2 (1.5 
mL) was added 0.45 M tetrazole in MeCN (0.22 mmol, 483 µL), and the mixture was stirred at 20 
°C. After 45 min, a solution of tBuOOH 5.5 M in nonane (0.22 mmol, 40 µL) was added, and the 
mixture was stirred at 20 °C for 1 h before concentration in vacuo. The residue was purified by 
flash chromatography (hexane/EtOAc 5:1) to give 122 mg of a clear oil that was dissolved in 
CH2Cl2 (1 mL). DBU (0.13 mmol, 19 µL) was added and the mixture was stirred at 20 °C for 1 h. 
After that time, the mixture was concentrated in vacuo and the crude mixture was purified by flash 
chromatography (CH2Cl2/MeOH 9:1) to give 105 mg of the intermediate compound. This was then 
dissolved in EtOAc (1 mL) under Ar. 10 % (w/w) Pd/C (0.005 mmol, 5mg) was added carefully, 
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and the atmosphere was exchanged with H2. The suspension was stirred at 20 °C for 15 h, and the 
mixture was filtered through celite. The Pd residue was rinsed with EtOAc, and the combined 
organic phases were concentrated in vacuo, to give 82 mg of white compound, that was dissolved in 
CH2Cl2 (3.2 mL) and MeCN (8 mL) and the solution was cooled to 0 °C, treated with 40 % w/w 
aqueous HF (312 µL), and the mixture was stirred vigorously at 0 °C for 3 h. The excess reagent 
was quenched by addition of MeOSiMe3 (3 mL) at 0 °C, the mixture was stirred for 30 min at 20 
°C, and NaHCO3 (0.8 mmol, 64 mg) was added to the reaction mixture. The desired phospholipid 
was isolated in 47% yield (60 mg) after flash chromatography (CH2Cl2/MeOH/H2O 9:1:0 to 
65:25:4) as white amorphous solid. Rf = 0.13 (CH2Cl2/MeOH 9:1). 1H NMR (300 MHz, 
CDCl3/CD3OD 4:1): δ 7.30-7.213 (m, 5H, C6H5), 5.27-5.19 (m, 1H, C17H35-COO-CH2-CH-CH2), 
4.38 (dd, J = 12.1, 3.0 Hz, 1H, C17H35-COO-CH2), 4.21-4.10 (1H, C17H35-COO-CH2, under HDO 
signal), 4.03-3.90 (m, 4H, C17H35-COO-CH2-CH-CH2 and -O-CH2-CH-CH2-OH), 3.86-3.78 (m, 
1H, P-O-CH2-CH-CH2-OH), 3.68-3.60 (m, 2H, P-O-CH2-CH-CH2-OH), 2.62-2.57 (m, 2H, CH2-
Ph), 2.32 (t, J = 7.5 Hz, 2H, Ph-C10H20-CH2-COO), 2.30 (t, J = 7.5 Hz, 2H, C16H33-CH2-COO), 
1.67-1.55 (m, 6H, CH2-CH2-Ph, CH2-CH2-COO and Ph-C9H18-CH2-CH2-COO), 1.39-1.21 (m, 46H, 
CH3-C14H28-CH2-CH2-COO and Ph-CH2-CH2-C9H18-CH2-CH2-COO), 0.88 (t, J = 6.7 Hz, 3H, CH3-
C16H32-COO). 13C NMR (50 MHz, CDCl3/CD3OD 4:1): δ 174.0, 173.6, 143.1, 128.5 (2C), 128.3 
(2C), 70.9, 70.0, 67.7, 64.7, 62.3 (d, J = 9.5 Hz), 36.1, 34.3, 32.1, 31.7, 29.8 (13C), 29.6 (6C), 29.4, 
29.3 (2C), 25.0 (2C), 22.8, 14.1. 31P NMR (202 MHz, CDCl3/CD3OD 4:1): δ -1.659. IR (neat): 
3500 (br.), 2916, 2849, 1732, 1467, 1106, 1056 cm-1 
 
1-Stearoyl-2-O-(tert-butyl-dimethylsilyl)-3-O-(para-methoxybenzyl)-sn-glycerol (46) 
To a solution of 19 (1.25 mmol, 600 mg) in DMF (12 mL), were added TBSCl (1.38 mmol, 208 
mg) and imidazole (2.5 mmol, 170 mg), and the resulting mixture was stirred at 20 °C for 3.5 h. 
The reaction was then quenched with 1% HCl (20 mL). The organic layer was separated, and the 
aqueous phase was washed with Et2O. The combined organic layers were washed with brine, dried 
over MgSO4, concentrated in vacuo and the crude oil thereby obtained was purified by flash 
chromatography (heptane/EtOAc 20:1) to afford the desired product as clear oil in 70 % yield (510 
mg). Rf = 0.63 (heptane/EtOAc 4:1). ሾ∝ሿ஽ଶ଴= 9.35 ° (c = 1.39, CHCl3). 1H NMR (300 MHz, CDCl3): 
δ 7.29-7.26 and 6.92-6.88 (AA’XX’ pattern, J = 8.7 Hz, 4H, aromatic), 4.49 (s, 2H, CH2-Ph), 4.22 
(dd, J = 13.6, 6.6 Hz, 1H, C18H35-COO-CH2-CH-CH2), 4.08-4.00 (m, 2H, C18H35-COO-CH2-CH-
CH2), 3.84 (s, 3H, O-CH3), 3.45 (d, J = 5.1 Hz, 2H, C18H35-COO-CH2-CH-CH2), 2.31 (t, J = 7.6 
Hz, 2H, CH2COO), 1.71-1.59 (m, 2H, CH2-CH2-COO), 1.41-1.20 (m, 28H, CH3-C14H28-CH2-CH2-
COO), 0.96-0.87 (m, 12H, C17H32-CH3 and Si-C-(CH3)3), 0.10 (s, 6H, Si-(CH3)2). 13C NMR (75 
MHz, CDCl3): δ 173.7, 159.1, 130.2, 129.2 (2C), 113.7 (2C), 73.1, 71.5, 69.7, 66.2, 55.2, 34.3, 
31.9, 29.7 (7C), 29.6, 29.5, 29.4, 29.3, 29.2, 25.7 (3C), 24.9, 22.7, 18.1, 14.1, -4.7, -4.8. IR (neat): 
2923, 2853, 1739, 1613, 1513, 1463, 1247, 1172, 1143, 1099, 1036, 1005, 830, 777 cm-1.HRMS 
(ESI +) C35H64O5Si, m/z [M+Na+] 615.4421, found 615.4421. 
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1-Stearoyl-2-O-(tert-butyl-dimethylsilyl)-sn-glycerol (47) 
Compound 46 (0.80 mmol, 472 mg) was dissolved in a mixture of CH2Cl2 (4 mL) and phosphate 
buffer (pH=7) (0.6 mL), and DDQ (1.4 mmol, 320 mg) was added in two portions over 45 min. The 
two-phase mixture was stirred vigorously at 20 °C for 1.5 h, and ice sat. aq. NaHCO3 (5 mL) and 
CH2Cl2 (5 mL) were added at 0 °C. The organic phase was separated, and the aqueous layer was 
extracted with CH2Cl2 (3  5 mL) and the combined organic layers were washed with cold brine 
(15 mL), dried over Na2SO4 and concentrated in vacuo. The product was purified by flash 
chromatography (heptane/EtOAc 7:1) and obtained as colourless oil in 87% yield (330 mg). Rf = 
0.30 (heptane/EtOAc 3:1). ሾ∝ሿ஽ଶ଴= -4.31 ° (c = 1.95, CHCl3). 1H NMR (500 MHz, CDCl3): 4.10 (dd, 
J = 11.0, 5.7 Hz, 1H, C18H35-COO-CH2-CH-CH2), 4.07 (dd, J = 11.0, 5.5 Hz, 1H, C18H35-COO-
CH2-CH-CH2), 3.95-3.91(m, 1H, C18H35-COO-CH2-CH-CH2), 3.63-3.53 (m, 2H, C18H35-COO-
CH2-CH-CH2), 2.31 (t, J = 7.6 Hz, 2H, CH2COO), 1.97 (t, J = 5.9 Hz, 1H, OH), 1.64-1.59 (m, 2H, 
CH2-CH2-COO), 1.35-1.22 (m, 28H, CH3-C14H28-CH2-CH2-COO), 0.90 (s, 9H, Si-C-(CH3)3), 0.88 
(t, J = 6.9 Hz, 3H, C17H32-CH3), 0.11 (s, 3H, Si-(CH3)2, 0.10 (s, 3H, Si-(CH3)2. 13C NMR (75 MHz, 
CDCl3): δ 173.8, 70.5, 64.7, 63.8, 34.2, 31.9, 29.7 (6C), 29.6 (2C), 29.4 (2C), 29.2, 29.1, 25.7 (3C), 
24.9, 22.7, 18.0, 14.1, -4.7, -4.8. IR (neat): 3500 (br.), 2923, 2853, 1741, 1463, 1251, 1172, 1115, 
1057, 992, 835, 777 cm-1.HRMS (ESI +) C27H56O4Si, m/z [M+Na+] 495.3846, found 495.3831.  
 
1-Stearoyl-sn-glycero-3-phospho-(S)-glycerol (48) 
To a solution of 47 (0.70 mmol, 330 mg) and 2,3-di-O-(tert-butyldimethylsilyl)-sn-glycero-2-
cyanoethyl-N,N-diisopropylphosphoramidite (32) (0.94 mmol, 492 mg) in anhydrous CH2Cl2 (5 
mL) was added 0.45 M tetrazole in MeCN (0.94 mmol,2 mL), and the mixture was stirred at 20 °C. 
After 45 min, a solution of tBuOOH 5.5 M in nonane (0.96 mmol, 175 µL) was added, and the 
mixture was stirred at 20 °C for 1 h before concentration in vacuo. The residue was purified by 
flash chromatography (hexane/EtOAc 5:1) to give 470 mg of a clear oil that was dissolved in 
CH2Cl2 (3.9 mL), DBU (0.54 mmol, 81 µL) was added and the mixture was stirred at 20 °C for 1 h. 
After that time, the mixture was concentrated in vacuo and the crude mixture was purified by flash 
chromatography (CH2Cl2/MeOH 9:1) to give 396 mg of the intermediate compound. This was then 
dissolved in CH2Cl2 (28 mL) and MeCN (67 mL) and the solution was cooled to 0 °C, treated with 
40 % w/w aqueous HF (2.7 mL), and the mixture was stirred vigorously at 0 °C over 3 h. The 
excess reagent was quenched by addition of MeOSiMe3 (27 mL) at 0 °C, the mixture was stirred for 
30 min at 20 °C, and NaHCO3 (4.3 mmol, 364 mg) was added to the reaction mixture. The desired 
phospholipid was isolated in 52% yield (194 mg) after flash chromatography (CH2Cl2/MeOH/H2O 
9:1:0 to 65:25:4) as white amorphous solid. Rf = 0.14 (CH2Cl2/MeOH 4:1). 1H NMR (300 MHz, 
CDCl3/CD3OD 4:1): δ 4.16-4.10 (m, 2H,), 4.05-3.77 (m, 6H,), 3.66-3.56 (m, 2H), 3.54-3.52 (br. s, 
1H, OH), 3.36-3.33 (m, 1H, CH-CH2-OH), 3.26-3.24 (br. s, 1H, OH) 2.35 (t, J = 7.6 Hz, 2H, 
C16H33-CH2-COO), 1.66-1.57 (m, 3H, CH2-CH2-COO), 1.33-1.22 (m, 28H, CH3-C14H28-CH2-CH2-
COO), 0.88 (t, J = 6.8 Hz, 3H, CH3-C16H32-COO). 13C NMR (50 MHz, CDCl3/CD3OD 4:1): δ 
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174.7, 71.2, 70.0, 67.0, 65.0, 62.6, 34.2, 32.1, 29.8 (8C), 29.7 (2C), 29.5 (2C), 29.3, 25.0, 22.8, 
14.1.  
 
13-Phenyl-3,6,9,12-tetraoxatridecan-1-ol (49) 
To a solution of tetraethyleneglycol (10.30 mmol, 2g) in anhydrous DMF (10 mL) cooled to 0 °C 
under Ar, was added NaH (60 % in mineral oil 10.29 mmol, 412 mg) in four portions over 10 min 
and the resulting suspension was stirred at 0 °C for 10 min, then at 20 °C for additional 10 min. 
BnBr (2.06 mmol, 245 µL) was then added dropwise and the reaction mixture was stirred at 20 °C 
for 20 h. The reaction mixture was poured into ice water (50 mL) and extracted with Et2O (3  50 
mL). The combined organic layers were dried (MgSO4), concentrated in vacuo and purified by flash 
chromatography (heptane /EtOAc 1:1 to 0:1) to afford 49 as a colourless oil in 92 % yield (540 mg), 
and unreacted tetraethyleneglycol was recovered (7.10 mmol, 1.380 g). Rf = 0.2 (EtOAc/heptane 
2:1). 1H NMR (300 MHz; CDCl3): δ 7.35-7.27 (m, 5H, C6H5), 4.57 (s, 2H, CH2-Ph), 3.70-3.58 (m, 
16H, O-CH2-CH2-O), 2.54 (t, J = 5.5 Hz, 1H, OH). 13C NMR (75 MHz, CDCl3): δ 138.2 (C6H5), 
128.3 (2C, C6H5), 127.7 (2C, C6H5), 127.5 (C6H5), 73.2 (CH2-Ph), 72.5 (O-CH2-CH2-O-), 70.6 (4C, 
O-CH2-CH2-O-), 70.3 (O-CH2-CH2-O-), 69.4 (O-CH2-CH2-O-), 61.7 (CH2-OH).  
 
13-Phenyl-3,6,9,12-tetraoxatridecanyl methanesulfonate (50) 
To a solution of 49 (7.52 mmol, 2.14 g) in CH2Cl2 (15 mL) was added Et3N (13.53 mmol, 1.9 mL). 
The reaction mixture was cooled to -30 °C and MsCl (12.03 mmol, 930 µL) was added dropwise 
and the mixture was stirred for 10 min at that temperature then allowed to reach 20 °C slowly over 
1 h and stirred for additional 14 h. Sat. aq. NH4Cl (20 mL) was added, the organic layer was 
separated, and the aqueous layer was washed with CH2Cl2 (3  20 mL). The combined organic 
layers were washed with H2O (20 mL), sat. aq. NaHCO3 (20 mL), and brine (20 mL) and dried over 
MgSO4 to afford 2.64 g of crude oil (crude yield 97%) used without further purification. Rf = 0.42 
(EtOAc/heptane 9:1). 1H NMR (300 MHZ; CDCl3): δ 7.34-7.26 (m, 5H, C6H5), 4.56 (s, 2H, CH2-
C6H5), 4.37-4.34 (m, 2H, CH2-OMs), 3.76-3.73 (m, 2H, CH2-CH2-OMs), 3.65-3.64 (m, 12H, (O-
CH2-CH2)3-OBn), 3.05 (s, 3H, SO2-CH3). 13C NMR (75 MHz, CDCl3): δ 138.2, 128.3 (2C), 127.7 
(2C), 127.5, 73.2, 70.6 (3C), 70.5 (2C), 69.4, 69.3, 69.0, 37.7; HRMS (ESI +) C16H26O7S, m/z 
[M+Na+] 385.1297, found 385.1294. 
 
1,2-O-Isopropylidene-3-O-(13-phenyl-3,6,9,12-tetraoxatridecyl)-sn-glycerol (51) 
To a flame dried round bottomed flask was added powdered KOH (17.95 mmol, 1 g) and anhydrous 
DMSO (20 mL) under Ar, and the resulting suspension was stirred at 20 °C for 1 h. A solution of 
(S)-(+)-1,2-isopropylideneglycerol (10.77 mmol, 1.42 g), crude 50 (7.18 mmol, 2.6 g) in anhydrous 
DMSO (20 mL) was added, and the reaction mixture was stirred at 40 °C for 20 h. Aq. NH4Cl (50 
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% w/w, 40 mL) was added, the aqueous layer was extracted with EtOAc (3  50 mL), the 
combined organic layers were washed with H2O (100 mL), dried over MgSO4, concentrated in 
vacuo and purified by flash chromatography (heptane/EtOAc 1:1) to afford 2.1 g of 51 as colourless 
oil (76 %). Rf = 0.18 (heptane/EtOAc 1:1). ሾ∝ሿ஽ଶ଴= +3.51 ° (c = 1.51, CHCl3). 1H NMR (300 MHz; 
CDCl3): δ 7.34-7.24 (m, 5H, C6H5), 4.56 (s, 2H, CH2-C6H5), 4.32-4.22 (m, 1H, CH2-CH-CH2), 4.04 
(dd, J = 8.3, 6.4 Hz, 1H, CHaHb-CH-CH2-OTEG), 3.72 (dd, J = 8.3, 6.4 Hz, 1H, CHaHb-CH-CH2-
OTEG), 3.69-3.60 (m, 16H, (O-CH2-CH2)4), 3.57 (dd, J = 10.0, 5.7 Hz, 1H, CH2-CH-CHaHb-
OTEG), 3.48 (dd, J = 10.0, 5.5 Hz, 1H, CH2-CH-CHaHb-OTEG), 1.41 (s, 3H, CH3), 1.35 (s, 3H, 
CH3); 13C NMR (75 MHz, CDCl3): δ 138.5 (aromatic), 128.6 (2C, aromatic), 128.0 (2C, aromatic), 
127.8 (aromatic), 109.6 (CH3-C-CH3), 74.9 (CH2-CH-CH2), 73.5 (CH2-C6H6), 72.6 ((O-CH2-
CH2)4), 71.2 ((O-CH2-CH2)4), 70.9 (2C, (O-CH2-CH2)4), 70.8 (3C, (O-CH2-CH2)4), 70.7 ((O-CH2-
CH2)4), 69.6 (CH2-CH-CH2-OTEG), 67.0 (CH2-CH-CH2-OTEG), 27.0 (CH3), 25.6 (CH3); IR 
(neat): 2985, 2866, 1454, 1370, 1252, 1212, 1095, 1049, 843, 738, 698 cm-1. HRMS (ESI +) 
C21H34O7, m/z [M+Na+] 421.2202, found 421.2193.  
 
3-O-(13-Phenyl-3,6,9,12-tetraoxatridecyl)-sn-glycerol (52) 
To a solution of 51 (11.4 mmol, 4.5 g) in MeOH (100 mL), was added HCl 1M in MeOH (100 mL), 
and the reaction mixture was stirred at 20 °C for 18 h, after what the solvent was removed in vacuo, 
and the desired product was isolated by flash chromatography (EtOAc/MeOH 90:10 to 75:25) as a 
clear oil in 93 % yield (3.8 g). Rf = 0.2 (EtOAc). ሾ∝ሿ஽ଶ଴= -1.27 ° (c =2.68, CHCl3). 1H NMR (300 
MHz; CD3OD): δ 7.33-7.21 (m, 5H, C6H5), 4.52 (s, 2H, CH2-C6H5), 3.75-3.40 (m, 21H, CH2-CH-
CH2- and O-CH2-CH2-O), 3.28 (s (br), 2H, OH). 13C NMR (75 MHz, CDCl3): δ 138.2 (C6H5), 
128.3 (C6H5, 2C), 127.7 (C6H5, 2C), 127.6 (C6H5), 73.2 (CH2-Ph), 72.9 (TEG + glycerol), 70.7 
(TEG + glycerol), 70.6 (TEG + glycerol, 2C), 70.5 (TEG + glycerol, 4C), 70.4 (TEG + glycerol), 
69.3 (TEG + glycerol), 63.9 (CH2-OH). IR (neat): 3419 (br.), 2867, 1453, 1350, 1296, 1249, 1090, 
1040, 924, 753 cm-1. HRMS (ESI +) C18H30O7, m/z [M+H+] 359.2070, found 359.2076. 
 
1,2-Di-O-octadecyl-3-O-(13-phenyl -3,6,9,12-tetraoxatridecyl)-sn-glycerol (53) 
In a flame-dried 25 mL round bottom flask, were added 52 (0.84 mmol, 300 mg) and DMSO (5 
mL), followed by KOH (4.19 mmol, 235 mg), and the resulting mixture was stirred at 20 °C for 3 h 
in order to solubilise KOH fully. When all the materials were into solution, 1-bromooctadecane was 
added slowly and the reaction mixture was stirred for 22 h. NH4Cl (10 mL) was then added and the 
aqueous phase was washed with EtOAc (3  20 mL), the combined organic layers were dried 
(MgSO4), concentrated in vacuo, and the desired product was obtained after purification by flash 
chromatography (heptane/EtOAc 1:0 to 1:3) in 68 % yield (490 mg) as a white amorphous solid. 
Mp.: 36.0-36.5 °C. Rf = 0.69 (EtOAc). ሾ∝ሿ஽ଶ଴= +0.16 ° (c = 1.26, CHCl3). 1H NMR (300 MHz; 
CDCl3): δ 7.34-7.23 (m, 5H, C6H5), 4.56 (s, 2H, CH2-C6H5), 3.69-3.36 (m, 21H, C18H37-O-CH2-
CH(O-C18H37)-CH2-O-(CH2-CH2-O)4-Bn), 1.57-1.50 (m, 4H, C17H35-CH2-O), 1.32-1.19 (m, 64H, 
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CH3-C16H32-CH2-O), 0.88 (t, J = 6.7 Hz, 6H, CH3-C17H34-O). 13C NMR (75 MHz, CDCl3): δ 138.2 
(C5H5-C-CH2), 128.3 (C6H6, 2C), 127.7 (C6H6, 2C), 127.6 (C6H6), 77.8 (CH2-CH-CH2), 73.2 
(C6H6-CH2), 71.6 (C18H37-O-CH2-CH-CH2), 71.4 (C17-H35-CH2-O- and TEG), 70.8 (C17-H35-CH2-
O- and TEG, 2C), 70.6 (C17-H35-CH2-O- and TEG, 5C), 70.5 (C17-H35-CH2-O- and TEG, 2C), 69.4 
(CH2-CH-CH2-OTEG), 31.9 (CH3-CH2-CH2-CH2, 2C), 30.1 (CH3-CH2-CH2-CH2-C14H28, 2C), 29.7 
(CH3-CH2-CH2-CH2-C14H28, 20C), 29.5 (CH3-CH2-CH2-CH2-C14H28, 2C), 29.4 (CH3-CH2-CH2-
CH2-C14H28, 2C), 26.1 (CH3-CH2-CH2-CH2-C14H28, 2C), 22.7 (CH3-CH2-CH2-CH2-C14H28, 2C), 
14.1 (CH3-CH2-CH2-CH2-C14H28, 2C). IR (neat): 2916, 2849, 1466, 1099 cm-1. HRMS (ESI +) 
C54H102O7, m/z [M+Na+] 885.7523, found 885.7545. 
 
Octadecyl-para-toluenesulfonate (54)106 
p-Toluenesulfonyl chloride (2.04 mmol, 387 mg) was added to a stirred solution of pyridine (1 mL) 
and octadecanol (1.85 mmol, 500 mg) maintained at 0 °C. The reaction mixture was stirred for 3 h 
and then quenched with H2O (5 mL) and extracted with CH2Cl2 (3  5 mL). The combined organic 
layers were washed with 3 M HCl (3  10 mL) followed by 10% NaHCO3 (10 mL), dried over 
Na2SO4 and concentrated under vacuum. The crude product was purified by flash chromatography 
(heptane/EtOAc 9:1), to afford the desired compound as white powder in 70 % yield (555 mg). Rf = 
0.4 (heptane EtOAc 9:1). Mp.: 55.8-56.2 °C. 1H NMR (300 MHz; CDCl3): δ 7.79 (d, J = 8.3 Hz, 
2H, 2SO2-C-CH-CH-C-CH3), 7.34 (d, J = 8.3 Hz, 2H, 2SO2-C-CH-CH-C-CH3), 4.01 (t, J = 6.5 
Hz, 2H, CH2-O-SO2), 2.46 (s, 3H, O-CH3), 1.67-1.58 (m, 2H, CH2-CH2-SO2), 1.33-1.17 (m, 30H, 
CH3-(CH2)15), 0.88 (t, J = 6.7 Hz,3H, CH3-(CH2)15). 13C NMR (75 MHz; CDCl3) δ 144.6, 133, 2, 
129.8 (2C), 127.9 (2C), 70.7, 31.9, 29.7 (9C), 29.6 (3C), 29.5, 29.4(2C), 28.9, 28.8. 
 
1,2-Di-O-octadecyl-3-O-(12-hydroxy-3,6,9-trioxadodecyl)-sn-glycerol (55) 
Compound 53 (4.64 mmol, 4 g) was dissolved in EtOAc (45 mL) under N2 atmosphere, and w/w 10 
% Pd/C (0.23 mmol, 247 mg) was added. The atmosphere was then exchanged with H2, and the 
reaction mixture was stirred at 20 °C under H2. After 20 h, some starting material still remained, 
and the atmosphere was exchanged with N2, w/w 10 % Pd/C (0.23 mmol, 247 mg) was added, and 
the atmosphere was exchanged to H2 again. After 24 h, TLC showed full conversion of 53, the 
reaction mixture was filtered through celite, the residue was rinced with EtOAc and the solvent was 
removed in vacuo. The crude solid was purified by flash chromatography (heptane/EtOAc 1:1) to 
afford 55 as white crystals in 83 % yield (2.97 g). Mp.: 46-47 °C. Rf = 0.16 (heptane/EtOAc). 
ሾ∝ሿ஽ଶ଴= -0.7 ° (c =1.0 , CHCl3). 1H NMR (300 MHz; CDCl3): δ 3.74-3.36 (m, 25H, glycerol + 
TEG+ C17H35-CH2-O), 2.0 (s, 1H, OH), 1.60-1.51 (m, 4H, CH3-C15H30-CH2-CH2-O), 1.36-1.24 (m, 
60H, CH3-C15H30-CH2-CH2), 0.88 (t, J = 6.7 Hz, 6H, CH3). 13C NMR (75 MHz, CDCl3): δ 77.8 
(CH2-CH-CH2), 72.5 (C18H35-O-CH2-CH-CH2), 71.6 (C17H33-CH2-O-CH2-CH-CH2), 71.4 (TEG), 
70.8 (TEG), 70.7 (TEG), 70.6 (3C, TEG), 70.5 (2C, C17H33-CH2-O-CH-CH2 and TEG), 70.3 (CH2-
OTEG), 61.7 (CH2-OH), 31.9 (2C, C15H30), 30.1 (C15H30), 29.7 (14C, C15H30), 29.6 (7C, C15H30), 
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29.5 (2C, C15H30), 29.3 (2C, C15H30), 26.1 (2C, C15H30), 22.7 (2C, CH2-CH3), 14.1 (2C, CH3). IR 
(neat): 3461 (br.), 2916, 2849, 1467, 1109 cm-1. HRMS (ESI +) C47H96O7, m/z [M+Na+] 795.7054, 
found 795.7055.  
 
1,2-Di-O-octadecyl-3-O-(13-oxo-3,6,9,12-tetraoxaheptadec-16-ynyl)-sn-glycerol (56) 
To a solution of 55 (0.129 mmol, 100 mg) and 4-pentynoic acid (0.129 mmol, 13 mg) in anhydrous 
CH2Cl2 (1.5 mL) was added DMAP (0.220 mmol, 27 mg) followed by EDC•HCl (0.194 mmol, 37 
mg) and the resulting mixture was stirred at 20 °C for 17 h, after what 0.3 more equivalents of 4-
pentynoic acid (0.04 mmol, 6 mg) were added and the reaction mixture was stirred for 6 h. The 
crude mixture was then concentrated on silica and purified by flash chromatography 
(heptane/EtOAc 5:1 to 4:1), to afford 102 mg (93 % yield) of 56 as white amorphous solid. Rf = 
0.26 (heptane/EtOAc 3:1). ሾ∝ሿ஽ଶ଴= -1.00 ° (c = 1.00, CHCl3). 1H NMR (300 MHz; CDCl3): δ 4.27-
4.24 (m, 2H, CH2-O-C=O), 3.71-3.46 (m, 21H, glycerol + TEG+ C17H35-CH2), 3.42 (t, J = 6.9 Hz, 
2H, glycerol + TEG+ C17H30-CH2), 2.61-2.56 (m, 2H, CH2-CH2-CΞCH), 2.53-2.47 (m, 2H, CH2-
CH2-CΞCH), 1.97 (t, J = 2.4 Hz, 1H, CΞCH), 1.56-1.52 (m, 4H, C16H33-CH2-CH2-O-), 1.35-1.22 
(m, 60H, CH3-C15H30-CH2-CH2), 0.87 (t, J = 6.7 Hz, 6H, CH3). 13C NMR (75 MHz, CDCl3): δ 
171.7 (C(O)O), 82.40 (CH2-CΞCH), 77.8 (CH2-CH-CH2), 71.6 (TEG + glycerol + C17H33-CH2), 
71.4 (TEG + glycerol + C17H33-CH2), 70.8 (2C, TEG + glycerol + C17H33-CH2), 70.6 (5C, TEG + 
glycerol + C17H33-CH2), 70.5 (TEG + glycerol + C17H33-CH2), 69.0 (2C, CH2-O-C(O) + CΞCH), 
63.8 (CH2-O-TEG), 33.2 (CH2-C(O)-O), 31.9 (2C, C15H30), 30.1 (C15H30), 29.7 (21C, C15H30), 29.5 
(2C, C15H30), 29.4 (2C, C15H30), 26.1 (2C, C15H30), 22.7 (2C, CH2-CH3), 14.3 (CH2-CΞCH), 14.1 
(2C, CH3). IR (neat): 3272, 2956, 2916, 2849, 1736, 1467, 1108 cm-1. HRMS (ESI +) C52H100O8, 
m/z [M+Na+] 875.7316, found 875.7339. 
 
1,2-Di-O-octadecyl-3-O-(17-azido-13-oxo-3,6,9,12-tetraoxaheptadecyl)-sn-glycerol (57) 
To a solution of 55 (0.129 mmol, 100 mg) and 5-azidopentanoic acid (0.182 mmol, 26 mg) in 
anhydrous CH2Cl2 (1.5 mL) was added DMAP (0.220 mmol, 27 mg) followed by EDC.HCl (0.194 
mmol, 37 mg) and the resulting mixture was stirred at 20 °C for 17 h, after what 0.3 more 
equivalents of 5-azidopentanoic acid (0.04 mmol, 6 mg) were added and the reaction mixture was 
stirred for 6 h. The crude mixture was then concentrated onto silica and purified by flash 
chromatography (heptane/EtOAc 5:1 to 4:1), to afford 100 mg (86 % yied) of 57 as white 
amorphous solid. Rf = 0.2 (heptane/EtOAc 3:1). ሾ∝ሿ஽ଶ଴= -0.26 ° (c = 1.15, CHCl3). 1H NMR (300 
MHz; CDCl3): δ 4.25-4.21 (m, 2H, CH2-O-C=O), 3.70-3.40 (m, 23H, glycerol + TEG+ C17H35-
CH2-O), 3.29 (t, J = 6.5 Hz, 2H, CH2-C=O-O); 2.37 (t, J = 7.1 Hz, 2H, CH2-N3), 1.78-1.60 (m, 4H, 
CH2-CH2-CH2-N3), 1.58-1.50 (m, 4H, CH3-C15H30-CH2-CH2-O), 1.36-1.22 (m, 60H, CH3-C15H30-
CH2-CH2), 0.87 (t, J = 6.6 Hz, 6H, CH3). 13C NMR (75 MHz, CDCl3): δ 173.7 (C(O)O), 77.8 (CH2-
CH-CH2), 71.6 (TEG + glycerol + C17H33-CH2), 71.4 (TEG + glycerol + C17H33-CH2), 70.8 (TEG + 
glycerol + C17H33-CH2), 70.7 (TEG + glycerol + C17H33-CH2), 70.6 (TEG + glycerol + C17H33-CH2, 
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4C), 70.5 (TEG + glycerol + C17H33-CH2, 2C), 69.1 (CH2-O-C(O)), 63.5 (CH2-O-TEG), 51.0 (CH2-
N3), 33.5 (CH2-C(O)-O), 31.9 (C15H30, 2C), 30.1 (C15H30), 29.7 (C15H30, 14C), 29.6 (C15H30, 7C), 
29.5 (C15H30, 2C), 29.3 (C15H30, 2C), 28.2 (CH2-CH2-N3), 26.1 (C15H30, 2C), 22.7 (CH2-CH3, 2C), 
22.0 (CH2-CH2-CH2-N3), 14.1 (CH3, 2C). IR (neat): 2916, 2849, 2096, 1735, 1467, 1109 cm-1. 
HRMS (ESI +) C52H103N3O8, m/z [M+Na+] 920.7643, found 920.7669.  
1,2-Di-O-octadecyl-3-O-(12-(methanesulfonyloxy)-3,6,9-trioxadodecyl)-sn-glycerol (58) 
To a solution of 55 (1.29 mmol, 1 g) and Et3N (2.33 mmol, 325 µL) in anhydrous dichloromethane 
(4 mL) cooled to 0 °C, was added MsCl (6.47 mmol, 500 µL), and the reaction mixture was allowed 
to reach slowly 20 °C. After stirring for 16 h, 55 was not fully converted, and MsCl (6.47 mmol, 
500 µL) was added at 0 °C, and the reaction mixture was stirred at 20 °C for additional 20 h. Sat. 
aq. NH4Cl (20 mL) was added, the organic phase was separated, and the aqueous phase was washed 
with dichloromethane (3  20 mL), the combined organic layers were dried over MgSO4, 
concentrated in vacuo and purified by flash chromatography (heptane/EtOAc 3:1 to 1:1) to afford 
58 as white solid in 80 % yield (883 mg). Mp.: 51.0-51.5 °C Rf = 0.26 (heptane/EtOAc 1:1). ሾ∝ሿ஽ଶ଴= 
+0.6 ° (c =1.04, CHCl3). 1H NMR (300 MHz; CDCl3): δ 4.40-4.37 (m, 2H, CH2-OMs), 3.78-3.75 
(m, 2H, CH2-CH2-OMs), 3.68-3.40 (m, 21H, C17H33-CH2 + O-CH2-CH2- + CH2-CH-CH2), 3.08 (s, 
3H, S-CH3), 1.55 (tt, J = 6.5, 6.5 Hz, 4H, CH3-C15H30-CH2-CH2-O), 1.35-1.23 (m, 60H, CH3-
C15H30-CH2-CH2), 0.87 (t, J = 6.7 Hz, 6H, CH3-C17H34). 13C NMR (75 MHz, CDCl3): δ 77.8 (CH2-
CH-CH2), 71.6 (TEG + glycerol + C17H33-CH2), 71.4 (TEG + glycerol + C17H33-CH2), 70.8 (TEG + 
glycerol + C17H33-CH2), 70.7 (TEG + glycerol + C17H33-CH2), 70.6 (4C, TEG + glycerol + C17H33-
CH2), 70.5 (2C, TEG + glycerol + C17H33-CH2), 69.2 (CH2-CH2-OMs), 69.0 (CH2-CH2-OMs), 37.7 
(SO2-CH3), 31.9 (2C, C15H30), 30.1 (C15H30), 29.7 (14C, C15H30), 29.6 (7C, C15H30), 29.5 (2C, 
C15H30), 29.3 (2C, C15H30), 26.1 (2C, C15H30), 22.7 (2C, CH2-CH3), 14.1 (2C, CH3). IR (neat): 
2916, 2849, 1467, 1350, 1173, 1107 cm-1. HRMS (ESI +) C48H98O9S, m/z [M+Na+] 873.6829, 
found 873.6834. 
 
1,2-Di-O-octadecyl-3-O-(3,6,9-trioxa-12-azapentadec-14-ynyl)-sn-glycerol (59) 
To a solution of 58 (0.47 mmol, 400 mg) in anhydrous THF (1 mL) under argon, was added Et3N 
(1.175 mmol, 164 µL) followed by Bu4NI (0.235 mmol, 87 mg) and propargyl amine (0.940 mmol, 
80 mg). The reaction mixture was stirred at 20 °C for 18 h, then at 70 °C for 3.5 h, after what the 
crude mixture was concentrated in vacuo on silica and 59 was obtained as yellow amorphous solid 
in 79 % yield (300 mg) after purification by flash chromatography (EtOAc/heptane/Et3N 66:33:1). 
Rf = 0.16 (EtOAc/heptane 3:1). ሾ∝ሿ஽ଶ଴= -0.45 ° (c = 1.32, CHCl3). 1H NMR (300 MHZ; CDCl3): δ 
3.89 (t, J = 4.74 Hz, 2H, CH2-CH2-NH), 3.81 (d, J = 2.0 Hz, 2H, NH-CH2-CΞCH), 3.71-3.40 (m, 
21H, glycerol + TEG+ C17H35-CH2-O), 3.19-3.22 (m, 2H, CH2-NH-CH2-CΞCH), 2.48 (t, J = 2.0 
Hz, 1H, CΞCH), 1.58-1.51 (m, 4H, 2CH3-C15H30-CH2-CH2-O), 1.35-1.20 (m, 60H, 2CH3-
C15H30-CH2-CH2), 0.87 (t, J = 6.64 Hz, 6H, 2CH3). 13C NMR (75 MHz, CDCl3) δ 82.0 (CΞCH), 
77.8 (CH2-CH-CH2), 71.6 (TEG + glycerol + C17H33-CH2), 71.4 (TEG + glycerol + C17H33-CH2), 
71.3 (CΞCH), 70.8 (TEG + glycerol + C17H33-CH2), 70.7 (TEG + glycerol + C17H33-CH2), 70.6 
134 
 
(3C, TEG + glycerol + C17H33-CH2), 70.5 (2C, TEG + glycerol + C17H33-CH2), 70.4 (TEG + 
glycerol + C17H33-CH2), 70.3 (TEG + glycerol + C17H33-CH2), 48.0 (CH2-NH-CH2-CΞCH), 38.2 
(CH2-NH-CH2-CΞCH), 31.9 (2C, C15H30), 30.1 (C15H30), 29.7 (14C, C15H30), 29.6 (7C, C15H30), 
29.5 (2C, C15H30), 29.3 (2C, C15H30), 26.1 (2C, C15H30), 22.6 (2C, 2CH2-CH3), 14.1 (2C, 
2CH3). IR (neat): 3250 (br.), 2915, 2849, 1467, 1106 cm-1. HRMS (ESI +) C50H99NO6, m/z 
[M+Na+] 832.7370, found 832.7371.  
 
Methyl 10-oxodecanoate (60) 
In a flame dried 3-neck flask, a solution of DMSO (163.13 mmol, 11.6 mL) in CH2Cl2 (300 mL) 
was cooled to -78 °C. A solution of (ClCO)2 (81.57 mmol, 6.9 mL) in CH2Cl2 (15 mL) was added 
dropwise over 1 h at -78 °C, and the resulting mixture was stirred at that temperature for 30 min. A 
mixture of methyl 10-hydroxydecanoate (74.15 mmol, 15 g) in CH2Cl2 (75 mL) was added 
dropwise over 2.5 h at -78 °C, and the reaction mixture was stirred for 1h at that temperature before 
Et3N (370 mmol, 51 mL) was added slowly at -78 °C. The reaction mixture was stirred at that 
temperature for 15 min, and allowed to warm to 20 °C over 1 h. H2O (400 mL) was then added, the 
organic layer was separated, and the aqueous layer extracted with CH2Cl2, the combined organic 
layers were washed with aq. HCl 1%, H2O, Na2CO3 and brine, dried over MgSO4 and concentrated 
in vacuo to afford the desired product as colourless oil (12.3 g, 83%). 1H NMR (CDCl3, 300 MHz): 
δ 9.74 (t, J = 1.8 Hz, 1H, CH=O), 3.65 (s, 3H, CO2CH3), 2.40 (td, J = 7.4, 1.8 Hz, 2H, CH2-CH=O), 
2.28 (t, J = 7.5 Hz, 2H, CH2-CO2CH3), 1.55-1.65 (m, 4H, CH2-CH2-CO2CH3 and CH2-CH2-CH=O), 
1.32-1.23 (m, 8H, (CH2)4-COOCH3).217 
 
6-tert-Butyldimethylsilyloxy-hex-1-yne (62) 
To a solution of 5-hexyn-1-ol (101.90 mmol, 10.0 g) in anhydrous DMF (20 mL) cooled to 0 °C 
were added imidazole (152.84 mmol, 10.4 g) and t-butyldimethylsilyl chloride (122.3 mmol, 18.4 
g). The resulting mixture was stirred at 0 °C for 10 min then allowed to warm to 20 °C and stirred at 
that temperature for additional 2.5 h. After that time, a saturated aqueous solution of NH4Cl (50 
mL) was added, the two phases were separated, and the aqueous phase was extracted with Et2O (3 
 50 mL). The organic layers were combined, washed with water and brine, dried over anhydrous 
MgSO4 and concentrated under reduced pressure and purified through a short plug of silica 
(heptane/EtOAc 9:1) to yield the protected alcohol 62 as a colourless oil (21.08 g, 98%). 1H NMR 
(300 MHz, CDCl3): δ 3.63 (t, J = 6.0 Hz, 2H, CH2-OTBS), 2.21 (td, J = 6.7, 2.7 Hz, 2H, CH2-
CΞCH), 1.94 (t, J = 2.7 Hz, 1H, CH2-CΞCH), 1.68-1.53 (m, 4H, CHΞC-CH2-(CH2)2), 0.89 (s, 9H, 
Si-C-(CH3)3), 0.05 (s, 6H, Si-(CH3)2).218 
 
6-Benzyloxyhex-1-yne (64). 
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To a suspension of NaH (60 % w/w in moneral oil, 10.19 mmol, 407 mg) in DMF (4 mL) cooled to 
0 °C was added hex-5-yn-1-ol (10.19 mmol, 1g) dropwise. The mixture was stirred at 20 °C for 15 
min. To the mixture was added dropwise benzyl bromide (15.28 mmol, 1.8 mL) at 0 °C and the 
resulting mixture was stirred at 20 °C for 12 h. The mixture was poured in ice water (15 mL) and 
extracted with Et2O (3  10 mL), the combined organic layers were dried overNa2SO4, 
concentrated in vacuo and purified by flash chromatography (hexane/EtOAc 20:1) to give 64 (1.38 
g, 72%). 1H NMR (300 MHz, CDCl3): δ 7.35-7.29 (m, 5H, Ph), 4.51 (s, 2H, O-CH2-Ph), 3.50 (t, J = 
6.2 Hz, 2H, O-CH2-CH2), 2.22 (td, J = 6.8, 2.6 Hz, 2H, CH2-CΞCH), 1.95 (t, J = 2.6 Hz, 1H, 
CΞCH), 1.80-1.59 (m, 4H, CHΞC-CH2-(CH2)2).219 13C NMR (75 MHz, CDCl3): δ 138.75, 128.3 
(2C), 127.6 (2C), 127.5, 84.3, 72.8, 69.7, 68.4, 28.7, 25.2, 18.2.219 
 
10-(Benzyloxy)decan-1-ol (66) 
Decan-1,10-diol (10 g, 57.38 mmol) was added to a suspension of NaH (60% in mineral oil, 57.38 
mmol, 2.30 g) in dry DMF (45 mL) at 0 °C under an argon atmosphere, and the mixture was stirred 
for 20 min at that temperature. BnBr (5.74 mmol, 680 µL) was then added dropwise at 0 °C, and the 
reaction mixture was stirred at 0 °C for 30 min then at room temperature for 4 h. The reaction 
mixture was poured into ice-water (150 mL) and the resulting phase was extracted with EtOAc (3  
200 mL). The combined organic layers were dried over MgSO4, and concentrated in vacuo. The 
obtained white solid was recrystallized from EtOAc/heptane, to offer the starting material as white 
crystals (7.9 g) and the filtrate was concentrated in vacuo and purified by flash chromatography 
(heptane/EtOAc 2:1) to afford 66 in 90% yield (1.37 g). Rf = 0.27 (heptane/EtOAc 2:1). 1H NMR 
(300 MHz, CDCl3): δ 7.29-7.18 (m, 5H, Ph), 4.43 (s, 2H, CH2-Ph), 3.55 (t, J = 6.6 Hz, 2H, CH2-
OH), 3.39 (t, J = 6.6 Hz, 2H, CH2-OBn), 1.97 (s, 1H, OH), 1.58-1.46 (m, 4H, CH2-CH2-OBn and 
CH2-CH2-OH), 1.32-1.18 (m, 12H, OH-CH2-CH2-C6H12). 13C NMR (75 MHz, CDCl3): δ 138.6, 
128.3 (2C), 127.6 (2C), 127.4, 72.8, 70.5, 63.0, 32.7, 29.7, 29.5 (2C), 29.4 (2C), 26.1, 25.7. 
 
16-Benzyloxy-1-((tert-butyldimethylsilyl)oxy)hexadec-5-yn-7-ol (67) 
To a solution of DMSO (24.96 mmol, 1.95 g, 1.8 mL) in CH2Cl2 (45 mL) at -78 °C under an 
atmosphere of N2 was added a solution of oxalyl chloride (12.49 mmol, 1.58 g, 1.1 mL) in CH2Cl2 
(2.3 mL) slowly, maintaining the temperature below -60 °C while stirring. A solution of 66 (11.35 
mmol, 3.00 g) in CH2Cl2 (11 mL) was added dropwise to the resulting mixture while still keeping 
the temperature below -60 °C. After stirring for 1.5 h, Et3N (56.8 mmol, 5.74 g, 8.2 mL) was added 
and the reaction was allowed to warm slowly to 20 °C over 3 h. The reaction mixture was poured 
into water (60 mL), the phases were separated and the aqueous phase was extracted with CH2Cl2 (3 
× 60 mL). The combined organic phases were washed with 1% aq. HCl (90 mL), water (90 mL), 
sat. aq. NaHCO3 (90 mL) and sat. aq. NaCl (90 mL) and then dried with MgSO4, concentrated and 
used without further purification.  
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To a solution of 6-((tertbutyldimethylsilyl)oxy)hex-1-yne (62) (4.70 mmol, 1.00 g) in THF (4.7 
mL) at -78 °C was added t-BuLi (1.7 M in pentane, 4.24 mmol, 2.50 mL) dropwise. The resulting 
mixture was allowed to warm to 20 °C and then a solution of the crude aldehyde (4.24 mmol, 1.11 
g) in THF (4.2 mL) was added dropwise. The reaction mixture was stirred at 20 °C for 1 h, poured 
into sat. aq. NH4Cl (20 mL) and extracted with CH2Cl2 (3 × 30 mL). The combined organic phases 
were dried with MgSO4, filtered, concentrated and purified by column chromatography 
(EtOAc/heptane 1:9) affording 67 as a colourless oil (1.37 g, 68%). 1H NMR (300 MHz, CDCl3): δ 
7.37-7.24 (m, 5H), 4.50 (s, 2H), 4.38-4.29 (m, 1H), 3.62 (t, J = 5.9 Hz, 2H), 3.46 (t, J = 6.6 Hz, 
2H), 2.24 (td, J = 6.4, 3.3 Hz, 2H), 1.72-1.54 (m, 6H), 1.46-1.24 (m, 14H), 0.89 (s, 9H), 0.05 (s, 
6H). 13C NMR (75 MHz, CDCl3): δ 138.83, 128.48 (2C), 127.77 (2C), 127.61, 85.43, 81.66, 73.00, 
70.65, 62.91, 62.79, 38.35, 32.06, 32.03, 29.92, 29.64, 29.61, 29.42, 26.33, 26.11 (3C), 25.36, 
25.27, 18.64, 18.49, -5.12, -5.14. HRMS (ESI+) C29H50O3Si, m/z [M+Na+] 497.3427, found 
497.3413. 
 
16-Benzyloxy-1,7-bis((tert-butyldimethylsilyl)oxy)hexadec-5-yne (68) 
To a solution of 67 (2.30 mmol, 1.09 g) in DMF (4.6 mL) was added imidazole (3.44 mmol, 234 
mg) and TBSCl (2.76 mmol, 415 mg). The resulting mixture was stirred for 3 h, poured into sat. aq. 
NH4Cl (20 mL) and extracted with CH2Cl2 (3 × 25 mL). The combined organic phases were dried 
with MgSO4, filtered, concentrated and purified bycolumn chromatography (EtOAc/heptane 1:19) 
affording 68 as a colourless oil (1.27 g, 94%). 1H NMR (300 MHz, CDCl3): δ 7.37-7.24 (m, 5H), 
4.50 (s, 2H), 4.36-4.24 (m, 1H), 3.62 (t, J = 5.9 Hz, 2H), 3.46 (t, J = 6.6 Hz, 2H), 2.21 (td, J = 6.7, 
1.8 Hz, 2H), 1.75-1.50 (m, 6H), 1.45-1.23 (m, 14H), 0.90 (s, 9H), 0.89 (s, 9H), 0.12 (s, 3H), 0.10 (s, 
3H), 0.05 (s, 6H). 13C NMR (75 MHz, CDCl3): δ 138.85, 128.48 (2C), 127.76 (2C), 127.60, 84.27, 
82.35, 72.99, 70.66, 63.35, 62.80, 39.17, 32.09, 32.03, 29.92, 29.69, 29.63, 29.42, 29.18, 26.10 
(6C), 26.01, 25.50, 25.31, 18.66, 18.48, -4.29, -4.81, -5.16 (2C). 
 
10,16-Bis((tert-butyldimethylsilyl)oxy)hexadecan-1-ol (69) 
To a solution of 68 (2.05 mmol, 1.21 g) in EtOAc (20.5 mL) under a N2 atmosphere was added 10% 
Pd/C (218 mg) and an atmosphere of H2 was installed by bubbling H2 through the solution for 5 
min. The reaction was stirred under H2 for 20 h, filtered through Celite and concentrated, affording 
69 as a colourless oil (1.02 g, 99%). 1H NMR (300 MHz, CDCl3): δ 3.66-3.55 (m, 5H), 1.62-1.21 
(m, 26H), 0.89 (s, 9H), 0.88 (s, 9H), 0.04 (s, 6H), 0.03 (s, 6H). 13C NMR (75 MHz, CDCl3): δ 
72.49, 63.46, 63.19, 37.25, 32.98, 32.93, 29.98, 29.81, 29.72, 29.56, 26.13 (4C), 26.08 (4C), 25.96, 
25.88, 25.47 (2C), 18.52, 18.30, -4.27 (2C), -5.11 (2C). 
 
cis-2-Phenyl-1,3-dioxan-5-yl 10,16-bis((tert-butyldimethylsilyl)oxy)hexadecanoate (70)  
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To a solution of 69 (1.97 mmol, 991 mg) in CH2Cl2 (8 mL) and water (4 mL) was added PhI(OAc)2 
(1.65 g, 5.12 mmol) and TEMPO (62 mg, 0.39 mmol). The resulting mixture is stirred vigorously 
for 3 h, poured into 10%. aq. Na2S2O3 (20 mL) and extractedwith EtOAc (3 × 25 mL). The 
combined organic phases were dried with MgSO4, filtered, concentrated and taken up in CH2Cl2 (20 
mL). To this solution was added cis-5-hydroxy-2-phenyl-1,3-dioxane (2.56 mmol, 461 mg), DMAP 
(3.35 mmol, 409 mg) and EDC-HCl (2.96 mmol, 567 mg). The reaction was stirred for 18 h, SiO2 
was added, the mixture was concentrated and purified by column chromatography (EtOAc:heptane 
1: 9) affording 70 as a colourless oil (1.19 g, 89%). 1H NMR (300 MHz, CDCl3): δ 7.56-4.47 (m, 
2H), 7.43-7.34 (m, 3H), 5.57 (s, 1H), 4.75-4.71 (m,1H), 4.29 (d, J = 12.9 Hz, 2H), 4.18 (d, J = 12.9 
Hz, 2H), 3.65-3.56 (m, 3H), 2.44 (t, J =7.6 Hz, 2H), 1.76-1.59 (m, 2H), 1.56-1.45 (m, 2H), 1.45-
1.18 (m, 20H), 0.89 (s, 9H), 0.88 (s, 9H), 0.05 (s, 6H), 0.03 (s, 6H). 13C NMR (75 MHz, CDCl3): δ 
174.03, 138.11, 129.22, 128.43 (2C), 126.15 (2C), 101.37, 72.49, 69.28 (2C), 65.81, 63.46, 37.28, 
37.22, 34.54, 33.00, 29.81, 29.63, 29.42, 29.26, 26.13 (3C), 26.09 (4C), 26.03, 25.97, 25.48, 25.08, 
18.38, 18.30, -4.27 (2C), -5.11 (2C). 
 
cis-2-Phenyl-1,3-dioxan-5-yl 10,16-dihydroxyhexadecanoate (71) 
To a solution of 70 (0.22 mmol, 150 mg) in MeCN (23 mL) at 0 °C was added 20% aq. HF (10 
mmol, 1.0 mL) and the resulting mixture was stirred at 0 °C for 4 h. TMSOMe (28 mmol, 3.9 mL) 
was added, stirring was continued at 0 °C for 20 min, the mixture was poured into sat. aq. NH4Cl 
(30 mL) and extracted with CH2Cl2 (2 × 30 mL). The combined organic phases were dried over 
MgSO4, filtered, concentrated and purified by column chromatography (CH2Cl2:EtOAc 1:0 to 1:1) 
affording 71 (84 mg, 84%) as a white solid, m.p.: 70.5-72.1 °C. 1H NMR (300 MHz, CDCl3): δ 
7.56-7.48 (m, 2H), 7.42-7.34 (m, 3H), 5.56 (s, 1H), 4.72 (s, 1H), 4.29 (d, J = 12.9 Hz, 2H), 4.18 (d, 
J = 12.9 Hz, 2H), 3.64 (t, J = 6.6 Hz, 2H), 3.62-3.52 (m, 1H), (t, J = 7.5 Hz, 2H), 1.73-1.51 (m, 4H), 
1.50-1.21 (m, 20H). 13C NMR (75 MHz, CDCl3): δ 174.03, 137.94, 129.23, 128.45 (2C), 126.16 
(2C), 101.38, 72.07, 69.29 (2C), 65.84, 63.16, 37.61, 37.48, 34.52, 32.85, 29.73, 29.59, 29.53, 
29.33, 29.20, 25.85, 25.74 (2C), 25.05. HRMS (ESI+) C26H42O6, m/z [M+Na+] 473.2879, found 
473.2872. 
 
1,3-Dihydroxypropan-2-yl 10,16-dihydroxyhexadecanoate (72 [2-MHG]) 
To a solution of 71 (0.26 mmol, 118 mg) in THF (13 mL) under a N2 atmosphere was added 10% 
Pd(OH)2/C (60 mg) and an atmosphere of H2 was installed by bubbling H2 through the solution for 
5 min. The reaction was stirred under H2 for 10 h, filtered through Celite, concentrated and 
crystallized from EtOAc and heptane, affording 71 (79 mg, 83%) as a white solid, Mp.: 66.7-68.1 
°C. 1H NMR (300 MHz, CD3OD): δ 4.68-4.59 (m, 1H), 3.68 (dd, J = 12.1, 3.7 Hz, 2H), 3.64 (dd, J 
= 12.1, 3.7 Hz, 2H), 3.54 (t, J = 6.6 Hz, 2H), 3.53-3.50 (m, 1H), 2.37 (t, J = 7.4 Hz, 2H), 1,71-1.25 
(m, 24H). 13C NMR (75 MHz, CD3OD): δ 175.33, 76.51, 72.40, 62.98, 61.68 (2C), 38.42, 38.38, 
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35.13, 33.62, 30.79, 30.68, 30.59, 30.38, 30.17, 30.12, 26.95, 26.79, 25.97. HRMS (ESI+) 
C19H38O6, m/z [M+Na+] 385.2566, found 385.2553. 
 
(5-Bromo-1,3-phenylene)dimethanol (73) 
To a solution of dimethyl 5-bromoisophthalate (18.00 mmol, 4.91 g) in anhydrous THF (40 mL) 
cooled to 0 °C under an atmosphere of Ar, was added a solution of LiAlH4 (39.57 mmol, 1.5 g) in 
THF (40 mL) via cannula at 0 ºC, and the resulting mixture was stirred at that temperature for 10 
min, then at 20 °C for 2 h. The mixture was cooled to 0 °C again, and a sat. aq. solution of 
Rochelle´s salt (150 mL) was added carefully. After stirring for 10 min at 0 °C and 30 min at 20 °C, 
the reaction ixture was extracted with EtOAc (3  150 mL), the combined organic layers were 
washed with NH4Cl (300 mL) and brine, dried over MgSO4 concentrated in vacuo and used as 
crude without further purification. Rf = 0.2 (hexane/CH2Cl2/MeOH, 7:2:1). 1H-NMR (300 MHz, 
CD3OD): δ 7.42 (d, J = 1.5 Hz, 2H, 2CH-ortho), 7.28 (t, J = 1.5 Hz, 1H, CH-para), 4.59-4.58 (s, 
4H, Ar-CH2-OH). 13C NMR (75 MHz, CD3OD): δ 145.5 (2C, C3 and C5), 129.5 (2C, C2 and C6), 
124.9 (C4), 123.4 (C1), 64.3 (2C, 2CH2-OH). 
 
5-Bromoisophthalaldehyde (74) 
To a solution of anhydrous DMSO (197 mmol, 14 mL) in CH2Cl2 (200 mL) cooled to -78 °C under 
Ar, was added a solution of (ClCO)2 (114.6 mmol, 9.7 mL) in CH2Cl2 (23 mL) dropwise at -50 °C 
to -60 °C. The reaction mixture was stirred at -78 °C for 15 min and a solution of 73 (40.9 mmol, 
8.9 g) in a mixture of CH2Cl2 (40 mL) and DMSO (10 mL) was added dropwise at -50 °C to -60 °C. 
After stirring at -78 °C for 1 h, Et3N (409.5 mmol, 57 mL) was added at -78 °C and the mixture was 
stirred at that temperature for 15 min and then allowed to warm to 20 °C. Water (300 mL) was 
added and the mixture was extracted with CH2Cl2 (3  300 mL). The combined organic layers 
were washed with aq. HCl (1% w/w), water, aq. Na2CO3 (5% w/w) and water, dried over MgSO4, 
concentrated in vacuo and purified by flash chromatography (heptane/EtOAc 9:1 to 8:2) to afford 
6.88 g of the dialdehyde 74 as a white powder (79 %). Rf = 0.46 (heptane/EtOAc 2:1). mp: 127-128 
°C (lit. 118-120 oC)220. 1H NMR (300 MHz; CDCl3): δ 10.04 (s, 2H, CHO), 8.29 (t, J = 1.4 Hz, 1H, 
H4), 8.24 (d, J = 1.4 Hz, 2H, H2, H6);220 13C NMR (75 MHz, CDCl3): δ 189.5 (2C, CHO), 138.4 
(2C, C3, C5), 137.1 (2C, C2, C6), 129.2 (C4), 124.3 (C1). IR (neat): 3063, 2868, 1691 cm-1. HRMS 
(ESI +) C8H5BrO2, m/z [M+H+] 212.9551, found 212.9545.  
 
1-Bromo-3,5-di((R)-1-hydroxybut-3-enyl)benzene (75)  
The operations were carried out under an atmosphere of Ar. A solution of (+)-Ipc2BAll (1M in 
pentane, 26 mmol, 26 mL) was cooled to -78 °C. A solution of 74 (10.3 mmol, 2.2 g) in anhydrous 
THF (45 mL) cooled to 0 °C was added to the allylborane solution at -78 °C via cannula over 1 h. 
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The addition was performed on the side of the flask in order to cool the aldehyde mixture before it 
reaches the allylborane. The resulting reaction mixture was stirred at -78 °C for 4 h, after what 
MeOH (2 mL) followed by 3N NaOH (4.5 mL) and 35% H2O2 (9 mL) were added slowly at -78 °C. 
The mixture was stirred at -78 °C for 10 min and then at 50 °C for 15 h. sat. aq. NH4Cl (50 mL) was 
added and the reaction mixture was extracted with EtOAc (3  50 mL). The combined organic 
layers were dried over MgSO4, concentrated on silica in vacuo and purified by flash 
chromatography (heptane/EtOAc 9:1 to 2:1) to afford 2.87 g of 75 as a white solid (94 %). Rf = 0.28 
(heptane/EtOAc 2:1). mp = 48-49 oC. ሾ∝ሿ஽ଶ଴= +0.08 ° (c = 1.48, CHCl3). 1H NMR (300 MHz; 
CDCl3): δ 7.42 (d, 2H, J = 1.5 Hz, H2 and H6), 7.25 (t, J = 1.5 Hz, 1H, H4), 5.78 (dddd, J = 20.1, 
9.7, 7.8, 6.5 Hz, 2H, CH=CH2), 5.21-5.14 (m, 4H, CH=CH2), 4.70 (dd, J = 4.8, 7.8 Hz, 2H, CH-
OH), 2.57-2.38 (m, 4H, CH2-CH=CH2), 2.12 (broad s, 2H, OH). 13C NMR (75 MHz, CDCl3): δ 
146.4 (2C, C3, C5), 134.0 (2C, CH=CH2), 128.2 (2C, C2, C6), 122.8 (C1), 122.1 (C4), 119.3 (2C, 
CH=CH2), 72.7 (2C, CH-OH), 44.1 (2C, CH-CH=CH2). IR (neat): 3303, 2932, 2898, 1641, 1601, 
1571, 1485, 1429, 1403, 1339, 1230, 1062 918 cm-1. HRMS (ESI+) C14H17BrO2, m/z [M+Na+] 
319.0310, found 319.0302. HPLC (Chiralpak OD-H at 20 °C, λ= 215 nm, hexane with 2-propanol 
0-4% over 90 min at 0.5 mL/min flow rate). Retention times: 70.8-71.3 min (ent-(-)-75); 74.1-74.3 
(meso); 78.2-78.5 min ((+)-75). To obtain the retention time for ent-(-)-75, the reaction was 
performed with (-)-Ipc2BAll under identical conditions. 
 
1-Bromo-3,5-di((R)-1-methoxybut-3-enyl)benzene (76) 
To a suspension of NaH (60 % in mineral oil 176.76 mmol, 7.07 g) in anhydrous DMF (400 mL) 
cooled to 0 °C under Ar, was added a solution of 75 (58.92 mmol, 17.50 g) in anhydrous DMF (120 
mL). After stirring at 0 °C for 10 min, the resulting mixture had turned yellow. MeI (235.68 mmol, 
14.7 mL) was added slowly at 0 °C, and the resulting reaction mixture was stirred at that 
temperature for 10 min and then allowed to reach 20 °C slowly. After 14 h, the reaction mixture 
was poured into 10 % aq. Na2S2O3 (400 mL) at 0 °C and extracted with Et2O (3  400 mL). The 
combined organic layers were washed with H2O (1 L) and dried over MgSO4, concentrated on silica 
in vacuo and purified by short flash chromatography (heptane:EtOAc 19:1). The desired product 
was isolated as a colourless viscous oil in 92 % yield (17.71 g). Rf = 0.53 (heptane/EtOAc 9:1). 
ሾ∝ሿ஽ଶ଴= +79.63 ° (c = 1.08, CHCl3). 1H NMR (300 MHZ; CDCl3) δ 7.35 (d, J = 1.5 Hz, 2H, H2, 
H6), 7.12 (t, J = 1.5 Hz, 1H, H4), 5.80-5.66 (m, 2H, CH2-CH=CH2), 5.06-5.03 (m, 2H, CH2-
CH=CH2), 5.02-4.99 (m, 2H, CH2-CH=CH2), 4.14 (dd, J = 7.1, 6.0 Hz, 2H, CH-OCH3), 3.23 (s, 
6H, OCH3), 2.53 (dtt, J = 14.2, 7.1, 1.2 Hz, 2H, CH2-CH=CH2), 2.38 (dddt, J = 14.2, 7.1, 6.0, 1.2 
Hz, 2H, CH2-CH=CH2). 13C NMR (75 MHz, CDCl3): δ 144.2 (2C, C3, C5), 134.1 (2C, CH=CH2), 
128.9 (2C, C2, C6), 123.7 (C4), 122.6 (C1), 117.4 (2C, CH=CH2), 82.9 (2C, CH-OCH3), 56.9 (2C, 
OCH3), 42.3 (2C, CH2-CH=CH2). IR (neat): 3076, 2980, 2932, 2904, 2855, 2821, 1430, 1190, 
1092, 912 cm-1. HRMS (ESI +) C16H21BrO2, m/z [M+Na+] 347.0617, found 347.0615.  
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Mosher ester analysis of compound 75 
(2S,2'S)-((1R,1'R)-1,1'-(5-Bromo-1,3-phenylene)bis(but-3-ene-1,1-diyl)) bis(3,3,3-trifluoro-2-
methoxy-2-phenylpropanoate) ((S)-Mosher ester) 77 
To a solution of diol 75 (0.128 mmol, 38 mg) in pyridine (1.3 mL) was added (R)- 
methoxytrifluoromethylphenylacetyl chloride (0.396 mmol, 100 mg) and the resulting mixture was 
stirred at 20 °C. After 2.5 h, a saturated aqueous solution of NaHCO3 (3 mL) was added and the 
organic layer extracted with with CH2Cl2 (3  3 mL). The combined organic layers were dried over 
MgSO4, filtered and concentrated in vacuo to give the crude ester which was analysed by NMR 
spectroscopy. The crude was then purified by flash chromatography (heptane/EtOAc 2:1). 1H NMR 
(300 MHz, CDCl3): δ 7.44–7.32 (m, 10H, 2Ph), 7.21 (d, J = 1.52 Hz, 2H, 2H ortho to Br), 
7.02-7.00 (m, 1H, H para to Br), 5.84 (dd, J = 8.2, 5.3 Hz, 2H, 2Ar-CH), 5.74-5.60 (m, 2H, 
2CH=CH2), 5.14-5.05 (m, 4H, 2CH-CH2), 3.55 (s, 3H, -OCH3), 3.54 (3H, -OCH3), 2.66-2.44 
(m, 4H, 2CH2-CH=CH2). 19F NMR (282 MHz, CDCl3): δ -71.8. 
 
(2R,2'R)-((1R,1'R)-1,1'-(5-Bromo-1,3-phenylene)bis(but-3-ene-1,1-diyl)) bis(3,3,3-trifluoro-2-
methoxy-2-phenylpropanoate) 78 
To a solution of diol 75 (0.128 mmol, 38 mg) in pyridine (1.3 mL) was added (S)- 
methoxytrifluoromethylphenylacetyl chloride (0.396 mmol, 100 mg) and the resulting mixture was 
stirred at 20 °C. After 2.5 h, a saturated aqueous solution of NaHCO3 (3 mL) was added and the 
organic layer extracted with with CH2Cl2 (3  3 mL). The combined organic layers were dried over 
MgSO4, filtered and concentrated in vacuo to give the crude ester which was analysed by NMR 
spectroscopy. The crude was then purified by flash chromatography (heptane/EtOAc 2:1). 1H NMR 
(300 MHz, CDCl3): δ 7.44–7.32 (m, 12H, 2Ph and 2H ortho to Br), 7.22-7.20 (m, 1H, H para 
to Br), 5.91 (dd, J = 7.9, 5.5 Hz, 2H, 2Ar-CH), 5.55 (tdd, J = 7.0, 10.5, 17.3 Hz, 2H, 
2CH=CH2), 5.00-4.95 (m, 4H, 2CH-CH2), 3.44 (s, 3H, -OCH3), 3.43 (3H, -OCH3), 2.66-2.44 
(m, 4H, 2CH2-CH=CH2). 19F NMR (282 MHz, CDCl3): δ -71.4. 
 
Tris(3,5-bis((R)-1-methoxybut-3-enyl)phenyl)-phosphine oxide (79) 
Anhydrous THF (3 mL) was added to magnesium turnings (739 mg, 30.77 mmol) under an 
atmosphere of Ar. Approximately 200 mg of 76 (0.62 mmol) was added onto the magnesium 
turnings in order to obtain a high concentration of 76 around the turnings, followed by a crystal of 
iodine. The reaction was started by gentle heating of the unstirred mixture. When the reaction was 
started, the reaction was stirred at reflux and a solution of 76 (9.8 g, 30.15 mmol) in anhydrous THF 
(60 mL) was added dropwise over a period of 30 min. The mixture was stirred at reflux for 
additional 4 h, and turned black over that time. The resulting Grignard mixture was then cooled to 
20 °C, and freshly distilled PCl3 (814 µL, 9.32 mmol) was added dropwise over 15 min. The 
reaction mixture was stirred at 20 °C for 14 h, after what tBuOOH (2.5 mL, 13.99 mmol) was 
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added, and the reaction was stirred for additional 2 h. The crude mixture was poured into sat. aq. 
NH4Cl (100 mL). The layers were separated, and the aqueous layer was washed with Et2O (3  100 
mL). The combined organic layers were dried over MgSO4 and concentrated in vacuo. Purification 
by flash chromatography (heptane/EtOAc 1:1 to 1:4) afforded the desired phosphine oxide as 
viscous oil in 84 % yield (6.10 g). Rf = 0.31 (heptane/EtOAc 1:2). ሾ∝ሿ஽ଶ଴= 72.3 ° (c =1.09, CHCl3). 
1H NMR (300 MHz; CDCl3): δ 7.47 (dd, J =12.1, 1.6 Hz, 6H, H2 and H6), 7.43-7.40 (m, 3H, H4), 
5.66 (ddt, J = 17.5, 10.6, 7.0 Hz, 6H, CH2-CH=CH2), 4.99-4.95 (m, 6H, CH2-CH=CH2), 4.95-4.89 
(m, 6H, CH2-CH=CH2), 4.18 (m, 6H, CH-OCH3), 3.17 (s, 18H, OCH3), 2.48 (dtt, J = 14.1, 7.0, 1.1 
Hz, 6H, CH2-CH=CH2), 2.35 (dddt, J = 14.1, 7.0, 5.9 Hz, 2H, CH2-CH=CH2). 13C NMR (75 MHz, 
CDCl3): δ 142.6 (d, J = 11.7 Hz, 6C, C3, C5), 133.9 (6C, CH=CH2), 132.6 (d, J = 103.2 Hz, 3C, 
C1), 129.6 (d, J = 10.3 Hz, 6C, C2, C4), 128.6 (d, J = 2.7 Hz, 3C, C4), 117.4 (6C, CH=CH2), 83.0 
(6C, CH-OCH3), 56.8 (6C, OCH3), 42.3 (6C, CH2-CH=CH2). IR (neat): 3075, 29.80, 2932, 2903, 
2821, 1641, 1428, 1190, 1092, 986, 912 cm-1. HRMS (ESI +) C48H63O7P, m/z [M+Na+] 805.4209, 
found 805.4206.  
 
Phosphine oxide 82 
To a solution of 79 (0.64 mmol, 500 mg) in anhydrous CH2Cl2 (60 mL) were added 2,6-dichloro-
1,4-benzoquinone (0.13 mmol, 24 mg) and Grubbs’ catalyst 2nd generation (0.06 mmol, 36 mg), and 
the resulting mixture was stirred at reflux. Five more portions of 2,6-dichloro-1,4-benzoquinone (5 
 0.13 mmol, 5  24 mg) and Grubbs’ catalyst 2nd generation (5  0.06 mmol, 5  36 mg) were 
added at 1 h intervals at 40 °C, and the mixture was stirred for additional 17 h. The solvent was 
reduced to half volume under reduced pressure, and the curde mixture was purified stepwise by 
repeated preparative TLC (toluene/MeOH 9:1), then by preparative TLC in a different solvent 
system (EtOAc/MeOH 95:5), and another time by preparative TLC with the first eluent system 
(toluene/MeOH 8:2). Thereby, the desired product could be isolated in about 80% purity (judged by 
HPLC and 1H NMR). Final purification of the compound by preparative HPLC afforded the pure 
desired compound in 2% yield (9 mg). 
 
1H NMR (300 MHZ; CDCl3): δ 7.60 (s, 1H, H1), 7.54 (d, J = 11.7 Hz, 1H, H11), 6.93 (d, J = 12.5 
Hz, 1H, H10), 5.40-5.33 (m, 1H, H5), 5.30-5.23 (m, 1H, H6), 4.33 (dd, J = 10.0 Hz, J = 2.3 Hz, 1H, 
H2), 4.12 (d, J = 8.7 Hz, 1H, H9), 3.40 (s, 3H, OMe13), 3.30 (s, 3H, OMe12), 2.69 (d, J = 11.5 Hz, 
1H, H3), 2.58 (d, J = 13.9 Hz, 1H, H7), 2.36-2.28 (m,2H, H4 and H8). 13C NMR (100 MHz, CDCl3): 
δ 143.1 (d, J = 12.2 Hz, 3C, C-C-H2), 142.2 (d, J = 11.7 Hz, 3C, C-C-H9), 130.3 (d, J = 9.7 Hz, 3C 
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C-H11), 129.8 (d, J = 11.7 Hz, 3C, C-H10), 129.2 (3C, C-H6), 127.5 (3C, C-H5), 125.1 (m, 3C, C-
H1), 82.2 (3C, C-H2), 80.9 (3C, C-H9), 57.1 (3C, OMe13), 56.8 (3C, OMe12), 42.0 (3C, C-H3H4), 
41.2 (3C, C-H7H8) (signal for the aromatic carbons bound to phosphorous is not reported, it could 
not be observed, neither in hmbc nor in the 13C spectrum, presumably due to a long relaxation time 
and the coupling to phosphorous). 
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6.List of abbreviations 
Approx. approximately 
Aq.: aqueous 
Asp: aspartic acid 
ATRA: all-trans retinoic acid 
AUC: area under the curve 
Bn: benzyl 
br.: broad 
tBu: butyl 
cod: cycloocta-1,5-diene 
CD. circular dichroism 
CuAAC: copper(I)-catalyzed Azide-Alkyne Cycloaddition 
Cy: cyclohexyl 
d: duplet 
DBU: 1,8-diazabicyclo[5.4.0]undec-7-ene 
DCC: dicyclohexylcarbodiimide 
DDQ: 2,3-dichloro-5,6-dicyano-1,4-benzoquinone 
DDS: drug delivery system 
de: diastereomeric excess 
DHB: 2,5-dihydroxybenzoic acid 
(DHQD)2PHAL: hydroquinidine 1,4-phthalazinediyl diether  
DIAD: diisopropyl azodicarboxylate 
DIBAL-H: diisopropylaluminium hydride 
DIPAMP: ethane-1,2-diylbis[(2-methoxyphenyl)phenylphosphane] 
DIPEA: diisopropylethylamine 
DIPHOS, bis-diphenylphosphinoethane 
DH: dimethylglyoximato 
DHB: 2,5-dihydroxybenzoic acid 
DLS: dynamic Light Scattering 
DLPG: 1,2-dilauroyl-sn-glycero-3- phosphatidylglycerol 
DMAP: 4-(N,N-dimethylamino)pyridine 
DME: dimethoxyethane 
DMF: dimethylformamide 
DMSO: dimethylsulfoxide 
DMPG: 1,2-dimyristoyl-sn-glycero-3-phosphatidylglycerol 
DOPG: 1,2-dioleoyl-sn-glycero-3-phosphatidylglycerol 
DPPC: 1,2-hexadecanoyl-sn-glycero-3-phosphatidylcholine 
DPPG: 1,2-dipalmitoyl-sn-glycero-3-phosphatidylglycerol 
DPPE-PEG2000: 1,2-hexadecanoyl-sn-glycero-3-phosphatidylethanolamine- N-[methoxy(polyethylene glycol)-2000]  
DSC: differential scanning calorimetry 
DSPC: 1,2-distearoyl-sn-glycero-3-phosphatidylcholine 
DSPG: 1,2-distearoyl-sn-glycero-3-phosphatidylglycerol 
DSPE: 1,2-distearoyl-sn-glycero-3-phosphatidylethanolamine 
EDC.HCl: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
EDTA: ethylenediaminetetraacetic acid 
ee: enantiomeric excess 
EPR: enhanced permeability and retention 
equiv.: equivalent 
ESI: electron spray ionization 
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Et: ethyl 
FITC: fluorescein isothiocyanate 
FRET: fluorescence resonance energy transfer 
Gly: glycine 
HEPES: 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid 
His: histidine 
HPLC: high pressure liquid chromatography 
HRMS: high resolution mass spectrometry  
HWE: Horner–Wadsworth–Emmons  
Ipc2Ball: B-allyldiisopinocampheylborane  
ITC: isothiocyanate 
KHMDS: potassium bis(trimethylsilyl)amide 
LC-Ms: liquid chromatography-mass spectrometry 
LDA: lithium diisopropylamide 
L-DOPA: L-3,4-dihydroxyphenylalanine 
LHMDS: lithium bis(trimethylsilyl)amide 
MALDI-TOF-MS: matrix-assisted laser desorption/ionization - time of flight - mass spectrometry 
MD: molecular dynamics 
Me: methyl 
Ms: methanesulfonyl 
MTPA: α-methoxy-α- trifluoromethylphenylacetate 
MW: molecular weight  
NMR: nuclear magnetic resonance 
PBS: phosphate buffered saine 
PC: phosphatidylcholine 
Pd/C: palladium on charcoal 
PEG: poyethleneglycol 
Pg: protecting group 
PG: phosphatidylglycerol 
PdI: polydispersity index 
PMB: p-methoxybenzyl 
POPC: 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylcholine 
POPG: 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylglycerol 
ppm: parts per million 
q: quadruplet 
qnt: quintet 
quant. quantitative 
RCM: ring closing metathesis 
RES: reticulo-endothelial system 
rmsd: root mean square deviation 
Rt: retention time 
s: singlet 
S: substrate 
SD: standard deviations 
SMEAH: sodium bis(2-methoxyethoxy)aluminium 
sPLA2: secretory phospholipase A2 
t: triplet 
TBAHS: tetrabutylammonium hydrogen sulfate 
TBAF: tetrabutylammonium fluoride 
TBAI: tetrabutylammonium iodine 
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TBS: tert-butyldimethylsilyl 
TEG: tetraethylelene glycol 
TEMPO: 2,2,6,6-tetramethylpiperidine 1-oxyl 
THF: tetrahydrofuran 
TLC: thin layer chromatography 
TMEDA: tetramethylethylenediamine 
TMSOK: potassium trimethylsilanolate 
TRITC: tetramethylrhodamine isothiocyanate 
UV: ultraviolet 
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